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ABSTRACT 
 
 Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that causes severe 
disease and death in immune-compromised people. HCMV, like all herpesviruses, 
establishes a lifelong latent infection associated with the lack of production of infectious 
virus and the maintenance of the HCMV viral genome in CD34 (+) hematopoietic 
progenitor cells, and CD14 (+) monocytes.  Although many aspects of the mechanism 
involved in HCMV latency remain unknown, recently published results from our 
laboratory show the entire HCMV latent transcriptome in experimental as well as 
naturally infected CD34 (+) and CD14 (+) cells. The elucidation of all of the viral encoded 
factors during HCMV latent infection is a major step, however there is a critical need to 
identify HCMV genomic DNA elements that contribute to viral genome persistence. More 
recent work from our laboratory has now identified the terminal repeat (TR) element of 
HCMV as an origin of latent viral DNA replication.  Furthermore, we have identified viral 
and cellular factors necessary for maintaining HCMV latency.  Together, these results 
define, for the first time, vital elements in a model of HCMV latent infection. 
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INTRODUCTION 
Herpesviridae is an ancient family of viruses that have evolved with their hosts, 
developing very specific tropisms and elaborate mechanisms for evading host immune 
response resulting in life-long infection.  Worldwide there are more than 170 
herpesviruses currently known and likely many more that have yet to be discovered (1).  
Many species of animals, including mammals, birds, amphibians, and mollusks, have at 
least one associated herpesvirus.  There are eight known herpesviruses that afflict 
humans (Table 1). Herpesviruses are ubiquitously present throughout the animal 
kingdom, and share a unique capability to establish a permanent infection, known as 
latency. Latency is a covert stage of the viral life cycle that is defined by persistence of 
the viral genome for the life of the host.  During latency there is no virus production and 
the viral genome is maintained by a limited number of viral encoded factors. Host 
encoded factors are likely recruited and usurped for assistance in propagation of the 
viral genome during cell division.  By remaining below the threshold of immune 
detection, HCMV, and all herpesviruses, ensure their own survival and remain poised for 
reactivation when the opportunity arises. 
Table 1. Human herpesvirus sub-families and clinical manifestation. 
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 Herpesviruses are further divided into three sub-families: alpha, beta, and 
gamma (Table 1).  Sub-families are distinguished by their relative growth rate in culture, 
their respective sites of latency within the host, as well as their genomic features (2).   In 
general, alpha members grow quickly and establish latency in neurons, while beta 
members, including HCMV, grow more slowly and establish latency in hematopoietic 
progenitor and myeloid lineage cells. In contrast, gamma members exhibit a more varied 
growth rate and establish latency in B-cells.   All families are able to infect and replicate 
in a variety of cell types with epithelial cells comprising a common entry and exit route 
for spread of viral infection. 
Herpesviruses are large, enveloped, double stranded DNA viruses.  The 
genomes are linear and range in size from 125-240 kbp (1).  All Herpesviruses share a 
common subset of 43 core genes (3). Most of the core genes are required for 
propagation of the virus in culture and perform vital functions including DNA replication, 
virion packaging, and virion entry/egress. After infection, gene expression occurs in a 
temporal fashion and viral proteins are classified by their timing with respect to DNA 
synthesis: Immediate Early, Early, and Late genes. Immediate Early (IE) genes are the 
very first viral proteins expressed after entry into the host cell.  Early proteins require the 
expression of IE genes, which are transactivators of Early gene promoters in some 
cases, and are a prerequisite for viral DNA replication; therefore, they are resistant to 
nucleoside analog inhibitors of viral DNA synthesis such as ganciclovir.  Late proteins 
are expressed only after the initiation of viral DNA replication and are mainly proteins 
necessary for DNA packaging and formation and egress of the virion. Each class of viral 
proteins is dependent upon the expression of the previous class with the exception of 
immediate early gene expression.   
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Virtually all Herpesviruses express large numbers of various non-coding RNAs 
(ncRNAs) including miRNAs and long non-coding RNAs (lncRNAs). In fact, the only 
herpesvirus to not express any detectable miRNAs is varicella zoster virus (4).  In some 
cases, the ncRNAs make up the majority of viral transcription; however, the function of 
these abundant ncRNAs still remains to be elucidated (5-7).   The more well studied 
ncRNAs exhibit a myriad of functions including global regulation of cellular and viral 
genes, prevention of cell apoptosis, and modulation of host immunity (6, 8-12).  
Since Herpesviruses have distinct lytic and latent life stages there is also a 
requirement for corresponding unique DNA replication mechanisms and gene 
expression (Figure 1). These two stages of DNA replication vary by virus and cell type 
and will be discussed in further detail for HCMV. 
Figure 1.  Human cytomegalovirus life cycle. 
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HUMAN CYTOMEGALOVIRUS 
Structure and Function 
  HCMV is the largest of the herpesviruses with a double stranded DNA genome 
of 240 kbp and over 200 genes, many of which remain uncharacterized. It exhibits 
relatively slow growth in culture and is a member of the Beta subfamily of Herpesviruses. 
The HCMV virion particle is composed of a lipid bilayer envelope surrounding the 
tegument and capsid.  The tegument is a compact protein dense layer composed of 
approximately 30 viral proteins and is a unique feature of herpesviruses (13).  The 
tegument is responsible for 40% of the virion mass, the majority of which consists of five 
viral proteins: UL47, UL48, UL32, UL82, and UL83 (13). The tegument proteins are 
delivered to the host cell immediately upon fusion of the virus with the cell membrane, 
and many play a crucial role in initial infection such as transactivation of the immediate 
early promoter, block of major histocompatibility complex I viral antigen presentation, 
release of virus DNA from the capsid, and DNA replication, while other tegument 
proteins are more crucial for packaging and egress of the virus yet come in with the virus 
and therefore have dual functionality (14-20). In addition to protein, there are also 
several species of both viral and cellular RNA present in the tegument including non-
coding and coding RNA (21-23).  Delivery of viral RNA with the tegument may facilitate 
protein expression in the absence of new viral transcription (22). 
The icosahedral capsid is embedded within the tegument and contains the linear 
viral genome which is packaged as naked, non-chromatinized DNA (24).  The virion 
envelope is richly coated with several types of viral glycoprotein receptors, which 
mediate either binding or fusion and entry of virion contents (25). Contents of the 
tegument as well as the intact capsid are released into the cytoplasm and, in the case of 
the capsid, transported to the nucleus for replication of the viral genome.  Genetic 
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material is occupied with histones and chromatinzed after deposition into the nucleus. 
After replication, the HCMV genome has a unique capability to isomerize and form any 
of four different architectures as a result of inversion of two unique segments flanked by 
inverted repeats (Figure 2).  The significance of this ability is unknown as each isomer 
results in equally infectious particles and “frozen” viruses lacking the ability to isomerize 
are also equally fit (1). 
 After DNA replication and packaging, the viral capsid is transported via cellular 
transport mechanisms and goes through a series of envelopment and de-envelopment 
processes as it moves from the nucleus through the perinuclear space to the cytoplasm 
(26).  Tegumentation and final envelopment occurs in the cytoplasm along with final 
processing of glycoproteins and eventual egress and budding from the cell.   
 
Epidemiology, Pathology, and Clinical Relevance 
Human herpesviruses are extremely widespread, with as much as 90% of the 
population carrying at least one.  HCMV alone is present in approximately 50-80% of the 
United States population, with 40% infected by 11 years of age and world wide 
anywhere from 50-90% (27-29).  An initial or primary HCMV infection typically occurs at 
‘a’ UL US TRL TRS IRS IRL ‘a’ ‘a’ ‘a’ 
‘a’ UL US TRL TRS IRS IRL ‘a’ ‘a’ ‘a’ 
‘a’ UL US TRL TRS IRS IRL ‘a’ ‘a’ ‘a’ 
‘a’ UL US TRL TRS IRS IRL ‘a’ ‘a’ ‘a’ 









Figure 2.  Human cytomegalovirus genome isomers and 
conformation. Genome is shown in a linear form as four different 
combinations of unique segments.  The circularized genome is also 
shown.   UL: unique long region; US: unique short region; TR/TRL: 
terminal inverted repeat sequence; IR/IRL: internal inverted repeat 
sequence; ‘a’: the ‘a’ repeat sequences. 
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an early age and is generally asymptomatic. However, HCMV is an opportunistic 
pathogen with the ability to reactivate from latency in individuals with a compromised 
immune system.  It is the cause of life-threatening disease and disorders in solid organ 
and bone marrow transplant patients, cancer patients, and AIDS patients (30, 31).  
Vertical transmission from mother to fetus causes severe developmental complications 
and is the number one cause of birth defects in the United States and developed 
countries (32).  
The driving force behind HCMV pathology is a very damaging cycle of lytic DNA 
replication, in which localized virion propagation causes severe tissue necrosis and 
dissemination of virus to further propagate in other tissues throughout the host.  While 
viral replication is quickly suppressed by a competent immune response, this does not 
affect the ability of HCMV to establish latency within the host for reactivation when the 
opportunity arises.  Furthermore, current anti-viral therapies only target actively 
replicating viral DNA and do nothing to purge the host of the virus, leaving them at risk 
for further complications.  The most widely used treatment for HCMV, as well as other 
herpesviruses, are chain terminating nucleoside analogs: ganciclovir and derivatives (31, 
33).  Ganciclovir is a deoxy-guanidine prodrug that is phosphorylated by a viral kinase, 
UL97, and is preferentially incorporated into the actively replicating herpesvirus genome 
by the virally encoded polymerase, UL54, thus uninfected cells are less susceptible the 
toxic effects of ganciclovir.  Unfortunately, ganciclovir has poor bioavailability, many toxic 
side effects, and eventually results in viral resistance from mutations developed in UL97 
and UL54 (31).  
While it’s tempting to continue development of anti-virals targeting actively 
replicating virus, utilizing the more readily available information and experimental 
models, the profound need is really for anti-latency drugs.  Viruses with the ability to 
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enter a state of latency, like herpesviruses, HIV, and human papilloma virus, pose an 
exceptional challenge.  The latent stage can be particularly hard to study and by nature 
of quiescence, typically offers fewer therapeutic targets.  As a result, there is very little 
known about the mechanism of genome maintenance used by HCMV during latent 
infection.  One particular strategy may be to develop drugs that can prevent cells from 
harboring latent HCMV genomes in combination with a “forced” reactivation and 
subsequent inhibition by ganciclovir.  This method can be referred to as “shock and kill” 
when used in an attempt to rouse the latent virus in the presence of anti-virals and a 




 HCMV genome replication can be divided into two mutually exclusive events that 
define the critical stages of the virus’s lifetime, namely lytic and latent  (Figure 1).  It is 
important to understand how lytic infection is differentiated from latency. The lytic stage 
is defined as the period of time when viral DNA replication in permissive cells results in 
release of infectious virion particles and eventually cell apoptosis. The latent stage refers 
to carriage or persistence of viral genomes in the absence of infectious virion production 
and in the presence of limited viral gene expression.  HCMV has a broad affinity for 
infecting many different, if not all, cell types yet it must be appreciated that the cell types 
which are permissive for virion production are generally not permissive for latent genome 
carriage. The different aspects of lytic vs. latent HCMV DNA replication will be discussed 
in further detail. 
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Lytic DNA Replication 
Lytic DNA replication and subsequent virion production can occur in many 
different cell types, including connective tissue fibroblasts, smooth muscle of the 
gastrointestinal tract, and cells of glandular, mucosal, and vascular epithelial origin, with 
the main exception being cells of lymphoid origin (25).  Even in cells not permissive for 
productive infection, or virion production, virus entry and expression of viral gene 
products is still observed. The HCMV genome is linear as packaged in the virion but is 
circularized after entering the nucleus and replicated using a rolling circle mechanism 
with head to tail concatemer formation followed by cleavage into genome length 
fragments and packaging into the viral capsid (35).  
Herpesviral DNA replication requires 6 core proteins for propagation of the viral 
genome, all of which are encoded by the virus and are interchangeable between 
different herpesviruses, however each herpesvirus requires additional, virus specific 
factors  (Table 2) (1).  In the case of HCMV there are 5 additional specialized proteins 
required to replicate the genome. The core proteins are generalized DNA replication 
proteins such as polymerase, single stranded binding protein, helicase, and primase.  
Whereas the HCMV unique proteins perform more specialized functions such as origin 
binding and synthesis initiation, anti-apoptosis, and transactivation of viral and cellular 
gene expression (36).  Other gene products and cellular factors provide ancillary 
functions.  All herpesvirus genomes code for their own replication machinery, which 
subsequently provides the naked DNA with infectious properties and can be used for 
virion production from permissive cells.   
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In addition to the protein repertoire, an important element required in DNA 
synthesis is an origin of replication.  As an immobile cis-acting factor, the significant 
influence of the origin on DNA replication occurs by recruitment of mobile viral and 
cellular trans-acting counterparts to a region of DNA for initiation of synthesis.  In HCMV, 
the origin of replication, oriLyt, is a 3.4 kbp region containing multiple complex functional 
elements including repetitive sequences, A+T rich regions, an oligopyrimidine stretch 
known as the y-block, an RNA-DNA hybrid region with the ability to form a stem loop 
secondary structure, and transcription factor binding sites (37-41).  The RNA-DNA hybrid 
stem loop structure has been shown to interact with the proposed initiator protein UL84, 
which changes the conformation of the RNA structure, possibly contributing to changes 
required for DNA synthesis (38). Transcription factor C/EBPa binding sites within oriLyt 
Table 2. Herpesvirus DNA Replication Proteins 
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interact with UL84 and C/EBPa and may also contribute to replication (42).  A strong 
promoter sequence within oriLyt is essential to replication however it is not known what 
function it contributes (43). Many of the complicated attributes of oriLyt were functionally 
studied in a cell based in vitro replication assay, in which plasmid subclones of the 
requisite 11 replication proteins were transfected into fibroblast cells along with oriLyt 
and DNA replication measured by levels of DpnI digestion resistance (44). 
Some of the most studied and arguably the most dynamic proteins required in 
lytic DNA replication are IE2 and UL84.  The proteins interact with each other, as well as 
function alone and in concert with other cellular and viral factors, including non-coding 
RNA.  Together IE2 and UL84 activate the promoter within oriLyt and while required in 
the context of the transient replication assay, it is still unknown what function this may 
serve (43).  UL84 is required for DNA replication yet it can have a suppressive effect 
when transfected before infection and has a regulatory effect on IE2 transactivation 
activity.  UL84 is considered to be the origin binding protein for lytic DNA synthesis and 
binds RNA present in oriLyt, shuttles viral mRNA, and interacts with viral non-coding 
RNA4.9 (38, 45, 46).  It is mono-ubiquinated and phosphorylated and has been shown to 
exhibit UTPase activity however the implications of these modifications and activity have 
not been determined (47, 48).  UL84 interaction with RNA4.9 is thought to mediate 
polycomb repression complex regulation of immediate early gene expression during 
latent infection (46). 
While HCMV has evolved sophisticated mechanisms for preventing cell 
apoptosis and immune detection, virus production and egress ultimately results in host 
mediated suppression of lytic DNA replication and, as a viral self-protective measure, a 
switch to latency in certain cell types. 
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Latent DNA Replication 
HCMV can infect a broad spectrum of cell types, however in most cell types 
infection is abortive and only a very narrow subset of cells will support carriage of the 
viral genetic material beyond lytic replication and virion production.  This latency 
permissive population of cells is the hematopoietic CD34 (+) stem cells (HSCs) of the 
bone marrow, as well as their myeloid lineage progeniture, CD14 (+) monocytes (49).  
CD34 (+) cells are a self-renewing population and are the major constituent of bone 
marrow, giving rise to both lymphoid and myeloid lineages of circulating immune cells 
(50, 51). 
After initial HCMV infection, lytic DNA replication, and virion production, the host 
immune system quickly suppresses the virus’s lytic machinery but not before the virus 
has a chance to set up latency.  The early stage of latency establishment, or the “switch” 
from lytic to latent infection, is a process requiring the quiescence of many viral genes 
and an alternative mechanism for propagation of the viral genome that does not trigger a 
host response. In HCMV this process is still poorly understood; however, the latent 
CD34 (+) reservoir is known to undergo a process of self-renewal within the bone 
marrow. Therefore the HCMV genome must be renewed with each cell division as well 
and a mechanism for this process must be in place.  
Early experiments have shown that the HCMV viral genome is maintained as an 
episome during latent infection consistent with all other herpesviruses (52).  It was 
reported that the episome is present in 1 out of 100-250 cells at 2-13 copies per infected 
cell in naturally infected peripheral blood monocytes and bone marrow after granulocyte 
colony-stimulating factor mobilization (52, 53). A circular episomal latent conformation is 
conserved among other herpesviruses, and in particular is very well studied in the 
gammaherpesvirus family (54-56).  Gammaherpesviruses, KSHV and EBV (Table 1), 
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have a virally encoded tethering protein that interacts with both the viral episome and 
host chromosomes, linking the viral genome to host chromosomes and recruiting cellular 
replication factors to a latency dedicated origin (57, 58). Latent origins function in a 
mutually exclusive manner from lytic origins, thus allowing for a very specialized 
mechanism of replication that does not trigger an immune response.  In the case of 
KSHV and EBV, a single viral protein accomplishes maintenance and replication of the 
viral genome (LANA and EBNA respectively) (59-63). These proteins are multifunctional 
in that they also regulate cellular processes such as cell cycle and immune response 
(64-68).    It is likely that HCMV employs a similar mechanism of maintenance but this is 
an area that remains very enigmatic.  Identification of a latent origin and a tethering 
protein is a critical piece of information that is vitally needed for HCMV and is addressed 
in the following chapters. 
Interestingly, while CD34 (+) cells are the progenitor for all blood cells, HCMV 
genomic DNA is only passed on to circulating CD14 (+) monocytes and not to the 
lymphoid lineage derived T and B cells (69-71).  CD14 (+) cells maintain the virus in its 
latent state but differentiation into macrophages and dendritic cells causes a cascade of 
events triggering reactivation of the latent viral genome, or renewed virion production 
(72, 73).  The exact mechanism leading to reactivation and stimulation of the major 
immediate early promoter with renewed expression of IE2 remains to be completely 
defined.  
Until recently, the most well studied repertoire of genes expressed during latency 
included only LUNA, UL138, UL111a, UL144, and US28.  Using RNA-seq technology, 
our group described the expression of several more RNA transcripts, including IE1 in the 
absence of IE2 (46, 74-78). UL138 is one of the most extensively studied latently 
expressed viral transcripts.  It was originally identified by analysis of high passage 
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laboratory strain viruses and the observation that a region from UL133-UL151, known as 
UL/b’ and containing UL138 and UL144, is deleted (75).  These laboratory strains do not 
have the ability to establish latency and further analysis has described that the presence 
of the UL/b’ region actually attenuates lytic infection (79).  UL138 has been shown to 
down regulate multi-drug resistance protein MRP during latent infection thus rendering 
infected cells susceptible to chemotherapeutics such as vincristine (80). UL144 is a 
transmembrane glycoprotein with immunomodulatory functions during lytic infection and 
is ancillary during latency but little has been done to characterize its exact role (81).  
UL111a encodes a viral homologue of IL-10, an immunosuppressive cytokine, and may 
function to help HCMV avoid immune detection during latency (82). Studies have shown 
that a LUNA deleted mutant virus in CD14 (+) monocytes fails to reactivate upon cell 
differentiation, suggesting that LUNA may mediate reactivation from latency (74, 78, 83).  
 There have been several proposals on mechanisms for control of viral gene 
expression, in particular immediate early gene expression, during latency.   It has been 
shown that two latency expressed genes LUNA and UL144 are controlled by the 
hematopoietic cell transcription factor GATA-2 (84, 85).  Epigenetic means have also 
been shown to play an important role (84-87).  For example histone deacetylases and 
methylases are recruited to the major immediate promoter for chromatin remodeling 
during latency and reactivation and our lab has shown that a viral long non-coding RNA, 
RNA4.9, also recruits members of the polycomb repression complex to the major 
immediate early promoter and may participate in the increase of the epigenetic 
repressive mark, H3K27me3, and a decrease in the activation mark, H3K4me3, and is 
further discussed in the following chapters (88, 89).  
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Major Immediate Early Promoter and Products IE1 and IE2 
The HCMV Major Immediate Early enhancer/promoter (MIEP) is widely 
considered to be the most robust and universally active cis-acting element used for in 
vitro gene expression.   The transcriptional ability of the MIEP to drive gene expression 
at very high levels in a broad range of cell types has made it invaluable as a molecular 
tool. Unfortunately, the MIEP’s transcriptional strength is matched only by an equally 
strong penchant for transcriptional silencing. These characteristics reflect the virus’s 
fundamental need to balance gene expression necessary for virion production with 
immune evasion, prevention of apoptosis, and ultimately support a life long infection.  
There are different mechanisms proposed for control of the MIEP; however it is well 
established that the highly regulated, temporal expression of MIEP gene products by 
both cellular and viral factors is tightly linked to cell type and differentiation state allowing 
fine-tuning of both lytic and latent infection.   
The MIEP is composed of a modulator, a unique region and an enhancer (90). 
Within the enhancer are multiple repeated transcription factor binding sites for CREB, 
NFKB, Sp1, and RAR-RXR in addition to a cis-repression signal, the CRS (Figure 3A).  
At least one Sp1 site is the minimum necessary for viral replication in fibroblasts, 
however it replicates with severe attenuation.  Heavy mutation of the CRS results in 
inhibition of initiation of viral replication during lytic infection, while accumulation of high 
levels of MIEP products also represses activation, therefore creating a feed-back loop to 
regulate optimal levels of MIEP gene products (91).   
The MIEP controls expression of Immediate Early 1 (IE1) and Immediate Early 2 
(IE2) proteins.  This region is heavily spliced and codes for at least 6 different splice 
isoforms (Figure 3B). IE1 and 2 share two exons at their N termini and then diverge to 
include either exon 4 (IE1 specific) or exon 5 (IE2 specific).  There are several different 
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smaller splice variants for either IE1 or IE2 as well as non-spliced truncated forms of IE2 
that arise from cryptic start sites between exon 4 and 5 (IE2-60) and within exon 5 (IE2-
40, Figure 3B) (92-96).  The region is highly dynamic with respect to both products and 
regulation and allows for high levels of adaptation. 
Within hours of infection, the gene products of the MIEP, IE1 and IE2, are 
expressed and are the first viral genes transcribed de novo. IE1 is more abundantly 
expressed and creates an environment suitable for supporting viral DNA replication by 
Enhancer Modulator Unique 
TATATAA 
CREB/ATF in a 19bp repeat 
C/EBP 
SP1, YY1, & ERF in a 21bp repeat 
NF-kB in an 18bp repeat 













Figure 3.  Major Immediate Early Promoter and gene products. 
A) HCMV Major Immediate Early Promoter is divided into a modulator, unique, and enhancer regions.  
Transcription factor binding sites, IE2 responsive cis- repression sequence, and start of transcription are 
indicated. 
B) Splice isoforms and products of the major immediate early promoter.   
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modulation of the host immune response.  However, IE1 is dispensable for viral DNA 
replication at higher multiplicity of infection (MOI), while IE2 is unequivocally required for 
DNA replication as evidenced by mutant HCMV virus with deletions in exon 5 as well as 
in a transient replication assay (44, 97-99).  While not required for lytic replication when 
high MOI conditions are used in vitro, experiments with IE1 mutant viruses have shown 
that at lower MOI, which is considered to be a more accurate depiction of the natural 
infection environment, IE1 mutants are attenuated.  During a natural infection viral input 
is lower than in the case of experimental infection when MOI several orders higher than 
in an in vivo setting can be achieved.  Furthermore, it was shown that when a clinical 
isolate of virus is used in an experimental setting, as opposed to the highly passaged 
and adapted laboratory strains, even a high MOI could not overcome the replication 
deficiency that is a result of IE1 deletion, further evidence that IE1 is critical to viral 
fitness under conditions that closely mimic natural infection (100).    
The earliest and most well studied mechanism of IE1 immune modulation is 
interaction with and dispersal of promyelocytic leukemia (PML) associated nuclear 
bodies (PODs), also known as nuclear domain 10 or ND10 (101-103).   PML nuclear 
bodies are a component of the nuclear matrix that are implicated in regulation and 
scaffolding for DNA replication, transcriptional activity, and anti-viral activity of DNA 
viruses (104, 105).  PODs are formed by multimerization of the individual PML subunits 
when sumoylated and organized into higher order spherical structures that recruit and 
contain additional factors with anti-viral activity, such as Sp100, Daxx, and ATRX (106-
113).   The mechanism of IE1 mediated POD dispersal has been shown to be through 
de-sumoylation of the POD oligomers resulting in disruption of the higher order 
structures (114, 115). It has also been proposed that the transactivational activity of IE1 
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could be mediated through interaction with PODs and disruption of associated 
transcription (115).   
IE1 is also capable of modulating host immune response by interrupting the type 
I Interferon pathway (IFN-α and IFN-β stimulated) through interaction with STAT1 and 
STAT2 in the nucleus and preventing their association with IFN responsive promoters 
(116).   Furthermore, unphosphorylated STAT3 is sequestered by IE1 in the nucleus 
thereby interrupting the canonical STAT3 signaling pathway, which relies on 
phosphorylation of STAT3 by Janus kinase (JAK) in the cytoplasm for transcriptional 
activity (117).  Additionally, inhibition of STAT3 expression severely attenuates viral DNA 
replication suggesting that IE1 mediated sequestration of STAT3 in the nucleus may be 
intended for initiation of viral DNA replication (117). 
IE1 has been shown to function as a transactivator of both cellular and viral gene 
expression.  No direct DNA binding has been shown; however, IE1 promiscuously forms 
complexes with transcription factors, histone modifying enzymes, and histones 
themselves, thereby usurping their functionality for the purpose of viral transcription and 
modification of the cellular environment (100, 118-122).  IE1 also creates a proliferative-
like environment and induces cellular replication machinery by interaction with a cell 
cycle regulator, p107, resulting in activation of E2F transcription factor and upregulation 
of cyclin E (115, 123-126).  
Early on, IE1 was observed to interact with mitotic chromosomes (14).  More 
recently, crystal structure studies have further defined the mechanism of this interaction 
by showing that IE1 interacts specifically with the nucleosome pocket of the H2A-H2B 
dimer (127, 128).  Together with data suggesting that IE1 mediates nucleosome 
deposition on the HCMV genome upon release into the host cell nucleus, these studies 
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point to a model of transcription regulation via chromatin organization in addition to 
regulation via binding of transcription factors and regulators (100).   
The IE1 protein can be divided into different functional groups whose respective 
activities can operate independent of each other are termed the N-terminus, globular 
domain (GD), acidic domain (AD), and chromatin tethering domain (CTD) (Figure 4).  
The N-terminus contains a nuclear localization signal and the first 85 amino acids are 
shared with IE2, which corresponds to exons 2 and 3.  As part of exon 4, the central GD 
is unique to IE1 and constitutes the largest portion of the protein.  The GD is a highly 
ordered hydrophobic region whose functionality is very sensitive to mutations and is both 
necessary and sufficient for disruption of PML bodies and transactivation of cell cycle 
progression via interaction with the growth inhibitor protein, p107 (115, 123-126).  
Following the GD are two highly disordered and acidic residue rich regions: the AD and 
the CTD. The AD is 56 amino acids long, interacts with STAT proteins and is the only 
portion of IE1 able to complement the MOI dependent growth defects observed in IE1 
mutant viruses (129).  The CTD is a mere 16 amino acids long, yet alone it is sufficient 
for targeting green fluorescence protein GFP to mitotic chromosomes and docking on 













Figure 4. Functional domains of immediate early protein 1 (IE1).  Shown 
are the known functions of IE1 protein domains. NLS = nuclear localization 
signal, AD = acidic domain, CTD = chromatin tethering domain, aa = amino 
acids.  
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IE1 has a single sumoylation site at lysine 450. Sumoylation of IE1 has been shown to 
not be necessary for POD disruption, but is necessary for STAT2 interaction and there 
are conflicting reports of whether it is required for lytic replication (115, 129, 131, 132).	   
It would be extremely detrimental to both host and virus if lytic HCMV DNA 
replication proceeded unchecked without quiescence, resulting in immune system 
detection and clearance, or in the absence of a competent immune response, host 
disease and death – neither situation is desirable for viral propagation. Similarly, it would 
be disadvantageous if lytic replication were not initiated on occasion, via reactivation 
from latency, for spread of viral progeny to other hosts.  Furthermore, without a 
mechanism for surreptitiously passaging the viral genome among cells, utilizing a latent 
origin of DNA replication, the virus would ultimately be diluted out. This complicated 
environment required for optimal livelihood of herpesviruses, necessitates an equally 
comprehensive mechanism for infection such that the virus can be turned on and off 
readily, yet judiciously, to maintain the balance between host and virus.   
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HYPOTHESIS 
The mechanism of viral DNA retention during HCMV latency is unknown and 
there is a critical need to identify HCMV genomic DNA elements that contribute to viral 
genome persistence.  Therefore, our goal is to understand the mechanism of HCMV 
genome replication/maintenance in latently infected cells by defining the viral trans factor 
responsible for maintenance and tethering of the latent episome.  Next generation RNA-
sequencing of the latent HCMV transcriptome in CD34 (+) cells surprisingly revealed 
expression of IE1.  IE1 has previously been shown to tether to mitotic chromosomes 
during lytic infection however it has never been shown to be expressed during latency 
and the tethering function has been an enigma.  While not known to directly bind DNA, 
IE1 has several different functional protein motifs and binding domains that have been 
well characterized and may serve a function in tethering during latency.  Utilization of 
separate DNA binding domains to act as a bridge between DNA elements is a well-
characterized mechanism employed by gamma herpesvirus proteins LANA (KSHV) and 
EBNA (EBV) for tethering of the viral genome to cellular chromatin during latency.  
Functional homology between IE1 and the established episome maintenance proteins 
LANA and EBNA, together with RNA-seq data showing expression of IE1 in HCMV 
latent CD34 (+) has led us to form the following central hypothesis: IE1 along with 
cellular factors, mediates maintenance and replication of the latent virus genome via 
interaction with the terminal repeat region.  Our hypothesis has been formulated on the 
basis that IE1 is expressed during latency and has a known chromatin tethering function.  
These aspects of IE1 in HCMV latency could be indicative of a tethering function, a role 
not associated with any other HCMV protein to date.  The rationale for the following 
research is that the elucidation of the mechanism of HCMV genome latency will greatly 
facilitate the generation of innovative approaches to eradicate HCMV latent infection.  
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 The parameters involved in human cytomegalovirus (HCMV) latent infection in 
CD14 (+) and CD34 (+) cells remain poorly identified.  Using next generation sequencing 
we deduced the transcriptome of HCMV latently infected CD14 (+) and CD34 (+) cells in 
experimental as well as natural latency settings.  The gene expression profile from 
natural infection in HCMV seropositive donors closely matched experimental latency 
models, and included two long non-coding RNAs (lncRNAs), RNA4.9 and RNA2.7 as 
well as the mRNAs encoding replication factors UL84 and UL44.  Chromatin 
immunoprecipitation assays on experimentally infected CD14 (+) monocytes followed by 
next generation sequencing (ChIP-Seq) were employed to demonstrate both UL84 and 
UL44 proteins interacted with the latent viral genome and overlapped at 5 of the 8 loci 
identified.  RNA4.9 interacts with components of the polycomb repression complex 
(PRC) as well as with the MIE promoter region where the enrichment of the repressive 
H3K27me3 mark suggests that this lncRNA represses transcription.  Formaldehyde 
Assisted Isolation of Regulatory Elements (FAIRE), which identifies nucleosome-
depleted viral DNA, was used to confirm that latent mRNAs were associated with 
actively transcribed, FAIRE analysis also showed that the terminal repeat (TR) region of 
the latent viral genome is depleted of nucleosomes suggesting that this region may 
contain an element mediating viral genome maintenance.  ChIP assays show that the 
viral TR region interacts with factors associated with the pre replication complex and a 
plasmid subclone containing the HCMV TR element persisted in latently infected CD14 
(+) monocytes, strongly suggesting that the TR region mediates viral chromosome 







Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus where infection is usually 
subclinical.  HCMV initial infection is followed by the establishment of latency in CD34 
(+) myeloid cells and CD14 (+) monocytes.  Primary infection or reactivation from latency 
can be associated with significant morbidity and mortality can occur in immune 
compromised patients.  Latency is marked by the persistence of the viral genome, lack 
of production of infectious virus and the expression of only a few previously recognized 
latency associated transcripts.  Despite the significant interest in HCMV latent infection, 
little is known regarding the mechanism involved in establishment or maintenance of the 
viral chromosome.  We have now identified the transacting factors present in latently 
infected CD14 (+) monocytes and CD34 (+) progenitor cells as well as identification of a 
region of the HCMV genome, the terminal repeat locus that mediates viral DNA 
maintenance.  This is a major step toward understanding the mechanism of HCMV latent 
infection.   








 Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that infects 60-90% 
of the population and is usually subclinical, however virus infection can cause severe 
disease and mortality in immune compromised patients [1].  Disease manifestations 
include retinitis, pneumonia and hepatitis [2].  
 HCMV lytic phase of infection is typically studied in cell culture using human 
fibroblasts (HFs) and viral encoded genes are expressed in a temporally regulated 
manner.  HCMV lytic DNA replication requires cis and trans acting factors and results in 
the production of infectious virus [3-9].  Recent high-resolution transcriptome mapping 
during a lytic HCMV infection, revealed a complex pattern of transcription [10].  This 
analysis also showed that during lytic infection most viral RNA production is 
concentrated in four long non-coding RNAs (lncRNAs), RNA2.7 (also known as ß2.7), 
RNA1.2, RNA4.9, and RNA5.0 [10].  The high expression level of viral encoded lncRNAs 
suggests that that these transcripts may be significant factors for regulating viral and 
cellular processes required for efficient viral replication.     
 Herpesvirus latency is defined as the persistence of the viral genome in the 
absence of production of infectious virus.  Certain properties of latency have emerged 
from study of the gamma herpesviruses including maintenance of the viral chromosome 
is as a circular episome [11], which is controlled by virus-encoded proteins that interact 
with viral and host cell chromatin [12-23].  With respect to maintenance and replication of 
the HCMV DNA episome, previous studies have quantified the number of genomes 
during experimental and natural infection [24,25].  However the cis acting element 
required for maintenance of the viral genome is unknown. Lifelong HCMV latency is 
established in myeloid lineage, from bone marrow-derived CD34 (+) progenitors through 





DNA without supporting lytic replication although virus can be reactivated and recovered 
through differentiation [34-40].  The regulation and maintenance of latency is poorly 
understood although reactivation of latent virus is a major source of virus associated with 
serious disease and mortality in immunocompromised hosts, hence a better 
understanding of HCMV latency may lead to treatments to resolve latent HCMV 
genomes from infected cells.  Differentiation of CD34 (+) or CD14 (+) cells, to 
macrophages or dendritic cells through the use of various cytokines results in 
reactivation and subsequent production of infectious virus [41-45].  Several in vitro 
experimental systems have been developed to study HCMV latency.  These systems 
use either cultured CD14 (+) monocytes or CD34 (+) hematopoietic stem cells.  CD14 
(+) or CD34 (+) cells cultured in vitro can be infected with HCMV clinical strains, 
resulting in latent infection and efficient reactivation of latent virus [26,37,43,46,47].  
 The mechanism of HCMV latent infection is unknown and the mechanism 
involved in the establishment and maintenance of the latent virus genome has not been 
addressed in either natural or experimental models of latency.  In experimental models, 
as well as during natural latency in CD34 (+) and CD14 (+) cells, a limited number of 
latency specific HCMV transcripts have been identified [41,42,48,49].  Three consistently 
identified viral genes expressed during latency are UL138, a TNF modulator, UL111A, a 
variant cmvIL-10 cytokine and the UL81-82 antisense transcript encoding LUNA 
[41,50,51].  HCMV UL138 is expressed during, though dispensable for HCMV lytic 
replication such that UL138 mutant viruses altered latency [41,52,53].  This may result 
from the fact that UL138 has been shown to upregulate TNFR1 and sensitizes infected 
cells to TNFα [54,55].  UL138 has been shown to interact with proteins encoded by 
nearby genes within the UL133-UL138 locus [52].  HCMV latency UL111A transcript 





viruses that lack the ability to express UL111A are capable of establishing latency and 
efficiently reactivate, however latently infected cells express higher levels of surface 
MHC class II in the absence of UL111A expression and suggests that UL111A may 
function to inhibit the recognition of latently infected cells by CD4 (+) T cells [57].   The 
expression of LUNA during lytic infection is regulated by IE72 expression and the 
interaction with hDaxx [58].  LUNA has recently been implicated as having a role in virus 
reactivation [59].  
 To elucidate the factors involved in HCMV latency, we infected CD14 (+) 
monocytes or CD34 (+) progenitor cells with an HCMV clinical isolate [37,46].  We have 
now used these experimental latency protocols, coupled with next generation 
sequencing, to reveal the complete high-resolution HCMV transcriptome (RNA-Seq) 
during early and latent infections.  RNA-Seq analysis shows that during HCMV 
experimental and natural latency in CD14 (+) monocytes, viral transcripts encoding 
UL44, UL84, UL95, UL87, UL52, UL50, LUNA, UL138 and the lncRNAs 2.7 and 4.9 
were detected.  For latently infected CD34 (+) cells, all of the mRNAs detected in latently 
infected CD14 (+) cells were present, however additional transcripts encoding UL28/29, 
UL37/38, UL114, UL133/135 and US17 were also detected.  Using chromatin isolation 
by RNA purification (ChIRP), lncRNA4.9 was shown to physically interact with the HCMV 
major immediate early promoter region and results in an enrichment of the repressive 
H3K27me3 mark at the MIEP during latency suggesting that HCMV latent genomes are 
silenced by PRC2 interaction.  
 To address the HCMV cis requirements for latency, we show that a plasmid 
containing the terminal repeat (TR) element persisted in latently infected cells, strongly 






Materials and Methods 
 Isolation of CD14 (+) and CD34 (+) cells from blood.  Cord blood was received 
from the Colorado Cord Blood Bank (Univ. of Colorado).  Pooled peripheral whole blood 
for natural infection studies was obtained from Renown Medical Center (Reno, NV) and 
processed with in 5 hours to isolate CD14 (+) or CD34 (+) cells.  All protocols to obtain 
blood products were approved by IRB and Office of Human Research Protection.  The 
pooled blood samples represented approximately 25 individual HCMV seropositive 
donors.  Cells were isolated using human cord blood CD34 positive selection kit 
(Stemcell technologies) according to manufacturer’s instructions.  Briefly, samples were 
incubated with a pre-enrichment cocktail containing antibodies directed against CD66b 
and glycophorin A. This was step was performed for negative selection of granulocytes 
and erythrocytes.  CD34 selected cells were retained from the non-selected cells by the 
use of the EasySep magnet. Cells were resuspended in culturing media or for natural 
infection studies immediately processed to extract total RNA.  Human CD14 (+) were 
isolated using positive selection MACS bead and LS columns (Miltenyi Biotec) according 
to manufacturer’s instructions and cells were resuspended in culturing media or 
immediately processed to extract total RNA. 
 Purity of isolated CD14 (+) and CD34 (+) was assessed by flow cytometry using 
antibodies for human CD14-FITC or CD34-FITC (Miltenyi Biotec), along with human 
CD45-Pacific Blue (BioLegend) for total cell staining.  Isotype controls included IgG2a-
FITC (Miltenyi Biotec) and IgG1-Pacific Blue (BioLegend).  Approximately 0.5 x 106 cells 
were stained for 30 minutes at 4°C with the fluorescently labeled antibody, washed once 
and resuspended in 1X PBS with 0.5%FBS, 2 mM EDTA and 1% methanol-free 
formaldehyde.  Cells were determined to be free from red blood cells and >95% CD34 





 HCMV natural infection was evaluated from pooled blood from 25 seropositive 
individual donors.  From 120 ml of pooled blood approximately 175,000 CD34 (+) cells 
and 32 x 106 CD14 (+) were isolated, total RNA was extraction and DNase treated, 
resulting in 300 ng of RNA for CD34 (+) and 28.5 mg of RNA for CD14 (+).  The RNA 
was used generate a sequencing library as described below. 
 Culturing conditions for CD14 (+) and CD34 (+) cells.  CD34 (+) cells were 
cultured in IMDM supplemented with 10% BIT serum substitute (StemCell Technologies), 
2 mM L-glutamine, 20 ng/ml low-density lipoprotein (Sigma Aldrich), 50 mM 2-
mercaptoethanol, 10 ng/ml Stem Cell factor, 10 ng/ml IL-3, 10 ng/ml G-CSF (R & D 
Systems)[26,41,60] or cultured in X-Vivo 15 (lonza) [27].  Media was refreshed every 
three days until latency had been established and verified.  To reactive latent virus, 
CD34 (+) cells were stimulated to proliferate and differentiate with the addition of 10 
ng/ml GM-CSF, 10 ng/ml Flt-3 ligand, 10 ng/ml TPO, and 10 ng/ml TNF for three days, 
followed by the addition of 50 ng/ml lipopolysaccharide (LPS) (Sigma-Aldrich) for an 
additional four days. 
Human CD14 (+) cells purchased (Lonza and ReachBio) or isolated from cord 
blood were maintained in Iscove DMEM (Hyclone) supplemented with 20% heat-
inactivated FBS (Atlanta Biologicals), 50 ng/mL M-CSF, 50 ng/mL stem cell factor (SCF), 
50 ng/mL G-CSF, 50 ng/mL GM-CSF, 50 ng/mL IL-3 (R&D Systems) at a density of 1 x 
106 cells/mL on low cell-binding plates (Nunc Hydrocell).  Medium was replaced every 3 
days.  BAC-derived FIX strains were propagated in human foreskin fibroblasts (HF) 
cells.  After 12-14 days post infection cells were scraped and subjected to a freeze-thaw 
to release virus from the cells.  Virus titer was determined with standard plaque assay on 





multiplicity of 5 pfu/cell.   Cells were incubated with virus for 1 hr.  Cells were then 
washed twice with Hanks Balanced Salt solution (HBSS). 
HCMV infected CD14 (+) or CD34 (+) cells were maintained and monitored for 
HCMV gene expression by qPCR analysis.  Latency was determined to be established 
when no IE2 gene expression was detected by qPCR, detection of the virus genome and 
expression of LUNA and UL138.  For reactivation of latent virus, CD14 (+) cells were 
differentiated by adherence to plastic tissue culture dishes supplemented with 100 
ng/mL IL-6 (R&D Systems) at 16-18 days post infection.  The reactivation from latency in 
either CD14 (+) or CD34 (+) was monitored for IE2 gene expression using qPCR. 
 For UV inactivation, 120 mls of 5 X 106 pfu/ml of FIX BAC virus was evenly 
distributed in a thin layer onto a 150 mm tissue culture dish.  The virus was irradiated on 
ice in a Stratalinker 2400 (Stratagene) for 4 min at 9.9 x 105 mJ.  UV inactivation was 
confirmed by the absence of immediate-early (IE) gene expression in infected human 
foreskin fibroblasts using qPCR. 
 Co-culturing conditions of HF’s and CD34 (+).  Human foreskin fibroblast cells, 
maintained in DMEM supplemented with 10% FBS, were plated in a 6-well tissue culture 
plate at 0.1 x 106 cells per well.  24 hours after plating half of the media was removed 
and replaced with reactivated CD34 (+) cells (approximately 0.5 x 106) along with its’ 
media.  Cells were co-cultured together for 10-12 days and monitored by the 
appearance of green plaque formation in the HF cells. 
Next generation sequencing (strand specific RNA-Seq) of experimentally or 
naturally infected CD14 (+) and CD34 (+) cells.  Total RNA from experimentally or 
naturally infected (as determined above) CD14 (+) or CD34 (+) cells was isolated using 
PureLink RNA mini kit (Life Technology) followed by removal of genomic DNA using 





Dynabeads oligo (dT)25 (Life Technology) according to manufacturers instructions.  The 
resulting Poly-A RNA was used in dUTP based NEXTflex Directional RNA-Seq Kit with 
Illumina compatible adaptors (Bioo Scientific) according to manufacturers instructions.  
The resulting libraries were verified on a Bioanalyzer High sensitivity DNA chip (Agilent) 
and quantified with real-time PCR using Illumina compatible kit and standards (KAPA).  
Final libraries were sequenced using an Illumina MiSeq instrument.  HCMV transcript 
discovery and alignment was performed using CLC Genomics Workbench software and 
strand specific RNA-Seq parameters. Transcripts were aligned to the Fix strain 
(VR1814) reference genome.  
 Chromatin Isolation by RNA purification (ChIRP).  Tiling of RNA 4.9 with 
biotin labeled DNA probes retrieves specific RNA 4.9 bound proteins and DNA 
sequences.  Original protocol is from Chu et al [61].  All probes were biotinylated at the 3’ 
end with an 18-carbon spacer arm; probes were designed against RNA 4.9 full-length 
sequence using an online designer at http://www.singlemoleculefish.com, and 
synthesized at Protein and Nucleic Acid Facility (Standford University).  Samples were 
processed as described previously [62].  Eluted DNA was resuspended in 50 ml of water 
and used for end point PCR.  Primers for the PCR include MIEP-1 forward: 
GTGTTTGTCCGAAATACGCG, reverse: GCCTCATATCGTCTGTCACC; MIEP-2 
forward: GTTACATAACTTACGGTAAATGGCC, reverse: CCAAAACCGCATCACCATG; 
MIEP-3 forward: GATTTCCAAGTCTCCACCCC, reverse: 
GCGGTACTTACGTCACTCTTG; MIEP-4 forward: CCCCGCTTCCTTATGCTATAG, 
reverse: AAGAACCCATGTCCGGAAC; MIEP-5 forward: CTCCTTGCTCCTAACAGTGG, 
reverse: GTACTGCTCAGACTACACTGC; UL19 forward: 
CCTGTATGAGCTGTTTCGACG, reverse: GACTCACATCTAGCTCGTCTTC.  ChIRP 





 Supernatant Virus Detection by real-time PCR.  For CD14 (+) and CD34 (+) 
culturing media was changed every three days in order to replenish nutrients and 
cytokines necessary to maintain the cell in culture.  The supernatant that was removed 
from the cells was collected and used for quantitative real-time PCR to obtain relative 
values for the amount of virus being produced.  The supernatant was subjected to two 
low speed spins, 400 x g for 10 minutes in a table top centrifuge to remove any residual 
cells.  For the real-time PCR reaction 5 ml of supernatant was used in a total reaction 
volume of 20 ml using Taqman Universal 2X master mix (Life Technology) and 20X 
primer-probe (IDT).  Relative Ct values of viral supernatant DNA were correlated to 
standard curve from a known concentration of purified FIX-BAC DNA.   
 Trypan blue exclusion test of cell viability.  Cell viability, density and growth 
was monitored by using trypan blue exclusion test.  Briefly, cells were gently 
resuspended and a small aliquot was removed.  A 1:1 dilution of cell suspension and 
0.4% Trypan Blue solution (MP Biomedicals) was counted in a hemacytometer to 
determine and monitor total number of live cells.   
 H3K27me3/H3K4me3 ChIP and quantitative real-time PCR analysis.  
Evaluation of changes in histone modifications was performed as previously described 
[62].  Fold-enrichment of histone marks at various genomic loci was calculated as IgG-
subtracted %Input of the locus normalized by the IgG-subtracted %Input of the reference 
gene GAPDH.  3 separate experiments were performed.  PCR primers are listed in 
Table S4 in Text S4. 
 Transfection of demethylases JMJD3 and UTX into latently infected CD14 
(+) cells.  5 x 106 latently infected CD14 (+) cells were transfected with 2.5 mg each of 
JMJD3-HA and UTX-HA expression plasmids (Addgene), or 5 milligrams of GFP-control 





Nucleofector device and Amaxa Human Monocyte Nucleofector kit (Lonza) according to 
manufactures instructions.  Transfection efficiency was monitored by GFP expression.  
72 hours post transfection RNA and protein was harvested using RNA/DNA/Protein 
purification kit (Norgen BioTek Corp.).  Total RNA was subjected to removal of genomic 
DNA using Turbo DNA-free (Life Technology) according to manufacturers instructions.  
The purified RNA was then used for cDNA synthesis as previously described.  The 
resulting cDNA was quantified using real-time PCR and Taqman primers targeting 
specific HCMV transcripts.   
 Expression of UTX and JMJD3 was confirmed by Western blot where total cell 
protein extracts were resolved by SDS-PAGE gel that was subsequently transferred to a 
polyvinylidene difluoride (PVDF) membrane, blocked with 5% nonfat dry milk powder in 
1X TBST buffer and reacted with antibodies specific for HA-tag (Sigma-Aldrich).  After 
one hour incubation with the primary antibody the membrane was washed in 1X TBST 
three times 5 minutes each.  The secondary antibody donkey anti-mouse IgG 
conjugated to Alexa Fluor-680 (Life Technology) was diluted in blocking buffer and 
added to the membrane for 30 minutes as which time it was again washed with 1X TBST 
three times 5 minutes each.  Specific proteins bands were visualized using the Odyssey 
by LI-COR. 
Real-time PCR (qPCR).  Total RNA was isolated from cells using PureLink RNA 
mini kit (Life Technologies), followed by removal of genomic DNA using Turbo DNA-free 
(Life Technologies).  cDNA was synthesized from 1 mg of total RNA in the presence of 
random hexamers, dNTPs, and Superscript III reverse transcriptase (Life Technologies).  
The resulting cDNA was then used along with Taqman Universal PCR Master Mix (Life 
Technologies) and specific primers and FAM labeled probes (IDT) in an Eppendorf 





minutes, and forty cycles of 95°C for 15 seconds and 60°C for 1 minute.  Primers used 
for detection of specific gene expression are shown in Table S3 in Text S1.  
UL84 and UL44 ChIP-Seq. 4-5 x 106 latently infected CD14 (+) monocytes were 
cross-linked by the addition of formaldehyde to a final concentration of 1%, incubated at 
room temperature for 10 minutes and quenched with 0.125M glycine.  After washing with 
ice cold PBS, cells were lysed in 1 ml/5 x 106 cells ice-cold lysis buffer (0.5% NP-40, 150 
mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA, and protease inhibitors).  Lysed cells were 
dounced followed by collection of the crude nuclear extract by centrifugation.  The 
nuclear pellet was resuspended in 1 ml of RIPA (50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
Triton-X, 0.1% SDS, 0.5% sodium deoxycholate, 1 mM EDTA) and sonicated with a 
Fisher Scientific Sonic Dismembrator and micro-tip at 40% amplitude for 40 cycles of 
20s on followed by 20s off in a wet ice bath.    The sonicated chromatin was collected by 
centrifugation at 20,000 xg for 15 min at 4oC to remove cellular debris.   Chromatin 
shearing to 150-200bp fragments was confirmed by agarose gel electrophoresis.  100 ul 
of chromatin was reserved for input library preparation and the remainder was pre-
cleared for 1 hour at 4oC with 100ul normal mouse IgG sepharose beads followed by 
incubation overnight with 20 ug UL84 or 100 ug UL44 mAb.  200ul of Active Motif 
magnetic IgG coated beads were prepared by blocking overnight with 5 mg/ml BSA and 
200 ug/ml yeast tRNA (Ambion) in PBS.  Beads were washed once with 5 mg/ml BSA in 
PBS and added to immunoprecipitated chromatin.  Immunoprecipitation was performed 
for 4-5 hours at 40C.  The beads and immunoprecipitated complexes were washed at 
room temperature with rotation twice for 1 min with RIPA, five times for 5 minutes each 
with LiCl2 buffer (500mM LiCl2, 100mM Tris pH 7.4, 1% NP-40, 1% sodium 
deoxycholate), and one brief wash with TE (10 mM Tris, pH 8.1, 1 mM EDTA).  DNA 





NaHCO3) and reversed cross-linked overnight at 650C.   Reserved input DNA was also 
reverse cross-linked and treated the same as ChIP samples from this point forward.  
Reversed cross-linked UL84 ChIP DNA or UL44 Chip DNA and respective Input DNA 
were purified with a Qiagen min-Elute kit.  Purified DNA was quantified using an 
Invitrogen Qubit Flourometer and sequencing libraries were created from 10 ng of ChIP 
or Input DNA with a Bioo Scientific NEXTflex ChIP-Seq library preparation kit (#5143-01).  
Library integrity was analyzed with an Agilent 2100 Bioanalyzer and quantified using a 
KAPA q-PCR kit.  12 pM each of UL84 ChIP or UL44 ChIP library and 6 pM of 
respective Input library were sequenced on an Illumina MiSeq.  ChIP-Seq data analysis, 
including read mapping to FIX genome (VR1814) and peak calling was performed using 
CLC Genomics Workbench with a maximum false discovery (FDR) rate of 5%, a window 
size of 250 bp, and reads were shifted based on a length of 200 bp.  The data is the 
result of four separate experiments. 
Reverse Transcription PCR (RT-PCR).  10 x 106 CD14 (+) or CD34 (+) cells 
were infected with FIX virus and cells were monitored for IE gene expression using 
qPCR.  Once latency had been established, approximately 18 dpi, total RNA was 
isolated from cells using PureLink RNA mini kit (Life Technologies), followed by removal 
of genomic DNA using Turbo DNA-free (Life Technologies).  The resulting RNA was 
used with Qiagen OneStep RT-PCR kit with primers designed to mRNA shown in Table 
S3 in Text S3. 
RNA cross-linking Immunoprecipitation (RNA CLIP).  20 x 106 CD14 (+) cells 
were infected with FIX virus.  18 days post infection cells were harvested and processed 
as described previously [62].  RNA-protein complexes were precipitated by adding 300µl 
lysate, 5 µl antibody, UL84, UL44, SUZ12 (Active motif, cat. # 39357), EZH2 (Active 





(Active Motif), and 1 µl RNase Out.  Primers used for PCR are shown in Table S1 in Text 
S1. 
 Transfection of CD14 (+) monocytes and Gardella gels.  CD14 (+) monocytes 
were infected with BAC-derived FIX virus at a multiplicity of 5 pfu/cell.  Cells were 
maintained and monitored for HCMV gene products by qPCR analysis.  Latency was 
determined to be established when no IE gene expression was detected by qPCR 
analysis.  After established latency pGEM7zf(-), pGEM-oriLyt, or pGEM-TR plasmids (4 
ug) were added to 3 x 106 CD14 (+) latent or control non-infected cells using 
Nucleofector 2b device and Human Monocyte Nucleofector kit (Lonza) according to 
manufacture’s instructions for program Y-001 on the device.  Transfected cells were 
immediately transferred to 12-well low cell-binding plates (Nunc Hydrocell) containing 
37°C prewarmed media and placed back into 37°C/5% CO2 incubator.  Cells were 
evaluated for viability using trypan blue and for transfection efficiency using a spike of a 
plasmid expressing EGFP.  Cells were determined to be 80 % viable and a transfection 
efficiency of over 70 % was achieved.  For analysis of transfection input, 24hrs post 
transfection total DNA from 2 x 105 cells was harvested using Norgen DNA/RNA/Protein 
purification kit according to manufacture’s instructions.  DNA was eluted from the column 
in 100 mls of DNA elution buffer, 50 mls was then used for EcoRI (New England Biolabs) 
restriction digest.  The total sample of EcoRI digested DNA was loaded onto a 0.8 % 1X 
TAE (40 mM Tris-HCl, 20 mM Acetic Acid, 1 mM EDTA) agarose gel and 
electrophoresed in 1X TAE buffer until the dye front reached the bottom of the gel.  For 
analysis of plasmid maintenance, approximately 2 million latently infected and 
transfected (15 dpt) CD14 (+) cells/well were prepared, loaded, and electrophoresed on 
Gardella gels as previously described [63]. DNA was transferred to Zeta-Probe 





instructions and hybridized to using a 32P-labled pGEM probe.  Membranes were 
hybridized with 5 ng of probe in 10 ml of hybridization buffer (1.5X SSPE, 1 mM EDTA, 
7% sodium dodecyl sulfate [SDS], 10% [wt/vol] polyethylene glycol) for 16 hrs at 65°C in 
a hybridization oven (Robbins Scientific).  Post-hybridization washed were performed 
with 2X SSC and 0.1% SDS twice for 15 minutes each at 65°C, and then with 0.1X SSC 
and 0.1% SDS twice for 30 minutes at 65°C.  Southern blot were exposed and visualized 
using the Storm Scanner imaging system (GE Healthcare).   
FAIRE-Seq (Formaldehyde Assisted Isolation of Regulatory Elements).  
FAIRE was performed as previously described [64].  Briefly, 3 x 106 CD14 (+) monocytes 
infected with HCMV strain FIX at 4 dpi or 18 dpi were cross-linked with formaldehyde 
and lysed, followed by sonication to shear chromatin.  10% of the sheared cross-linked 
chromatin was reserved for input and the remainder was extracted twice with 
phenol:chloroform to remove regions of DNA associated with nucleosomes.  The 
aqueous layer containing open regions of the chromatin corresponding to nucleosome 
depletion was reserved, reverse cross-linked, and further purified by ethanol 
precipitation.  Input DNA was also reverse cross-linked and purified by ethanol 
precipitation.  Sequencing library preparation was performed using an Illumina Tru-Seq 
DNA library kit.  Input and FAIRE libraries were sequenced by the University of 
California-Irvine High Throughput Genomics Facility on an Illumina Hi-Seq 2000.  
Approximately 60 million reads per library were generated.   Read alignment with FIX 
strain (VR1814) was done using CLC Genomics Workbench. 
Cloning of HCMV Terminal Repeat.  PCR primers were designed to specifically 
amplify the terminal repeat region using FIX BAC DNA as a template and PrimeSTAR 
GXL DNA polymerase (Takara).  After PCR was completed the product was precipitated 





resuspended in 100 mls of water and 100 mls of 2X Easy-A Master mix (Stratagene) 
was added.  The DNA was incubated at 70°C for 30 minutes and then precipitated with 
1/10 volume 3M NaAcetate and 2.5 X volume 100% ethanol.  The DNA pellet was 
resuspended in 20 ml of water and 3 ml was used in pGEM T-easy (Life Technology) 
cloning reaction according to manufacturers instructions.  The resulting clones were 
subjected to restriction enzyme digestion and DNA sequencing to determine clones with 
the correct insert.  
Chromatin immunoprecipitation assay (ChIP) to identify licensing factor 
interaction with HCMV TR/IR regions.  Each ChIP was performed with chromatin from 
approximately 200,000 latently infected CD14 (+) monocytes.  DNA-protein complexes 
were immunoprecipitated using CDT1 (Abcam, ab70829), MCM3 (Abcam, ab4460), or 
an isotype control antibody.  PCR for TR region was performed using PrimeSTAR GXL 
DNA Polymerase (Takara).  Primers to detect the TR region were: Set #1 Forward 5’-
ACA CCT CCG ACG TCC ACT ATA TAC CA-3’/ Reverse 5’-CGT CCA CAC ACG CAA 
CTC CAA TTT-3’ or Set #2 Forward 5’- GGT GAC GTC GGA GAC AGG G-3’/Reverse 
5’- TGC TGT GGT GTA AGG GTA AGG TGT-3’. 
PCR amplification of genomic DNA from latently infected CD14 (+) 
monocytes.  Genomic DNA was isolated from approximately 2 million mock infected, 18 
dpi, and 20 dpi FIX BAC latent CD14 (+) monocytes using a Norgen DNA/RNA/Protein 
purification kit.  Primers amplifying a region within the TR or IR were Forward: 5'-
aacgacagacgaagtacggcacaa-3' and Reverse 5'-acaaacaccgcagaactccttgacg-3'.  Takara 








 High-resolution transcriptome mapping for latent HCMV infection in CD14 
(+) monocytes and CD34 (+) hematopoietic stem cells (RNA-Seq).  Although 
previous studies investigated viral gene expression in HCMV latently infected CD14 (+) 
and primary hematopoietic progenitor cells [26,41,42,46,48,49,65,66], new technologies 
now allow for the high-resolution evaluation of the HCMV latent virus transcriptome.  
While there is little or no understanding with respect to the mechanism involved to 
maintain or replicate the virus genome in a latent environment, we speculate that viral 
encoded factor(s) play a significant role in viral DNA maintenance.  This assumption is 
solidly based on other herpesvirus systems, the most prominent being the gamma 
herpesviruses where at least one virus encoded factor is required for viral genome 
maintenance and replication [14,15,67-71].  Hence, the first step in identifying likely 
candidates involved in viral genome maintenance/replication is to identify all viral 
encoded transcripts present during latent infection.   
 CD14 (+) monocytes were cultured as previously described using specific growth 
media and culture plates that did not allow attachment/differentiation of cells [46].  
Undifferentiated CD14 (+) monocytes were infected with the FIX BAC clinical isolate 
virus strain and viral immediate early (IE1/IE2), LUNA and UL138 transcript levels were 
measured at various days post infection using qPCR (Fig. 1).  Immediate early mRNA 
was detected at days 2, 4, 7 and 11 days post infection (Fig. 1).  Immediate early gene 
expression was no longer detected by 14 days post infection (Fig. 1) suggesting that 
HCMV virus genomes were not producing immediate early proteins and lytic replication 
had concluded.  LUNA and UL138 transcripts were still detected, indicating that the virus 
entered the latent phase (Fig. 1).  HCMV genomic DNA was measured from infected 





latently infected cells at approximately 4 copies per cell at 18 days post infection.  Viral 
DNA was also detected using traditional PCR at 5 and 18 days post infection (Fig. 1, 
inset).  We also measured viral genome copy number over a 26-day period of infection 
(Fig. 1B).  Viral genomes were present at approximately 4 copies per cell during latent 
infection at 16 days post infection (Fig. 1B). Cells were monitored during infection and 
analyzed to ensure the absence of macrophage or dendritic cell markers (CD11c+, 
CD11b+, CD141+, CD303+, CD11b+, CD68+, CD80+).   
 For RNA-Seq, total cellular RNA from latently infected CD14 (+) monocytes was 
extracted at 5 and 18 days post infection.  Total cellular RNA was also extracted from 
HCMV latently infected CD14 (+) monocytes, after an 18-day incubation subsequent to 
treatment with IL-6 and re-plating of cells on a surface that allowed attachment.  This 
Figure 1.   Infected CD14 (+) cells express latency associated transcripts and stable DNA 
copy number after 14 days in culture.  (A) RT-qPCR analysis for the expression of IE1/IE2, LUNA 
and UL138 mRNA in infected CD14 (+) monocytes.  CD14 (+) cells were infected with FIX BAC 
virus and total cellular RNA was harvested various days post infection and subjected to RT-qPCR 
using TaqMan primers and probes specific for IE1 and IE2 mRNA.  Inset figure: Detection of viral 
genomic DNA in infected CD14 (+) monocytes by PCR.  Lanes: 1, uninfected; 2, 5-day post 
infection; 3, 18 day post infection.  Primers used were specific for the TR region of the genome. (B) 
CD14 (+) monocytes infected cell viral genome copy number.  Cells were harvested at various days 
post infection and subjected to qPCR using primers and probes specific for the HCMV viral 
chromosome.  Absolute viral genome copy number was determined by comparing to a standard 
curve and calculated on a per cell basis.  Error bars are the standard deviation of the mean for 4 






lytic virus reactivated sample, along with the 5 and 18 day samples were subjected to 
next generation sequencing (RNA-Seq).  RNA-Seq was performed using an Illumina 
HiSeq 2000 instrument (54 million reads per sample, paired end directional sequencing).  
Data was analyzed using CLC Bio Genomics Workbench software (RNA-Seq analysis) 
using mock-infected RNA as a control, 4 independent biological replicates were used for 
analysis.  Figure 2 is a “peak map” showing the location and relative abundance of 
transcripts from the HCMV FIX BAC viral genome identified by RNA-Seq.  The height of 
the peaks represents the relative number of reads for the transcripts detected and 
correlates to the relative abundance of the mRNA in cells.  At 5 days post infection 
almost all (99%) of the HCMV ORFs present within the viral genome were expressed 
(Fig. 2A).  Interestingly, and partly consistent with what was previously reported from an 
RNA-Seq analysis of HCMV lytic infection, the highest amount of transcript accumulation 
after a 5-day infection of CD14 (+) monocytes occurred from the expression of UL22A, 
lncRNAs 2.7 and 4.9 loci (Fig. 2A).  UL22A is expressed in HCMV infected dendritic cells 
during lytic infection but has not been previously described in early infection of CD14 (+) 
monocytes.  UL22A is responsible for immune evasion and selectively blocks CCL5 [72].  
Immediate early transcripts encoding IE1/2 (UL122-123) were also detected as well as 
all early transcripts encoding replication proteins (UL44, UL70, UL105, UL102, UL54 and 
UL57) (Fig. 2A).  Late transcripts encoding viral glycoproteins and capsid proteins were 
also present at 5 days post infection.  
 At 18 days post infection of CD14 (+) monocytes the transcriptome analysis 
showed that only a subset of viral-encoded RNAs were present in latently infected cells 
and confirmed that neither immediate early IE2 or IE1 mRNAs were expressed, nor were 
any other immediate early transcripts detected (Fig. 2B).  Transcripts were detected 





transcripts for the long noncoding RNAs RNA2.7 and RNA4.9 (Fig. 2B).  Very low levels 
of UL111A mRNA were detected, which cannot be seen on the peak map shown (cutoff 
was 20 reads).  A list of all transcripts detected during latent infection is shown in table 1 
along with the number of reads from the RNA-Seq analysis.  These data are the first 
reporting of the total virus encoded transcriptome from latently infected CD14 (+) 
monocytes using next generation sequencing.  To confirm the presence of RNA 
transcripts we performed reverse transcriptase PCR (RT-PCR) using RNA isolated from 
5 and 18 day infected CD14 (+) monocytes and primers specific for each of the 
transcripts detected as well as control transcripts.  All transcripts identified from RNA-
Seq analysis were detected using RT-PCR, whereas we were unable to detect IE2, 
UL13 or US21 mRNAs (Fig. 2B, Inset figure), confirming the results from the next 
generation sequencing.   
 Lytic reactivation of latent virus was also performed by incubating latently 
infected (18 days post infection) CD14 (+) monocytes with IL-6 and re-plating in tissue 
culture flasks that allowed for cell attachment.  After a 7-day incubation with IL-6, total 
cellular RNA was harvested and subjected to next generation sequencing.  RNA-Seq 
analysis showed that HCMV gene expression was observed from almost the entire viral 
genome consistent with lytic virus replication (Fig. 2C).  Together these data show that 
HCMV latent infection in CD14 (+) monocytes is characterized by the absence of 
transcripts encoding immediate early proteins and the expression of a several specific 
transcripts, some of which were normally associated with lytic DNA replication and 







Figure 2.  RNA-Seq analysis of HCMV infected CD14+ cells.  (A) HCMV transcriptome 5 days 
post infection.  (B) HCMV transcriptome 18 days post infection. Transcript analysis was performed 
using CLC Bio Genomics Workbench software.  Peaks were calculated and determined based on 4 
independent experiments and using a minimum of 20 read cut off and pValue of < 0.05 was used to 
determine peaks shown.  Peaks identified from 18 day CD14 (+) latent infection were: UL138, UL95, 
UL87, UL84, UL52, UL50, UL44, LUNA, RNA4.9 and RNA2.7.  Peak heights are indicative of 
relative transcript accumulation in infected cells.  Arrows indicate direction of transcripts.  Inset: RT-
PCR evaluation of identified ORFs during lytic or latent infection.  Negative controls for latent 
infection: IE2, UL13 and US21.  CycloA=cyclophillin A. (C) HCMV transcriptome upon reactivation of 
latently infected CD14 (+) monocytes with treatment of IL-6 and culturing cells on a surface that 







Table 4.  CD34 HCMV 







UL126a    976 
UL50    758 
UL84    730 
UL52    662 
UL44    213 
RNA4.9      75 
RNA2.7      39 
IE1      21 
UL28/29      11 





Table 1.  CD14 HCMV 















Table 2.  CD14 HCMV 
Natural Latent Infection 
Gene Reads 
RNA2.7    504 
LUNA    453 
UL95    343 
UL44    245 
UL50    187 
UL87    123 
RNA4.9    104 
UL52      54 
UL79      44 
UL84      36 
UL138      24 
!Table 3. CD34 HCMV 
























To test for the production of virus, supernatants were collected at 18 days post 
infection from reactivated samples and measured the amount of HCMV DNA by qPCR.  
In reactivated cells, supernatant virus was detected indicating that lytic virus infection 
was efficiently reactivated in these cells (Fig. 3).     
 For CD34 (+) cells, we evaluated mRNA expression at 3 days post infection as 
well as at a time point when IE2 transcripts were no longer detected.  RNA was 
harvested at 3 and 10 days post infection and qPCR was performed.  We measured the 
transcript abundance of IE2, UL44, UL84, RNA 2.7 and RNA4.9.  At 10 days post 
infection of CD34 (+) cells, no IE2 mRNA was detected, however transcripts for UL44, 
UL84 and the two lncRNAs were detected (Fig. 4A).  Based on the results of the qPCR 
showing that latency associated genes were expressed in the absence of detectable 
IE2, we harvested total cellular RNA and performed next generation sequencing.  The 
results of the RNA-Seq are shown in figure 4B.  For HCMV latent infection of CD34 (+) 
cells we harvested RNA at 11 days post infection and the RNA-Seq peak map shows the 
Figure 3.  Detection of supernatant virus from reactivated CD14 (+) 
monocytes.  Supernatants were collected from CD14 (+) monocytes infected with 
HCMV after 18 days post infection as well as from cell reactivated after 18 days in 
culture.  Uninfected supernatants were also collected.  qPCR was performed using 
primers and probes specific for the UL54 and UL95 loci.  A total of 6 wells (3 for each 
probe) for each sample were collected and error bars are the standard deviation from 






presence of the same transcripts detected in latently infected CD14 (+) cells (Fig. 4A, 11 
day latent).  Interestingly, several additional transcripts were detected.  RNA-Seq of 
latently infected CD34 (+) cells shows that the mRNAs for UL28/29, UL37/38, UL114, 
IE1 UL133/135, UL111A and US17 were detected (Fig. 4A).  Hence these data show 
that there are common transcripts associated with HCMV latent infection in both CD14 
(+) and CD34 (+) cells, including two lncRNAs and mRNAs that encode UL84 and UL44.  
At 3 days post infection less than half of the total HCMV genes were expressed and at a 
very low levels (Fig. 4B, 3 day PI).  In reactivated cells, the entire HCMV genome was 
activated and the relative amount of transcription was about 5-fold higher (Fig. 4B, 
reactivated).  Cells were co-cultured with HFFs and cells were observed for the 
formation of green plaques. Green plaques were readily visible after a 12-day incubation 
indicating that efficient reactivation from latent infection was achieved  (Fig. 4B, 
reactivated inset image of green plaques on HFF cells). 
 We also evaluated transcripts present in naturally latent infected CD14 (+) 
monocytes and CD34 (+) cells isolated from whole blood from pooled HCMV positive 
donors (Renown Hospital, Reno NV).  Cells were isolated, RNA was extracted and next 
generation sequencing libraries were generated.  RNA-Seq analysis performed on 
naturally latent infected cells showed that, although the relative abundance of individual 
transcripts varied between experimental and natural infection, the transcripts present 
were mostly consistent with experimental latency models (tables 1 and 2, tables 3 and 
4).  These data strongly suggest that the most of the transcripts detected during 
experimental latency in both CD14 (+) and CD34 (+) cells mirrors an HCMV natural 
latent infection and consequently validates in vitro HCMV latency infection protocols 







Figure 4.  RNA-Seq analysis of HCMV infected CD34 (+) cells.  Latent 
transcriptome from CD34 (+) cells shares core transcripts with those observed from CD14 (+) 
latent infection.  (A) qPCR evaluation of specific gene expression from CD34 (+) cells infected 
with FIX BAC virus at 3 and 10 days post infection.  (B) RNA-Seq detection of transcripts from 
infected CD34 (+) cells during latent (11 days post infection), 3 days post infection and from 
cells reactivated after 11 days post infection.  Peaks were calculated and determined based on 
3 independent experiments and using a minimum of 20 read cut off and pValue of < 0.05 was 
used to determine peaks shown.  Peak maps are shown where the number of transcript reads 
is shown to the left of the graphs.  CD34 (+) cells latency-associated transcripts identified were: 
RNA2.7, UL28/29, UL37/38, UL44, UL50, UL52, RNA4.9, LUNA, UL84, UL87, UL95, UL111A, 






 HCMV UV inactivation abrogates latent virus gene expression.  Since we 
observed robust transcription at 5 days post infection of CD14 (+) monocytes, we 
wanted to determine if virion associated transcripts could be detected from UV 
inactivated virus at 5 days post infection and evaluate the ability of virus encoded 
mRNAs to persist in CD14 (+) monocytes.  It was previously described that HCMV 
virions contain virus-encoded mRNAs [73,74].  Hence we infected CD14 (+) monocytes 
with UV inactivated virus and performed qPCR at 5 and 10 days post infection.  We 
evaluated infected cells for the presence of transcripts detected during latency as well as 
IE2 mRNA.  As expected all transcripts were detected at 1 hr post infection of CD14 (+) 
monocytes, suggesting that these transcripts are packaged within the HCMV virion (Fig. 
5, 1 hr UV).  At 5 and 10 days post infection the amount of fold increase for all 
transcripts from cells treated with non-UV inactivated virus was consistent with what was 
observed in the RNA-Seq, strongly suggesting lytic infection (Fig. 5, Day 5 and Day 10 
UV).  However in UV inactivated samples, at 5 or 10 days post infection, all transcripts 
were below 1-fold increase compared to mock infected samples suggesting that RNA 
transcripts observed during latency are not the result of input virus or from initial 
transcription observed at 5 days post infection (Fig 5, Day 5 and 10 UV).  These results 
indicated that there is a detectable amount of input mRNAs from virions in infected CD14 
(+) monocytes, however these input transcripts are short lived and absent by 5-days 





 HCMV UL84 and UL44 interact with the latent HCMV viral genome.  The 
RNA-Seq data identified the presence of two transcripts in HCMV latently infected cells 
that encode UL84 and UL44, two proteins that participate in virus lytic DNA replication in 
human fibroblasts [3,4].   UL84 and UL44 interact with oriLyt and other regions of the 
HCMV genome during lytic infection [5,6,75,76].  Also, UL84 interacts with UL44, the 
DNA polymerase processivity factor in infected cells [77].  Since UL44 and UL84 were 
the only two transcripts encoding apparent DNA binding proteins observed in the RNA-
Figure 5.  UV inactivation of virus abrogates accumulation of IE2 and latency associated 
transcripts in CD14 (+) monocytes.  CD14 (+) monocytes were infected with either wt FIX 
BAC virus or UV inactivated virus.  Total cellular RNA was harvested at 1 hr, 5  and 10 days 
post infection and qPCR was performed to detect transcripts IE2, UL44, UL84, LUNA, UL138, 
lncRNA 2.7 and lncRNA4.9.  Transcript fold increase was determined using mock infected as 






Seq analysis in latently infected cells, it allows for the possibility that these two proteins 
may participate in HCMV latent DNA replication.  The presence of these two transcripts 
in latently infected cells suggests that maintenance of the latent viral genome may 
involve some of the lytic virus machinery.  Hence we investigated if these two proteins 
interacted with the viral genome under latent conditions in CD14 (+) monocytes.   
 ChIP-Seq analysis for UL84 and UL44 was performed in latently infected CD14 
(+) cells to determine if these proteins interact with the latent HCMV genome in CD14 (+) 
cells.  Ten million CD14 (+) monocytes were infected with wt FIX BAC virus and mRNA 
levels were monitored until no IE gene expression was detected (18 days).  Infected 
cells were then processed for ChIP-Seq and DNA-protein complexes were 
immunoprecipitated using antibodies specific for UL84 or UL44.  Immunoprecipitated 
DNA was used to generate libraries for next generation sequencing using input DNA as 
a reference.  ChIP-Seq was performed using Illumina MiSeq instrument.  Data was 
analyzed and peaks were identified using CLC Bio Genomics Workbench software using 
the ChIP-Seq analysis package compared to input DNA. 
 ChIP-Seq analysis identified 5 major peaks corresponding to the binding 
domains for UL84 in the FIX BAC virus genome during latent infection (Fig. 6A, Red 
peaks).  Two of the peaks mapped to the promoter regions for UL84 and UL44 and 
suggests that UL84 may regulate the expression of these genes during latent infection 
(Fig. 6A, Red Peaks.).  Another peak was localized to the promoter region for 
UL112/113 and the upstream regions regulating LUNA and MIE gene expression.  Also, 
the region containing oriLyt and encoding the lncRNA4.9 showed specific binding to 
UL84 in latently infected cells (Fig. 6A, Red peaks).  For UL44, many of the binding 
domains in latently infected monocytes overlapped with those identified for UL84.  UL44 





peaks), one of the transcripts identified from the RNA-Seq analysis from latently infected 
CD14 (+) monocytes.  Interestingly, UL44 also interacted with the region of the genome 
encoding lncRNA2.7 and, along with UL84, the region upstream of its own coding 
sequence (Fig. 6A, Blue peaks).  Table 5 is shows the number of reads for UL44 and 
UL84 ChIP-Seq experiments corresponding to the peak map.      
Figure 6.  UL44 and UL84 interact with the HCMV latent viral genome in CD14 (+) 
monocytes.  (A) ChIP-Seq analysis peak map of UL44 and UL84 in HCMV latently infected CD14 
(+) monocytes.  UL44 or UL84 specific antibodies were used to immunoprecipitate protein-DNA 
complexes followed by next generation sequencing.  Shown is the HCMV (Fix strain) virus 
genome and the location of DNA sequence reads, Red peaks = UL84 protein binding, Blue peaks 
= UL44 protein binding.  (B) RNA4.9 interacts with components for the polycomb repressive 
complex.  HCMV latently infected monocytes were fixed and RNA-protein complexes were 
immunoprecipitated with antibodies specific for EZH2, SUZ12 or UL84.  RNA reverse-transcribed 
and cDNA was detected by PCR using primers specific for RNA4.9 or Cyclophilin A.  Control 
immunoprecipitations were performed using an isotype control antibodies, mAb control (isotype 
control for SUZ12 and UL84), pAb control (isotype control for EZH2 and UL44).  (C) SUZ12 and 
EZH2 interact with the MIEP region during latent infection.  ChIP assays were performed from 
latently infected CD14 (+) cells using antibodies specific for SUZ12 or EZH2.  Primers specific for 







 These data indicate that UL84 and UL44 interact with the HCMV genome during 
latent infection in CD14 (+) monocytes and suggests these proteins may activate or 
suppress several genes during latency and allows for the possibility that viral encoded 
replication proteins may participate in viral genome maintenance.  
 HCMV lncRNA4.9 interacts with UL84 and components of the polycomb 
repression complex (PRC) during latent infection in CD14 (+) monocytes.  Two 
HCMV transcripts identified in latently infected CD14 (+) monocytes and CD34 (+) cells 
were long noncoding RNAs.  Our previous studies investigating Kaposi’s sarcoma-
associated herpesvirus (KSHV) lncRNA PAN, showed that herpesvirus encoded 
lncRNAs can be regulators of both viral and cellular gene expression [62].  lncRNAs 







UL122/123 1070 6.84 X 10-64 
 
UL44 890 2.00 X 10-39 
 
UL84 217 2.08 X 10-07 
 
UL105/RNA5.0 174 4.13 X 10-12 
 
UL81/82 LUNA 143 0.0012 
 
RNA4.9/UL69 123 5.44 X 10-11 
UL44 ChIP-Seq 
RNA2.7 366 1.55 X 10-44 
 
UL122/123 311 4.08 X 10-10 
 
UL95 232 0.0797 
 
UL44 214 2.95 X 10-6 
 
UL105/RNA5.0 172 7.66 X 10-9 
 
RNA4.9/UL69 111 0.023 
UL112 79 0.098 
RNA2.7 25 0.468 
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polycomb repressive complex 2 (PRC2).  The PRC2 complex is composed of EZH2, 
SUZ12 and EED-1.  EZH2 is a protein that adds three methyl groups to lysine 27 of 
histone 3 [79].  SUZ12 is a protein that contains a zinc finger domain that is the point of 
contact with RNA [80].  EED-1 interacts with HDAC1 and histone deacetylase and 
various other proteins to mediate gene repression [81].  These PRC2 proteins can 
mediate changes in histone modifications (methylation) and subsequent repression of 
gene expression from various genetic loci.  Hence the interaction of lncRNAs with PRC2 
can globally influence gene expression.   Since the RNA-Seq identified HCMV encoded 
lncRNAs 2.7 and 4.9 during latent infection, we investigated if the newly discovered 
RNA4.9 could interact with components of the PRC2.  Also, since it was previously 
described that HCMV UL84 is an RNA binding protein [82] and UL84 is also present 
during latent infection, we also evaluated if lncRNA4.9 interacted with UL84 in latently 
infected CD14 (+) monocytes.   
 HCMV latently infected CD14 (+) monocytes were fixed and RNA crosslinking 
immunoprecipitation (rCLIP) was performed using antibodies specific for EZH2, SUZ12 
and UL84.  Also, as controls we used an isotype control antibody for 
immunoprecipitations.  Immunoprecipitated RNA-proteins complexes were reverse 
cross-linked and cDNA was generated.  cDNA was used for PCR amplification using 
primers specific for RNA4.9, cyclophilin A or UL138 RNA.  PCR amplification products 
were observed for immunoprecipitations using UL84, EZH2 and SUZ12 antibodies and 
PCR primers specific for RNA4.9 (Fig 6B).  No PCR amplification product was detected 
when the isotype control antibodies or an antibody to the cellular protein GAPDH was 
used or when using PCR primers specific for UL138 or cyclophilin A (Fig. 6B).  Also, no 
PCR product was observed when the reverse transcriptase was omitted from the PCR 





with viral encoded UL84 and components of the PRC2.  Hence, RNA4.9 has the 
potential to function as a regulatory RNA in the context of HCMV latent infection of CD14 
(+) monocytes. 
 EZH2 and SUZ12 interact with the MIEP region during latency.  Since it was 
demonstrated that RNA4.9 interacts with components of the PRC2 we wanted to 
evaluate if these same factors bound to the MIEP under latent conditions.  We 
performed ChIP assays using latently infected CD14 (+) cells and immunoprecipitated 
protein-DNA complexes with antibodies specific for EZH2 or SUZ12.  
Immunoprecipitated DNA was subjected to PCR using primers specific for the core 
promoter region for the major immediate early gene locus (PCR primer set MIEP-3, see 
figure 7 and Table S4 in Text S1).  Both SUZ12 and EZH2 were shown to interact with 
the MIEP region under latent conditions (Fig. 6C).  We also evaluated the LUNA 
promoter during latency for the presence of SUZ12 and EZH2.  Consistent with the 
constitutive expression of LUNA during latency no specific interaction of PRC2 
components was observed (Fig. 6C, LUNA-Pr).  Control immunoprecipitations using 
isotype specific antibodies showed no PCR product.  These experiments, coupled with 
the observation that RNA4.9 interacts with polycomb proteins, suggest that RNA4.9 
could mediate gene suppression at the MIEP during latency.  
 RNA4.9 physically interacts with the latent HCMV genome.  As mentioned 
previously, one of activities of lncRNAs is to mediate changes in gene expression by an 
interaction with PRC and chromatin.  Since we observed the presence of RNA4.9 during 
latent infection and the transcript was shown to interact with UL84 and PRC2 factors, it 
is logical to assume that RNA4.9 is involved in regulation of gene expression during 
latency.  The ChIP-Seq analysis showed that the major interaction domain for UL84 was 





the latent HCMV genome at the MIEP.  We performed chromatin isolation by RNA 
purification (ChIRP) using biotinylated oligonucleotides specific for RNA4.9 to determine 
if the transcript interacts with the MIEP region during both latent and initial infection of 
CD14 (+) monocytes.  We evaluated the ability of RNA4.9 to interact with the MIEP 
across 5 regions that mapped to the unique, enhancer, core promoter, exon 1 and the 
first intron of the IE gene (Fig. 7A). Five and 18 day infected CD14 (+) monocytes were 
used for ChIRP analysis of RNA4.9 binding to the MIEP.  At 5 days, the ChIRP analysis 
showed only a slight interaction of RNA4.9 with the MIEP and enhancer region (Fig. 7B 
CD14 (+) 5 dpi, lanes RNA4.9 ChIRP).  However during latent infection a strong 
interaction with the HCMV MIEP, enhancer and a lesser interaction with the first exon 
was detected (Fig. 7B CD14 (+) 18 dpi, lanes RNA4.9 ChIRP).  This interaction, coupled 
with the observation that RNA4.9 interacts with components of the PRC2 strongly 






Figure 7.  RNA4.9 physically interacts with the HCMV latent viral chromosome.  (A) 
Schematic of the HCMV MIE gene and promoter/enhancer region.  Regions amplified by PCR primers 
are shown that are specific for the unique, enhancer, core promoter, exon 1 and the first intron of IE2.  
(B) ChIRP analysis of RNA4.9 binding to regions of the MIE promoter and gene locus.  Infected CD14 
(+) cells were harvested at 5 and 18 days post infection and ChIRP was performed.  Control ChIRP 
was performed using biotinylated hybridization primers specific for LacZ.  Amplification of the UL19 
region was used as a control for ChIRP PCR amplification. (C) Increase in the enrichment of the 
repressive H3K27me3 mark at the MIEP during latency is consistent with the binding of RNA4.9.  
CD14 (+) cells infected with HCMV were harvested at 3-days post infection or during latency at 15 
days post infection and ChIP assays were performed using antibodies specific for H3K27me3, 
H3K4me3 or IgG control antibody.  Fold enrichment of H3K27me3 or H3K4me3 was calculated by IgG 
subtracted % input of each locus divided by the IgG subtracted % input of the control gene GAPDH.  
Each sample was evaluated in triplicate and the error bars are the SD of the mean.  Data is shown as 
fold enrichment compared to tri methylation state at 3 days PI.   Statistical analysis was done using 
multiple t-test, *P Value<0.001.  (D) Increase in IE mRNA accumulation in cells transfected UTX and 
JMJD3 expression plasmids.  Latently infected CD14 (+) cells were transfected with plasmids 
expressing UTX and JMJD3.  Expression of UTX and JMJD3 was confirmed by Western blot, left 
panel.  Graph shows the increase in fold accumulation of specific mRNAs.  Error bars are the standard 






latent infection is the epigenetic modification of chromatin regulating MIEP region 
mediated by the virus encoded lncRNA4.9.   
 Since the interaction of PRC2 with chromatin is associated with the increase in 
the H3K27me3 repressive mark, we investigated the relative marking of this histone 
modification at the MIEP region.  CD14 (+) cells were infected with FIX BAC virus and 
cells where harvested at 3-days post infection or during latency at 15 days post infection.  
ChIP assays were performed using antibodies specific for H3K27me3 or control proteins.  
The amount of H3K27me3 mark was evaluated for enrichment at MIEP-1, MIEP-2 and 
MIEP-3 regions (Fig. 7A) as well as at the LUNA and GAPDH promoters.  During latency, 
there was a significant increase in enrichment of the repressive H3K27me3 mark at 
regions MIEP-2 and MIEP-3 of the MIEP region (Fig. 7C).  These loci correspond to the 
regions where RNA4.9 binding is the most robust (Fig. 7B).  The enrichment of 
H3K27me3 at the LUNA promoter during latency changes only slightly during latent 
infection, which is consistent with the constitutive expression of LUNA during lytic and 
latent phases of infection (Fig. 7C).  We also evaluated the enrichment of the 
transcriptional activation H3K4me3 mark at the MIEP region.  This mark does decrease 
during latent infection, consistent with less gene activation (Fig. 7C).  The results of 
these experiments suggest that RNA4.9 interacts with the MIEP region and mediates the 
enrichment of the repressive H3K27me3 mark to repress HCMV transcription of IE2. 
 Since we observed the enrichment of the repressive H3K27me3 mark at the 
MIEP region we investigated if the over expression of specific H3K27me3 demethylases 
could have an affect on reactivation, specifically the release of repression of IE2 gene 
expression.  Plasmids expressing UTX and JMJD3 were cotransfected into latently 
infected CD14 (+) monocytes and 72 h post transfection total cellular RNA was 





RNA2.7 and UL54 (polymerase).  As a control, we transfected a plasmid that expressed 
EGFP.  mRNA expression levels were compared to mock transfected latently infected 
CD14 (+) cells.  In cells cotransfected with UTX and JMJD3 expression plasmids there 
was a 130 fold increase in IE2 mRNA accumulation (Fig. 7D).  Transcripts encoding 
RNA2.7, UL84 and UL54 also increased markedly in cells transfected with demethylases 
expressing plasmids (Fig. 7D).  Latently infected CD14 (+) cells transfected with the 
EGFP expressing plasmid show no significant increase in mRNA accumulation (Fig. 7D).  
These experiments strongly suggest that latent HCMV genomes are silenced, at least 
partly, by repressed chromatin marked with H3K27me3.  Also, our data suggests that 
RNA4.9 participates in transcriptional suppression of MIE gene expression.     
 Identification of nucleosome depleted regions within the HCMV genome 
during latent infection of CD14 (+) monocytes.  We postulate that the region(s) of the 
viral genome that could potentially serve as latent replication/maintenance elements 
should be depleted of nucleosomes and hence would define the major cis regulatory 
elements within the latent HCMV chromosome. This assumption is based on previous 
studies showing that origins of replication are depleted of bulk nucleosomes [68,83-86].  
It was further demonstrated in Saccharomyces cerevisiae that nucleosomes are 
positioned as flanking replication origins [87].  We employed the method Formaldehyde 
Assisted Isolation of Regulatory Elements (FAIRE) to determine which regions within the 
latent HCMV chromosome are depleted of nucleosome structures [88-90].  FAIRE is a 
powerful approach to identify genome-wide active regulatory elements in vivo.  FAIRE 
involves formaldehyde crosslinking of cells, followed by shearing of chromatin and 
subsequent phenol/chloroform extraction.  The procedure is based on the fact that 







Figure 8.  Analysis of nucleosome depletion in HCMV infected CD14 (+) 
monocytes. (A) Schematic of FAIRE method.  FAIRE-Seq was performed using 4 or 
18 day infected CD14 (+) monocytes. (B) FAIRE-Seq analysis of 4 day post infection 
of CD14 (+) monocytes.  (C) FAIRE-Seq analysis of 18 day latently infected CD14 (+) 
monocytes.  Sequencing reads were mapped to VR1814. Red Arrows indicate 






partitioned into the aqueous phase.  These genomic regions are then mapped back to 
the HCMV genome using next generation sequencing (Fig. 8A). 
 To study the HCMV chromosome during latent infection we used the CD14 (+) 
monocyte experimental model [46].  In this experimental latency model, CD14 (+) 
monocytes are cultured using specific growth media and culture plates that retain CD14 
(+) monocytes in an undifferentiated state.  Cells were infected with the HCMV clinical 
isolate FIX BAC strain and monitored for the expression of immediate early gene 
expression and the presence of the previously described latency associated transcripts 
UL138 and LUNA [41,53,91].  At 14 days post infection of CD14 (+) monocytes, the level 
of IE1/2 mRNA was undetectable by qPCR, however UL138 and LUNA transcripts were 
still present (not shown).   
Latently infected cells were harvested and subjected FAIRE followed by next 
generation sequencing. CD14 (+) monocytes were infected with FIX BAC virus and cells 
were harvested at 4 and 18 days post infection.  At 18 days post infection cells 
expressed latency-associated transcripts and were absent for expression of immediate 
early transcripts.  Cells were subjected to FAIRE and DNA was analyzed using next 
generation sequencing (60 million reads per sample, paired end sequencing).  FAIRE 
data was analyzed using CLC Bio Genomics Workbench software (ChIP-Seq analysis).  
At 4 days post infection of CD14 (+) monocytes over 130 peaks or nucleosome-depleted 
regions were elucidated (Fig. 8B).  These regions were distributed across the HCMV 
genome with a prominent peak at the major immediate early promoter region (Fig. 8B).  
These “open” active regions across the HCMV genome are consistent with robust 
transcription and replication during lytic infection.  The FAIRE profile was significantly 
different during a latent HCMV infection at 18 days.  Nucleosome depleted regions of the 





2B), in that active regions were specific for loci of the viral chromosome where latent 
viral transcription was observed (Fig. 8C).  One obvious exception was the high degree 
of sequence reads detected for the inverted and terminal repeat region (TR) of the 
genome (Fig 8C, Red Arrow).  Although nucleosome depleted regions were identified at 
both IR and TR regions of the genome, next generation sequencing could not distinguish 
between the two regions because of the high degree of homology.  Also, although a 
portion of the IR region is not present in FIX BAC, the IR region was identified because 
the FAIRE-Seq reads were mapped to the annotated parent virus strain (VR1814), 
hence the nucleosome depleted regions were localized only to the TR regions of the 
genome.  The presence of these highly nucleosome depleted loci, coupled with the 
observation that no viral transcripts were detected from this region by RNA-Seq during 
latent infection, strongly suggests that these regions of the genome could act as 
elements that mediate DNA replication/maintenance. 
HCMV terminal repeat region interacts with cellular encoded DNA 
replication licensing factors.  Since FAIRE data strongly suggested that the TR region 
was depleted of nucleosomes we investigated if the TR region associated with the 
protein components of the pre-replication complex (pre-RC).  HCMV latently infected 
CD14 (+) monocytes were fixed and a chromatin immunoprecipitation (ChIP) assay was 
performed using antibodies specific for pre-RC proteins MCM3 and CDT1 proteins. We 
also performed immunoprecipitations using isotype control antibodies and an antibody to 
GAPDH.  Figure 9A is a schematic showing the HCMV genome and the location of the 
terminal repeat (TR) region of the viral DNA.  Also shown are primer sets used for 
amplification of DNA immunoprecipitated from the ChIP assay.    Immunoprecipitated 
protein-DNA complexes were amplified using PCR primers designed to amplify the TR 





for the UL25 genomic locus.  PCR products were observed for ChIP samples using 
CDT1 or MCM3 specific antibodies when primer set 1 was used in the PCR mixture (Fig. 
9B).  No specific amplification product was observed from samples using isotype control 
or GAPDH antibodies, or using primers designed to amplify the UL25 region (Fig. 9B).  
These data strongly suggest that the TR region of the HCMV genome interacts with 
factors involved in cellular DNA replication and is consistent with previous results from 
other herpesvirus systems and latent origins.    
Figure 9.  Interaction of MCM3 and CDT1 with HCMV TR DNA sequences in latently 
infected CD14 (+) monocytes.  Latently infected cells were treated with formaldehyde and 
subjected to ChIP using antibodies specific for MCM3 or CDT1.  (A) Schematic of the HCMV 
genome showing the terminal repeat (TR) region.  Also shown are primer sets specific for the TR 
segment of the genome (1 and 2).  (B) ChIP assay showing an interaction of the TR region of the 
genome with MCM3 and CDT1 in latently infected cells.  Control immunoprecipitations were the use 
of an isotype antibody control and an antibody specific for GAPDH.  Control PCR primers were 





A plasmid clone containing the HCMV TR element persists in latently 
infected CD14 (+) monocytes.  Since our data suggested that the terminal repeat 
region of the HCMV genome was involved in replication/maintenance of the latent viral 
genome, our next step was to develop an assay to evaluate the ability of the TR element 
to mediate genome maintenance in latently infected cells.  We postulate that if the TR 
element mediates viral chromosome maintenance then a plasmid containing the TR 
element would persist in latently infected cells.  To this end we subcloned the HCMV FIX 
BAC TR element, as it would exist in the circular genome form (Fig. 10A), since previous 
data indicated that latent HCMV genomes exist as a circular episome [92].  This TR 
subclone, pTR, would be used to transfect HCMV latently infected CD14 (+) monocytes 
where required viral and cellular encoded factors would be supplied in trans from 
resident viral DNA and the host chromosome (Fig. 10B).  Latently infected CD14 (+) 
monocytes were transfected with pTR using Amaxa nucleofector and cells were 
processed as shown in figure 7C.   As controls, we also transfected the parent vector 
pGEM and a plasmid that contains the HCMV origin of lytic DNA replication, oriLyt.  After 
15 days post transfection (26 days post infection) cells were prepared and DNA was 
resolved using a Gardella gel [63].  The gel was transferred to a nylon membrane and 
hybridized to a radiolabeled pGEM probe.  Several bands were detected in the lane that 
contained cells that were transfected with the TR-containing plasmid whereas lanes that 
contained samples that were transfected with either pGEM, cloned oriLyt or mock 
infected TR transfected cells failed to show a hybridization product (Fig. 10D).  Two 
bands were detected on the Southern blot from cells containing pTR.  These two bands 
could be due to variable lengths of the repeat sequence present with the TR region of 
the genome.  We also evaluated 26 day latently infected CD14 (+) that were transfected 





transcripts, in the absence of IE2 gene expression, detected in the RNA-Seq analysis at 
26 days post infection (Fig. 10D, inset graph).   
 These data show that the cloned HCMV TR element is capable of persisting in 
latently infected CD14 (+) monocytes.  This is the first report describing the existence of 
a DNA element within the HCMV genome that mediates maintenance of the viral 
























































































































































































































































































































































































































 To date HCMV latency is defined as the lack of production of infectious virus, 
absence of immediate early gene expression and the presence of a few specific latency-
associated transcripts, as well as the ability to reactivate latent resident viral DNA.  
Previous studies have identified the expression of some latency-associated transcripts in 
both naturally and experimentally infected CD14 (+) and CD34 (+) cells [41,42,48,49].  
 We utilized two experimental systems to study HCMV latency; the first system 
developed for CD14 (+) monocytes is where cells are cultured in an undifferentiated 
state by using specific cytokines and a growth surface that retards cell attachment [46].  
Using CD14 (+) monocytes cultured under these specific conditions resulted in the 
presence of the HCMV genome in the absence of immediate early gene expression after 
approximately 18 days post infection.  For the HCMV latency infection protocol used 
here, we treated CD14 (+) monocytes with media formulation previously shown to 
maintain monocytes in an undifferentiated state [46].  Although it was previously 
reported that IE gene expression was not detected at 11 days post infection, in our 
hands the loss of IE gene expression required the culturing of cells for approximately 14 
days.   Hence, to ensure that viral infection was indeed in a latent phase, we evaluated 
transcription at 18 days post infection and only when cells were negative for IE gene 
expression.  RNA-Seq has major advantages over other previously employed methods 
to identify HCMV latency associated transcripts.  RNA-Seq allows for a quantitative 
unbiased evaluation of transcripts present in infected cells.  After a five-day infection, 
RNA-Seq showed the presence of transcripts originating from most of the HCMV 
genome.  Although this observation suggests that a lytic infection precedes the 
establishment of latency, more experiments are needed to confirm this finding.  Previous 





latency and several virus-encoded genes were identified [39,48].  Although at present 
we do not know the significance of wide spread gene expression in CD14 (+) at early 
time points post infection, a lytic-type infection upon initial infection of primary cells was 
observed previously for KSHV and EBV [93-95].  In those systems, this initial burst of 
lytic replication may be critical for subsequent establishment of latency.  The observed 
lytic infection for HCMV in monocytes warrants further investigation and will be the focus 
of future studies.  
 The second experimental latency system used infection of CD34 (+) cells where 
we isolated CD34 (+) cell populations, since evidence suggests that these cell types 
support HCMV latent virus [96].  RNA-Seq showed that infected CD34 (+) cells did not 
undergo the same robust HCMV viral gene expression pattern as observed with initial 
infection of CD14 (+) monocytes.  At three days post infection of CD34 (+) cells only a 
subset of genes were expressed, whereas in CD14 (+) cells almost the entire HCMV 
genome showed active transcription. Although the same core transcripts, including the 
lncRNAs RNA2.7 and RNA4.9, were detected in latently infected CD34 (+) cells and 
CD14 (+) monocytes, some differences were also observed.  One of the most notable 
was the presence of IE1 mRNA in latently infected CD34 (+) cells, which was also 
confirmed in naturally infected CD34 (+) cells.  The presence of IE1 mRNA in latently 
infected CD34 (+) cells was observed previously [26] and allows for the possibility that 
this protein could tether the HCMV chromosome to genomic DNA since it was previously 
demonstrated that IE1 interacts with cellular DNA [97,98].  The lack of detection of IE2, 
late gene expression or early genes involved in lytic DNA replication argue against the 
possibility that that a population of cells are undergoing lytic replication.   
 Previous studies have examined the expression patterns in HCMV latently 





of mRNAs [26,41,48].  Although these studies yielded important information regarding 
gene expression during latent infection, RNA-Seq has several advantages over 
microarrays [99-101].  One major advantage is that RNA-Seq is unbiased in that no prior 
knowledge about mRNA sequence is required.  One example of this demonstrated in the 
present study is that most microarrays target known ORFs, hence the presence of 
expressed lncRNAs or antisense transcripts may be overlooked.  Also, recent studies 
indicate that RNA-Seq is more sensitive than conventional microarrays [102,103]. 
 One of the most striking findings from the study presented here is the 
observation that transcripts that encode proteins associated with lytic DNA replication 
were expressed during latency.  These transcripts were present even though immediate 
early mRNAs were not expressed after approximately 14 days post infection of CD14 (+) 
monocytes.  Hence the observed expression of transcripts identified was not the result of 
transactivation from IE2.  One other explanation for the presence of apparent lytic 
mRNAs is the detection of transcripts with long half-lives that were still present from the 
initial infection and lytic replication.  This is unlikely since infection of CD14 (+) 
monocytes with UV-inactivated virus indicated that, although all latent RNAs were 
detected at 1 hr post infection due to apparent packaging in virions, we were unable to 
detect these transcripts at 5 or 10 days post infection.  This suggests that these mRNA 
half-lives are less than 5 days in CD14 (+) monocytes. 
 The RNA-Seq analysis showed that mRNAs encoding ORFs UL50 and 52 were 
present in latently infected cells.  The expression of these ORFs during latency is 
interesting since UL52 is implicated in cleavage-packaging.  UL52 a protein required for 
virus growth in human fibroblasts is localized to the nucleus and appears to enclose 
replication compartments.  Although implicated in encapsidation/cleavage of virus DNA, 





However, UL52 is quite unique with respect to other proteins involved in cleavage and 
packaging in that it is localized to the nucleus and found in replication compartments 
[104].  Hence, it could be that UL52 supplies a function in latency that is related to 
replication of the virus genome during latent infection.  
 For UL50, this protein is implicated in nuclear egress and is associated with the 
nuclear lamina as part to the nuclear egress complex (NEC) [105].  UL50 associates 
with the cellular factors p32 and protein kinase C (PKC).  UL50 is localized to the inner 
nuclear membrane and associated with the nuclear lamina along with UL53 [105,106].  
UL50 was shown to associate with BiP and this interaction was essential for 
phosphorylation of the nuclear lamina [106].  UL50 along with UL53 may act to remodel 
the nuclear lamina [107].  We speculate that UL50, like UL52, may play a role in 
maintaining the integrity of the HCMV latent virus genome.  
 In both latently infected CD14 (+) and CD34 (+) cells the transcripts encoding 
UL95 and UL87 were among the most abundant.  This observation also occurred in 
naturally infected cells.  UL87 and UL95 encode essential early transcripts that produce 
proteins that apparently affect late gene expression including the UL44 late kinetic 
transcription and colocalize with UL44 prior to initiation of viral DNA synthesis [108].  
Interestingly, the pre expression of UL87 inhibited the expression of MIE genes and virus 
DNA replication [108].  UL87 and UL95 are recruited to replication compartments during 
lytic infection [108].  Hence, during latent infection UL87 and UL95 could serve to 
enhance the expression of UL44 and/or UL50 and 52.  Another possibility is that UL87 
and UL95 may serve to help suppress the expression of IE2 during a latent infection. 
 UL84 is the putative initiator protein for lytic DNA replication and interacts with 
UL44 [5,76,82,109,110].  UL84 is a phosphoprotein that exhibits nucleocytoplasmic 





factor, however these herpesvirus proteins have recently been shown to have diverse 
functions with respect to regulation of gene expression and initiation of DNA synthesis 
[112-117].  The observation that transcripts encoding UL44 and UL84 are produced in 
latently infected cells suggests that the maintenance of the HCMV virus genome may 
involve a mechanism that utilizes some of the HCMV lytic DNA synthesis machinery.  
UL84 interacts with both Ku70 and Ku80 and the Ku70/80 complex is involved in DNA 
repair [76].  Ku70/80 is and ATP dependent helicase that is involved with DNA repair 
and interacts directly with the RNA component (hTR) of telomerase [118,119].  These 
interactions suggest that stability of the HCMV genomic DNA in latently infected cells 
may also involve DNA repair enzymes and telomerase.  We also demonstrated that 
UL84 protein interacted with the HCMV latent genome.  We speculate that UL84 may act 
to suppress IE gene expression, however UL84 may also mediate its own expression 
and that of UL44 and LUNA.  The interaction of UL84 with oriLyt could mean that the 
protein acts to suppress the activation of the lytic replication.  However, it is just as 
plausible that UL84 (possibly in cooperation with cellular factors) activates the promoter 
region within oriLyt to facilitate the expression of RNA4.9.  Another possibility could be 
that UL84 is acting in the capacity of a replication factor at oriLyt to replicate the latent 
genome.  Interestingly, UL84 is dispensable for lytic DNA replication in one clinical 
isolate, BACmid clone (TB40/E) [120].  Hence one possibility is that in clinical isolates 
UL84 is not required for lytic replication, but may mediate latent genome maintenance.    
 LncRNAs have emerged as significant regulators of gene expression in human 
cells.  Although the mechanisms used by lncRNAs vary, one well-defined mechanism 
involves their interaction with chromatin modifying complexes.  lncRNAs can act as 
molecular scaffolds to mediate epigenetic changes in histones, which results in 





affect gene expression patterns.  We have recently defined one mechanism of action for 
KSHV PAN RNA in lytically infected cells.  PAN RNA is a highly abundant transcript and 
we show that expression of PAN RNA can result in the disregulation of genes involved in 
immune response and cell cycle [62].  This suppression of gene expression is most likely 
achieved by the interaction of PAN RNA with polycomb proteins.  Activation of KSHV 
and cellular gene expression by PAN RNA appears to involve its interaction with the 
demethylases UTX and JMJD3, which remove the repressive H3K27me3 mark [62].  
Therefore evidence shows that viral lncRNAs are significant regulators of both cellular 
and viral gene expression.   
 In HCMV, the lncRNA2.7 was shown to regulate the apoptosis pathway during 
lytic infection [125].  Since we also observed the expression of RNA2.7 in latently 
infected cells it is likely that this transcripts plays the same role in latently infected CD14 
(+) cells.  Early studies did not detect the presence of this transcript in latently infected 
CD14 (+) cells [35].  One possibility for the discrepancy between this early study and the 
present one is that we used highly sensitive RNA-Seq, where the early studies used 
traditional RT-PCR.   
 The lncRNA4.9 was recently discovered by next generation sequencing of the 
HCMV transcriptome during lytic infection [10].  RNA4.9 initiates within oriLyt and 
extends upstream and terminates just downstream of UL69 [10].  Hence, since of the 
location of the 5 prime start of transcription for RNA4.9 is within oriLyt this suggests that 
the promoter region is also within oriLyt.  We previously identified a bidirectional 
promoter within oriLyt just upstream of the RNA4.9 transcriptional start site [126].  We 
now show data that strongly suggests that RNA4.9 may act as a regulatory RNA with the 
potential to control cellular and viral gene expression during HCMV latency in CD14 (+) 





PRC.  Using ChIRP we show that RNA4.9 physically interacts with the HCMV latent 
genome in the MIEP region.  This observation, combined with the data showing that 
RNA4.9 interacts with PRC proteins that are also bound to the same locus suggests that 
this transcript may repress the expression of IE2 during latency.  Previous studies have 
demonstrated epigenetic regulation of IE gene expression [27,37,47,127].   These earlier 
reports investigated the deposition of the acetylated H4 mark within the MIEP.  PRC2 is 
associated with the repressive H3K27me3 mark; hence we examined the presence of 
this mark at the MIEP.  Recent studies have shown that the presence of H3K27me3 is 
associated with herpesvirus latent genomes and repression of lytic gene expression 
[128-131].  One of the key factors for mediating gene silencing is lncRNAs [132,133].   
Data presented here strongly implicates lncRNA4.9 as a targeting factor for suppression 
of IE gene expression during latent infection in CD14 (+) cells.         
 For CD34 (+) latently infected cells, the presence of UL28/29 and UL37/38 is 
interesting.  It was recently reported that this locus encodes a spliced transcript and 
stimulate the accumulation of immediate early RNAs [134].  UL28/29 proteins interact 
with nucleosome remodeling and deacetylase protein complex, NuRD along with UL38 
and UL28/29 enhanced activity of the MIEP [135].  Recently, UL28/29 was shown to 
interact with UL84, p53 and suppresses cellular gene expression during lytic infection 
[136].  Hence the expression of UL28/29 during latency suggests viral control of p53-
regulated genes in the context of a latent infection.   
 Although RNA-Seq showed some differences between the CD34 (+) and CD14 
(+) latent transcriptome, many transcripts were common to both systems including the 
presence of lncRNAs, UL84 and UL44.  One explanation for the presence of different 
factors could be that specific viral factors may be required to maintain genome latency in 





 Our RNA-Seq evaluation of HCMV naturally latently infected CD14 (+) and CD34 
(+) cells isolated from seropositive donors showed an almost exact match to the 
transcripts observed from experimental latency, although relative abundances differed.  
Since pooled blood from HCMV seropositive donors was used, we do not know the 
prevalence or degree of transcript expression in individual donors.  Nevertheless, data 
shows that experimental latency closely matches natural latent infection.  This is the first 
evaluation of natural latent infection by next generation RNA sequencing.  Interestingly, 
RNA-Seq detected the previously transcript originating from UL126a in naturally infected 
cells [137,138].  This transcript was not detected in our experimental latency model.  
One explanation for the discrepancy is that some differences between natural and 
experimental latency may exist.  This could be due the fact that natural infection data 
was obtained from pooled donors and hence variations in expression levels are reflected 
in the RNA-Seq analysis.  Nevertheless, overall the transcripts present during natural 
and experimental infection vary little.  This is a very significant finding in that HCMV 
CD14 (+) and CD34 (+) experimental latency systems are widely used.  Our data 
suggests a strong link between transcripts expressed during HCMV natural latent 
infection and those that occur in cell culture.  
 It was previously demonstrated that herpesvirus latent origins are marked by lack 
of nucleosome structure and the presence of cellular factors involved in DNA replication 
or licensing [139].  Also, it was shown that nucleosome assembly proteins interact with 
herpesvirus-encoded proteins to regulate replication at the latent origins replication 
[140,141].  For EBV, EBNA-1 was shown to destabilize nucleosomes at the latent origin 
[142].  Also, for EBV, cellular factors play a significant role in replication of the latent 
virus origin [143-145].  Hence previous evidence indicates that specific herpesvirus and 





maintenance.  Currently little data exists regarding the mechanism involved in 
maintenance of the viral chromosome in HCMV latently infected cells.  Previous studies 
indicated the HCMV latent genome is in a circular form [25].  Based on the latency 
models from the gamma herpesviruses, it is assumed that the maintenance and 
replication of the HCMV latent viral genome requires trans and cis acting factors.  In this 
report we show that, consistent with the presence of active chromatin, that the TR region 
of the HCMV genome are depleted of nucleosomes during latent infection of CD14 (+) 
monocytes.  We developed a latent replication/maintenance assay where CD14 (+) 
monocytes harboring the latent HCMV chromosome were transfected with the TR 
containing plasmid.  Control plasmids, including a plasmid that contained oriLyt, failed to 
persist in latently infected cells.  The TR element of HCMV in the circular form contains 
two “a” sequences and many repetitive DNA sequence motifs.  Hence, during 
replication/maintenance there is a potential for variability of these repeat sequences.  
The fact that we observed two bands in the Gardella gel may indicate the presence of 
variable repeated regions.  This was also postulated for the KSHV latent origin, which 
also contains several repeated DNA sequences [15].  Although the Gardella gel clearly 
shows that the TR plasmid can persist in latently infected cells, further studies are 
needed to demonstrate if the TR element can direct plasmid replication.  Nevertheless, 
this is the first reporting of a region of the HCMV chromosome that mediates viral DNA 
maintenance. 
 The identification of cis and trans acting factors involved in HCMV latency in 
CD14 (+) monocytes and CD34 (+) cells now allows for a more in depth analysis of the 
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Reverse:  AACATAGTCTGCAGGAACGTC 
Probe:  /56-FAM/CCCGAGACA/ZEN/CCCGTGACCAAG 
IE2 
Forward: AAG ATG CGC ACC ATG ACC TGT TTG 
Reverse: AGC CTC AAA GAA TTG CAC ACC CAC 
Probe: /56-FAM/TTA CCG CAA /ZEN/CAT GAT CAT CCA CGC TG/3IABkFQ/ 
UL84 
Forward: TTT CTT CTT CTT GCA ACG TCG CGG 
Reverse: AGA ATT GCG GGA TCC CTT CCA GAT 
Probe: /56-FAM/TCT GCT CTC /ZEN/TAC GCC GCT GCA ATT /3IABkFQ/ 
UL44 
Forward: CAG CTG CAC GTT GAT ACG CAT GTT 
Reverse:  TCC ACC GGC CAT CAA GTT TAT CCT 
Probe: /56-FAM/ACA GCC AAT /ZEN/AAC CGC GTC AGT TTC CA/3IABkFQ/ 
UL81-82ast (LUNA) 
Forward:  ATC AGG CCG TTC ATT TGG AAC ACC 
Reverse:  ATG ACG TTG CTC CGT GGA AAG AGA 
Probe: /56-FAM/TTT GTC CGG /ZEN/TTT ACC GGG TGT GAG A/3IABkFQ/ 
RNA4.9 
Forward:  CTG TTC CGT GAT GCT ACC TAG 
Reverse:  AGC ACG AGA TGG TTT GAC G 
Probe:  /56-FAM/CG ACT CTT C/Zen/C TGT TTT CGC CCT GA/3IABkFQ/ 
UL105 
Forward: GCA CAT GTA CAC TAC CTT CCG 
Reverse: TGA TCT GAC AGT TGG CCT TG 
Probe:  /56-FAM/ACG TTG CCG/ZEN/CTCGTTACCTACAATC/3IABkFQ/ 
UL138 
Forward: TCC ACG TCG CTA ACC AGA GAA ACA 
Reverse: AAT GTA CCA TGG CTA CGG TGG TGA 
Probe: /56-FAM/ATC TGT TGA/ZEN/AAC CCG TGA CGG GAT/3IABkFQ/ 
UL54 
Forward: GTG CGC GAT CTG TTC AAC ACC ATT 
Reverse:  TGC TGT AGT GGT TGG GCA GGA TAA 
Probe:  /56-FAM/ATT CCG TTG /ZEN/CGG CGT GTC ATC TTT GA/3IABkFQ/ 
UL95 
Forward: ATT TGC CTT TAA AGC CCG TCT CGC 
Reverse:  TCA CGC GCG AGA TCT AAA CAG AGA 








Oligo name Probe (5' to 3') 
#1-RNA 4.9  gcgtactgacgacaattgaa 
#2-RNA 4.9  ttaagggacacggttttgtc 
#3-RNA 4.9  tttgaacagagaaaggtggg 
#4-RNA 4.9  ttcgctctgagcagaaaaaa 
#5-RNA 4.9  aggtgttcttttcttcgagc 
#6-RNA 4.9  ttcgtctacgtggtaagagt 
#7-RNA 4.9  aaacagatgcaaatcgccta 
#8-RNA 4.9  aaaaatataggtgccggacg 
#9-RNA 4.9  atggagggatatcaggtcat 
#10-RNA 4.9  cacatttctagtcgtgacgg 
#11-RNA 4.9  gtcgattcagaccgacaaaa 
#12-RNA 4.9  caaacgatggtaagaggtcg 
#13-RNA 4.9  taccgatagagcctgagatg 
#14-RNA 4.9  tccggaaagatggtgttttt 
#15-RNA 4.9  atagatccagagagcgtacc 
#16-RNA 4.9  gatgatgtggttcgtcgtac 
#17-RNA 4.9  accagagactaagtcggaaa 
#18-RNA 4.9  ctgtgacggtgattcttcag 
#19-RNA 4.9  gtgcatcatacaacgacact 
#20-RNA 4.9  ttcggtagagagctacagtc 
#21-RNA 4.9  gacgggaatcgatgtcattt 
#22-RNA 4.9  ctatgtacaagacgcatggg 
#23-RNA 4.9  ggtggtagtacaagggtttg 
#24-RNA 4.9  gtgacgatgatgatgtggtt 
#25-RNA 4.9 ttttggttcgaatcgagctt 
Supplemental Table S2.  ChIRP primers 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Supplemental Table S3. Primers used for RT-PCR. 
Gene Forward Reverse 
RNA Beta2.7 RT AGATGAAATTATCCCGTGTCCG GTGAAATCTGGCTTGGTTGTG 
UL13 RT AAATTCAACGCACACTCAACG CTATTCAGTTCTCCTTGTCCCG 
UL14 RT GGATTACTGGCTGACGGATC TTTCCTCTTCGGTGTTCAGAC 
UL44 RT TGCACGTGGATCTAGATTTCG ACTGACACGGTTATTGGCTG 
UL50 RT CGGTCTATTGTGTCGAGTATCTG AGCACATTGAACTCACCTACG 
UL52 RT TGTCCGAGTTTACGCATCTG TGGTTTAGGGTGACATTCTCG 
RNA4.9 RT ATTCCCCACCTTTCTCTGTTC CTCTCGACGCCATTTTCTCT 
UL79 RT AGCGTACGAACCCTTGATTC GTGAGAAAGAGGAGGATGGG 
LUNA UL8182ast RT TCCTCTTCTTCCTCCTCTTCC TGGGTTTTGGACTCTCACAC 
UL84 RT TCAAATCCACGCTACACTCG CAGGACTCGTTTTCTCTGTCG 
UL87 RT CAATTCGTACCAGATCCCCTTC CGTGAGGTTCTTGCTGTAGTC 
UL95 RT TTTCAACGTCCCTGTGCTC GCTACTGCTATCCAACACCG 
IE286 RT GACCCTGACAACCCTGACGAG TTGCGGTACTGGATGGTAAAG 
UL138 RT GATGAGATCTTGGTCCGTTGG TCACGGGTTTCAACAGATCG 
US21 RT AATGATCTCCATCGTGTGCC GCGTGAGGAAACAAAATAGCG 




Table S4. Primers used for H3K27me3 evaluation. 
GAPDH 
Forward: CCAAGAGAAAGATGGACCCTG 









Reverse:  TCAATGGGTGGAGTATTTACGG 
MIEP-3 
Forward:  CGGTACTTACGTCACTCTTGG 
Reverse:  ACGCTGTTTTGACCTCCATAG 
MIEP-4 
Forward:  GGAGATCCCACGCTATGTTT 
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Human cytomegalovirus (HCMV) can establish latent infection in hematopoietic 
progenitor cells (HPCs) or CD14 (+) monocytes. While circularized viral genomes are 
observed during latency, how viral genomes persist or which viral factors contribute to 
genome maintenance and/or replication is unclear. Previously, we identified a HCMV 
cis-acting viral maintenance element (TR element) and showed that HCMV IE1 exon 4 
mRNA is expressed in latently infected HPCs. We now show that a smaller IE1 protein 
species (IE1x4) is expressed in latently infected HPCs. IE1x4 protein expression is 
required for viral genome persistence and maintenance and replication of a TR element 
containing plasmid (pTR). Both IE1x4 and the cellular transcription factor Sp1 interact 
with the TR, and inhibition of Sp1 binding abrogates pTR amplification. Further, IE1x4 
interacts with Topoisomerase IIβ (TOPOIIβ), whose activity is required for pTR 
amplification. These results identify a HCMV latency-specific factor that promotes viral 




Human cytomegalovirus (HCMV) can cause significant disease and mortality in 
immune-compromised individuals. It is well established and accepted that HCMV latent 
infection occurs primarily in CD34 (+) hematopoietic progenitor cells (HPCs) or CD14 (+) 
monocytes (Goodrum et al., 2002, Maciejewski et al., 1992,Mendelson et al., 
1996, Reeves et al., 2005, Sinclair and Sissons, 1996, Sissons et al., 2002, Söderberg-
Nauclér et al., 1997, Taylor-Wiedeman et al., 1991,Zhuravskaya et al., 1997). Although 
latency has been studied in a variety of natural and experimental systems, the 
mechanisms involved in HCMV genome maintenance are poorly understood. It was 
previously reported that the viral genome is apparently circularized during latency in 
CD14 (+) monocytes (Bolovan-Fritts et al., 1999). However, beyond this observation little 
is known regarding how viral genomes persist in latently infected cells and which viral-
encoded factors contribute to genome maintenance and/or replication. 
Recent analysis of nucleosome occupancy in the HCMV latent chromosome 
revealed that the terminal repeat (TR) region was depleted of nucleosomes. Subsequent 
subcloning of the TR region into a plasmid vector showed that this region of the HCMV 
genome mediated viral chromosome persistence in latently infected CD14 (+) cells 
(Rossetto et al., 2013). These results strongly suggested that the TR element of the 
HCMV genome was sufficient for episome maintenance in latently infected cells. 
Several previous studies identified specific viral transcripts associated with latent 
infection in various cell types (Bego et al., 2005, Bego et al., 2011, Goodrum et al., 
2007, Jenkins et al., 2008, Khaiboullina et al., 2004, Kondo and Mocarski, 1995, Kondo 
et al., 1996, Kotenko et al., 2000). Recent published data from our laboratory using 
RNA-seq revealed the viral transcriptome from both experimentally and naturally HCMV 
latently infected CD14 (+) and CD34 (+) HPCs (Rossetto et al., 2013). HCMV 
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transcriptome analysis confirmed the expression of previously identified latency-
associated transcripts and identified the expression of several other mRNAs. These 
studies also showed that gene expression during experimental latency closely mirrored 
those transcripts expressed in natural latency. One surprising result from these studies 
was the observation that HCMV IE1 mRNA was detected in latently infected HPCs, but 
not in CD14 (+) monocytes, in the absence of IE2 mRNA in both natural and 
experimental latency systems. Since IE1 was shown to interact with mitotic 
chromosomes (Lafemina et al., 1989), the presence of IE1 during latency suggests that 
maintenance of the latent viral genome may occur through a mechanism involving 
tethering of the viral genome to the host cell chromatin (Mücke et al., 2014). This is not 
unlike the mechanism used by Kaposi’s sarcoma-associated virus (KSHV) and Epstein-
Barr virus (EBV) to maintain and propagate their latent virus genomes. 
We now show that the plasmid containing the HCMV TR element persists in 
latently infected HPCs and demonstrate that the presence of IE1x4 is sufficient to 
maintain and replicate the TR plasmid, pTR. Also, western blot analysis of latently 
infected HPCs revealed that a smaller than wild-type IE1 protein species is expressed 
during latency. These studies strongly suggest that HCMV genome 
maintenance/replication requires the cis-acting TR element and the expression of the 
latency-specific IE1x4 protein. 
  
Results 
IE1x4 Is Expressed in the Absence of Exons 2 and 3 in HCMV Latently 
Infected CD34 (+) HPCs.  Initial strand-specific RNA-seq data showed that IE1 (exon 4) 
but not IE2 mRNA was present in HCMV latently infected HPCs (Rossetto et al., 2013). 
This interesting observation prompted us to further investigate the origin of the IE1 
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transcript in latently infected HPCs. HPCs were infected with FixBac virus and cells were 
monitored for the expression of IE2 mRNA (Figure S1A). Reverse-transcriptase PCR 
(RT-PCR) from latently infected cells was performed using PCR primers complementary 
to IE1- or IE2-specific transcripts (Figure 1A). PCR products were detected only when 
using IE1 exon 4-specific primers (Figure 1B, lane 20), whereas primers for exons 2–3 
showed no PCR product (Figure 1B, lane 4). Also, no product was detected when 
primers spanning exons 3–4 were used (Figure 1B, lane 12). Hence, PCR data 
suggested that only exon 4 mRNA was expressed and not exons 2 and 3 in HCMV 
latently infected HPCs. Positive controls, lytically infected human fibroblast (HF) RNA, 
show the presence of all IE1/IE2 spliced products (Figure 1B). Negative controls (no 
reverse transcriptase) showed no specific PCR product. We also performed 5′ RACE on 
mRNA isolated from latently infected cells. RACE results suggest two possible mRNA 
initiation sites for IE1x4 in latently infected cells (Figure 1B). 
We next evaluated protein expression of IE1 in HCMV latently infected HPCs. 
Western blots show that, during HCMV latent infection of HPCs, a smaller MW species 
of IE1 protein (∼60 kDa) was expressed when compared to IE1 protein detected during 
lytic infection in HF cells or from an HF cell line that expresses IE1 (Figure 1C, compare 
lane 3 to lanes 1 and 2). As expected, no IE2 protein was detected in latently infected 
HPCs, whereas IE2 was readily detected during lytic infection of HF cells (Figure 1C). 
Mock infected HPCs showed no specific protein band when reacted with anti-iE1 
antibody (Figure 1C, lane 7). Also, IE2-60 and IE2-40 protein species were detected in 
infected HFs using anti-iE2-specific antibody, since these proteins originate from 
transcripts produced within exon 5 (Figure 1C, lane 4). We also confirmed the smaller 
IE1 species using a different IE1-specific antibody (Figure S1B). We performed an 
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Figure 1. Expression of IE1x4 in Latently Infected CD34 (+) Cells 
(A) Schematic of major immediate early region showing exons 1–5. Also shown are PCR 
primers used for RT-PCR from HCMV latently infected CD34 (+) cells, infected HFs, or an 
IE1-expressing HF cell line (gift from E. Mocarski). GAPDH control PCR amplifications are 
also shown. Continued on next page.   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 immunoprecipitation (IP) assay using IE1 antibody to show that, during HCMV 
latency in HPCs, no full-length IE1 protein was detected (Figure S1C). These 
experiments indicated that a smaller species of IE1 is specifically expressed during an 
HCMV latent infection of HPCs. 
The major immediate early promoter (MIEP) regulates expression of the HCMV 
MIE proteins IE2 and IE1 (Figure 1D). However, the observation that a smaller species 
of IE1, comprising only exon 4, suggests that a distinct promoter upstream of exon 4 
regulates expression of this latency-specific IE1 variant. RNA polymerase II (RNAPII) 
quantitative ChIP assays were performed using latently infected HPCs or reactivated 
HPCs. Occupancy of RNAPII was highest at the MIEP region (Figure 1D). However, no 
RNAPII was detected within exons 1 or 2. RNAPII occupancy was detected upstream of 
exon 4 within exon 3, as well as within exon 4 (Figure 1D), suggesting active 
transcription from exon 4. In HCMV lytically reactivated samples, RNAPII again showed 
a high degree of occupancy at the MIEP region however it was distributed throughout 
the MIE locus (Figure 1D). Taken together, these results strongly suggest that 
Figure 1 continued. (B) RT-PCR from latently infected or HF-infected cells and schematic of 5′ RACE 
showing putative IE1x4 protein initiation sites. The number of cDNA subclones isolated for each RNA start 
is shown in parentheses.  (C) Western blots of protein lysates prepared from either HF-infected cells, the 
HF IE1 cell line, or latently infected CD34 (+) cells. Arrows identify IE1 and IE2 protein species. IE1L refers 
to the IE1 species observed in latently infected CD34 (+) cells. Blots were initially reacted with anti-iE1 
antibody and then reacted with anti-iE2-specific antibody. Mock infected cells reacted with anti-iE1 are also 
shown. Actin shows the relative amounts of protein lysate loaded for visualization of IE1 species and 
comparison of their respective molecular weights. Mock infected cells reacted with anti-iE1 are also shown.  
(D) Latently infected CD34 (+) HPCs or reactivated cells were subjected to ChIP using an antibody specific 
for RNAPII. Immunoprecipitated DNA was quantitated by qPCR and compared to input samples. Graph 
shows RNAPII occupancy during latency and reactivation at specific genomic regions of the MIE gene loci. 
Error bars are the standard deviation from the mean for three separate experiments.  (E) Full-length IE1 is 
expressed upon reactivation of HCMV latently infected CD34 (+) HPCs. Blot was reacted with an IE1-
specific antibody. Lane 1: immunoprecipitated IE1 from reactivated CD34 (+) cells; IE1 and antibody 
heavy-chain IgG are indicated by black arrows. Lane 2: mock infected CD34 (+) cells. Lane 3: 4 days 
postinfection HF cells. Lane 4: mock infected HF cells.  (F) Production of infectious virus from reactivated, 
latently infected CD34 (+) HPCs. After reactivation, HPCs were cocultured with human fibroblasts for 10 
days. Shown is a photomicrograph image of HCMV-infected HF cells with reactivated FixBac virus. See 
also Figure S1. 
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transcription initiation for IE1x4 occurs within the MIE locus and confirms the quantitative 
PCR (qPCR) and western blot results showing that IE1x4 is transcribed during latency. 
We also investigated IE1 expression from reactivated cells. Interestingly, full-length IE1 
protein was produced upon reactivation (Figure 1E). Reactivated cells were incubated 
with HFs to confirm that infectious virus was produced (Figure 1F). Expression of IE1x4 
is apparently restricted to latent infection, as evidenced by the production of full-length 
IE1 upon lytic reactivation of HPCs. 
To identify the origin of the smaller IE1 protein species present during a latent 
infection of HPCs, we immunoprecipitated IE1 protein and sequenced the precipitated 
protein using LC/MS. Immunoprecipitated IE1x4 was sequenced (>80% coverage) and 
identified a putative start for the protein as the second ATG within exon 4 (Table S1). 
HCMV TR Is Replicated and Maintained in Latently Infected CD34 (+) HPCs.  
FixBac latently infected HPCs (experimental) were transfected with pTR or pGEM. High-
efficiency transfection of HPCs was achieved using a Nucleofector device (Figure S2A). 
The plasmid containing the HCMV terminal repeats (pTR) was maintained and amplified 
(resistant to DpnI cleavage) (Figure 2A, pTR). However, control pGEM DNA was not 
(Figure 2A, pGEM). The results of this experiment show that the TR region could persist 
and replicate in infected HPCs and strongly suggest that the TR region of the circular 
HCMV genome is the episomal maintenance element for the viral chromosome. 
We also identified factors that interact with HCMV TR by employing an in vitro 
affinity column protocol using nuclear extracts from latently infected HPCs. Table 
S2 shows the results of the proteomics study where viral proteins listed had confidence 
scores greater than 95%. Proteomics identified IE1 as a possible viral encoded protein 
that interacts with the TR (Table S2). 
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IE1x4 Interacts with the TR during Latent Infection of CD34 (+) HPCs.  To 
confirm the proteomics in vitro findings, an IE1 ChIP was performed in latently infected 
HPCs. ChIP DNA was PCR amplified using primers for the TR element or a negative 
control region (UL25) of the viral genome. IE1x4 did indeed interact with the TR element, 
whereas negative controls showed no detectable interactions (Figure 3A). These 
experiments demonstrate that IE1 interacts with HCMV TR and could potentially tether 
the latent viral genome to the cellular DNA, consistent with what was previously reported 
(Mücke et al., 2014). 
IE1 protein contains a chromatin tethering domain (CTD) and an acidic domain 
(AD) (Huh et al., 2008, Ahn et al., 1998, Krauss et al., 2009, Shin et al., 2012). To 
determine if the AD or CTD mediated the interaction of IE1x4 with the TR, 293FT cells 
were cotransfected with pTR along with plasmids that express either the CTD or the AD 
Figure 2. Amplification of pTR in Experimentally and Naturally Infected CD34 
(+) Cells.  Experimentally infected CD34 (+) HPCs transfected with pTR or pGEM. 
Data were calculated as fold change verses input DNA. Error bars are the standard 
deviation from the mean for three separate transfections. Plasmid copy number is 
shown in parenthesis. See also Figure S2A. 
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as EGFP fusion proteins (Figures S2B and S2C). Plasmids expressing EGFP alone or 
full-length IE1-EGFP were also used as negative and positive controls, respectively 
(CTD and full-length are gifts from E. Mocarski). The ChIP assay shows that AD-EGFP 
interacted with the TR region, whereas no PCR product was detected from CTD-EGFP 
or EGFP transfections (Figure 3B). These experiments confirmed that IE1 interacts with 
the TR region in the absence of other viral proteins, and the interaction is most likely 
mediated through the acidic domain (AD) of the protein. 
Identification of IE1 DNA Binding Motifs in CD34 (+) HPCs.  Previous studies 
showed that IE1 interacts with mitotic chromosomes through the CTD of IE1 (Lafemina 
et al., 1989). Although this domain does not contribute to lytic DNA replication in human 
fibroblasts (Reinhardt et al., 2005, Shin et al., 2012), we were interested in determining 
the viral and host cell chromatin DNA interaction motifs for IE1 in HPCs. For viral 
chromatin/IE1 interactions, latently infected HPCs were used for a ChIP-seq experiment 
with IE1 antibody followed by next-generation sequencing (NGS). For cellular-specific 
chromatin/IE1 interactions, we transfected noninfected HPCs with the IE1 CTD-EGFP 
plasmid. EGFP antibody was used for IP followed by NGS. DNA binding domains were 
identified by peak calling with CLC Genomics Workbench software and uploading the 
peak sequences to a motif identifier specific for large NGS data sets (Regulatory 
Sequences Analysis Tools, RSAT). ChIP-seq data are available at NCBI SRA under 
accession number SRP040115. 
RSAT analysis of ChIP-seq data from latently infected HPCs showed that IE1 
interacted with putative Sp1 motifs (Figure 3C, Viral DNA). Multiple Sp1 consensus 
sequences are present within the HCMV TR element (Figure 3D). This is consistent with 
the IE1 binding shown to occur within the TR element in ChIP experiments shown 
in Figure 3A. For cellular DNA binding, the CTD of IE1 interacted with a 5 bp tandem  
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Figure 3.  IE1 Interacts with the TR Element during Latent Infection of CD34 (+) 
HPCs and Identification of IE1 Binding Consensus Sequences by ChIP-Seq.  (A) 
ChIP assay in latently infected HPCs with anti-iE1-, GAPDH-, or isotype control-specific 
antibodies. Lanes: input DNA, isotype control antibody, immunoprecipitation using anti-
GAPDH antibody or IE1-specific antibody. (B) 293FT cells were cotransfected with pTR 
and either pIE1-FL-GFP, pIE1-AD-GFP, pIE1-CTD-GFP, or empty pEGFP vector. ChIP 
assays were performed using anti-EGFP-specific antibody and PCR primers specific for 
the TR region.  (C) Elucidation of viral (using latently infected CD34 (+) HPCs) and 
cellular (using noninfected CD34 (+) HPCs transfected with IE1-CTD-GFP) DNA binding 
motifs using ChIP-seq. Shown is the RSAT analysis identifying putative DNA motifs 
from either viral or cellular DNA. A consensus sequence containing Sp1 transcription 
factor binding sites was identified for viral DNA. A consensus sequence containing a 5 
bp tandem repeat (boxed) was identified in the cellular data.  (D) Schematic of the 
HCMV TR region showing the presence of putative Sp1 sites and the relative positions 
of DNA elements. See also Figure S2B. 
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repeat DNA motif that is specific to centromeres of chromosomes 1, 8, and 10 
(Figure 3C, Cellular DNA) (Alkan et al., 2011, Muro et al., 1992, Zhu et al., 1995, Zhu 
et al., 1996). This report of an IE1 cellular chromatin-binding motif suggests that IE1 
interacts with centromeres of cellular chromatin in HPCs. These data strongly suggest 
that IE1 interacts with both the latent viral genome and cellular chromatin during latency 
and implicates IE1 as a latent viral genomic DNA maintenance factor. 
Expression of IE1x4 Is Required for Long-Term Maintenance of Viral DNA in 
CD34 (+) HPCs.  We generated an IE1 exon 4 deletion FixBac recombinant 
virus, FixBacΔEX4 (Figure 4A), and revertant. FixBacΔEX4 was confirmed by Southern 
blot (Figure 4B), and the final BAC clone was sequenced. Consistent with what was 
previously described, the FixBacΔEX4 mutant was reconstituted using an IE1-
expressing cell line (a gift from E. Mocarski; IE1 expression shown in Figure 1C) and 
achieved viral titers equal to wtFixBac virus in infected HFs (data not shown). 
FixBacΔEX4 or wtFixBac was used to infect HPCs, and viral DNA accumulation was 
monitored by PCR over a 35 day period. At 35 days postinfection, FixBacΔEX4 viral 
DNA was undetectable, whereas wtFixBac virus was still detectable by PCR (Figure 4C). 
Revertant virus DNA was also detectable (data not shown). PCR for the c-fos cellular 
gene promoter served as a control (Figure 4C). qPCR for FixBacΔEX4 gene expression 
showed a similar gene profile when compared to wtFixBac infection of HPCs (Figure S3, 
compare LUNA day 19), suggesting that the lack of genome persistence was not due to 
the aberrant expression of latency-associated factors. qPCR evaluation of wtFixBac, 
FixBacΔEX4, and revertant virus confirmed endpoint PCR results by also showing that 
FixBacΔEX4 failed to maintain genomic DNA (Figure 4D). These results strongly 
suggest that IE1x4 expression is required for long-term HCMV genomic DNA 

































































































































































































































































































































































































































































IE1x4 Mediates pTR Maintenance and Replication.  We investigated if IE1x4 
could mediate replication and maintenance of pTR by making a recombinant lentivirus 
that expressed IE1x4 (Figure 5A) to generate a 293L cell line that constitutively 
expressed IE1x4 (Figure 5B). This cell line, 293-IE1x4, was transfected with pTR or 
pGEM, and cells were passed up to 20 times in culture. The accumulation of DpnI-
resistant pTR DNA was calculated compared to pGEM control transfected cells. At cell 
passage five, there were approximately 41 copies of pTR per cell and a 13-fold increase 
in replicated DNA versus control samples (Figure 5C). At cell passages 10 and 20, pTR 
Figure 5. IE1 Exon 4 Mediates Amplification of HCMV Terminal Repeat Plasmid.  (A) 
Generation of recombinant lentivirus expressing IE1x4. Exon 4 (blue) was subcloned from 
amino acid 95 to amino acid 491 into the lentiviral expression vector pLVX EF1α.  (B) 
Western blot showing expression of IE1x4 in the stably transduced 293L-IE1x4 cells. Lane 
1: mock infected HF cells. Lane 2: 4 day postinfection HF cells. Lane 3: mock infected 
293L cells. Lane 4: IE1x4 293L stable cell line.  (C) IE1x4 mediates amplification of pTR. 
293L cell line that expresses IE1x4 was transfected with pTR. Hirt extracts were 
performed, and fold increase in DpnI-resistant DNA was determined, as was plasmid copy 
number. Error bars are the standard deviation for three biological replicates. pTR copy 
number is shown in parentheses. See also Figure S4. 
  122 
copy number stabilized at approximately two copies per cells (Figure 5C). Results also 
showed that the IE1x4 AD is required for amplification of pTR in the transient assay 
(Figure S4). These data strongly suggest that expression of IE1x4 mediates 
maintenance and replication of pTR. 
IE1 Interacts with TOPOIIβ, and Inhibition of TOPOIIβ Results in a Decrease 
in pTR Amplification.  It was recently shown that HCMV IE1 interacts with cellular 
chromatin in a manner consistent with KSHV LANA (Mücke et al., 2014), and KSHV 
LANA interacts with TOPOIIβ (Purushothaman et al., 2012). Given the fact that IE1x4 
mediates viral DNA replication and maintenance during latency, we investigated if IE1x4 
interacts with TOPOIIβ. IP experiments show that IE1x4 interacts with TOPOIIβ 
(Figure S5A). Treatment of samples with DNase had no effect on the ability to 
coimmunoprecipitate TOPOIIβ and IE1x4, strongly suggesting that the binding of the two 
proteins was the result of a protein-protein interaction (Figures S5E and S5F). Since 
IE1x4 was shown to interact with the HCMV TR region in latently infected HPCs, we 
evaluated TOPOIIβ binding to the TR during latency. ChIP experiments confirm that 
TOPOIIβ interacts with the TR region during latency (Figure S5B). Hence, data suggest 
that IE1x4 recruits at least one factor involved in DNA replication to the HCMV TR 
element during a latent infection. 
Next, 293-IE1x4 cells were transfected with pTR and treated with Ellipticine, a drug that 
inhibits TOPOIIβ. In the presence of Ellipticine, the expression of IE1x4 was unaffected 
(Figure 6A); however, the accumulation of replicated pTR was dramatically reduced 
compared to DMSO control treated cells (Figure 6B). As a control for Ellipticine activity, 
we also evaluated cell cycle by flow cytometry to show that Ellipticine arrested cells in 
the S and G2 phases of the cell cycle (Riccardi and Nicoletti, 2006) (Figures 6C 
and S5G). These experiments suggest that IE1x4 recruits TOPOIIβ to the TR element in 
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latently infected cells and that HCMV latent DNA replication requires the activity of 
TOPOIIβ. 
The Interaction of Sp1 with the HCMV TR Is Required for Amplification and 
Binding of IE1x4 to the TR Element.  CoIP and ChIP experiments confirm interaction 
of Sp1 with IE1x4 and TR, respectively (Figures S5C and S5D). We next treated 293-
Figure 6. Inhibition of TopoisomeraseIIβ with Ellipticine Abrogates pTR Replication 
in the Transient Replication Assay. (A) Western blot of IE1x4 expression in the 293L-
IE1x4 cell line treated with 10 µM Ellipticine.  (B) Inhibition of TOPOIIβ activity with 
Ellipticine diminishes pTR amplification. 293-IE1x4 cells were transfected with pTR and 
treated with Elllipticine or DMSO. qPCR was used to measure the enrichment of 
replicated plasmid DNA relative to input DNA. Three separate experiments were 
performed, and error bars are the standard deviation of the mean from three experiments. 
(C) Flow cytometry of propidium iodide-stained 293L-IE1x4 cells treated with DMSO or 
Ellipticine for 3 days. Curve fitting to determine percentage of cells in each cycle was 
performed using the Watson method. The fitted histograms are shown in Figure S5. 
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IE1x4-expressing cells transfected with pTR with Mithramycin A (Mith A), a drug that 
binds to GC-rich DNA sequences and displaces Sp1 transcription factor binding (Blume 
et al., 1991, Snyder et al., 1991). Since it is known that the c-Myc gene is highly 
regulated by Sp1, we evaluated the accumulation of c-Myc mRNA and protein from cells 
treated with Mith A as a measure of the drug’s efficacy in our cell line. Mith A-treated 
cells showed a decrease in c-Myc mRNA and protein expression (Figures 7A and 7B). 
ChIP assays at 3 days posttreatment with Mith A were performed using Sp1 or IE1 
antibodies and PCR primers for the HCMV TR or, as a negative control, the myoglobin 
exon 2 genomic region. In the presence of Mith A, the interaction of IE1x4 or Sp1 with 
the TR element was no longer detectable (Figure 7C, IE1x4 Mith A). qPCR results 
confirmed a marked decrease in occupancy of IE1x4 at the TR element in the absence 
of Sp1 binding at the TR (Figure S6A). We next evaluated the ability of pTR to amplify in 
the absence of Sp1 and IE1x4 binding with the TR element. DNA from Mith A- or DMSO-
treated IE1x4-expressing cells transfected with pTR was Hirt extracted at 1 and 5 days 
posttreatment and evaluated for plasmid amplification. No amplification of pTR was 
detected at 5 days posttreatment in the presence of Mith A (Figure 7D). Lastly, we 
evaluated the ability of IE1x4 to interact with the TR element in HPCs infected with 
FixBac virus and treated with Mith A. Mith A-treated cells were evaluated for expression 
of c-Myc to ensure that Sp1 binding to the c-Myc promoter was inhibited (Figure S6B). 
DMSO and treated infected cells were harvested, and ChIP assays were performed 
using Sp1 or IE1 antibodies. The amount of IE1x4 that interacted with the TR element in 
infected cells decreased in the absence of Sp1 interaction with the TR element 
(Figure 7E). Mith A had a minimum effect on cell viability at 50 nM at 5 days 
posttreatment (Figure S6C). 
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Since Mith A treatment likely results in off-target effects, we performed Sp1 
knockdown experiments in the context of the transient assay to further support the 
involvement of Sp1 in TR replication. 293 cells were transduced with either a lentivirus 
that expressed shRNA specific for Sp1 mRNA or a control scramble shRNA. Efficient 
knockdown of Sp1 expression was confirmed by western blot (Figure 7F). shRNA-
treated cells were cotransfected with a pEGFP-IE1x4 plasmid and pTR. ChIP assays 
were performed using antibodies for IE1, Sp1, or GAPDH and primers specific for the TR 
element or the cellular myoglobin exon 2 genomic locus. In cells where Sp1 expression 
was knocked down, the amount of IE1x4 occupying the TR element was reduced 
(Figure 7G). Lastly, we measured the accumulation of replicated pTR under conditions 
where Sp1 expression was knocked down in the transient assay. Amplification of pTR 
was reduced in cells expressing shRNA specific for Sp1 mRNA (Figure 7H). Taken 
together, Sp1 shRNA knockdown or drug-induced inhibition of Sp1 binding to its 
consensus sequence reduces the amount of IE1x4 binding to the TR element and 
results in a reduction in amplification of pTR. These results suggest that Sp1 mediates a 
required interaction of IE1x4 for the amplification and maintenance of the HCMV TR.  
We also evaluated the ability of pTR to amplify when a cluster of Sp1 sites was 
removed from the TR element (Figure S7A). The removal of a cluster of Sp1 sites from 
pTR abrogated the ability of the plasmid to replicate in the presence of IE1x4 
(Figure S7B) and reduced the occupancy of Sp1 at the TR (Figure S7C), suggesting that 
the region of the TR containing a cluster of Sp1 sites is required for efficient latent DNA 
replication. 
Comparison of KSHV and HCMV latency cis- and trans-acting factors shows 
some similarities between IE1x4 and LANA and KSHV TR and HCMV TR (Mücke et al., 
2014) (Figures S7D and S7E, respectively). 
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Figure 7.  The Interaction of Sp1 with the HCMV TR Is Required for Amplification and Binding of 
IE1x4 to the TR Element.  (A) Treatment of cells with MithA decreases the expression of c-Myc RNA. 
qPCR showing relative expression levels of mRNA in DMSO- or Mith A-treated 293-IE1x4 cells was 
calculated using cyclophilin mRNA as an internal control. 
(B) Mith A decreases the expression of c-Myc protein. We performed western blots of cells treated 
with increasing concentrations of Mith A. Blots were reacted with anti-c-Myc, IE1, or GAPDH. (C) ChIP 
assays showing inhibition of Sp1 binding to the HCMV TR also blocks IE1x4 interaction with the TR 
element. 293-IE1x4-expressing cells were transfected with pTR and treated with Mith A or DMSO. (D) 
pTR amplification in 293-IE1x4 cells transfected with pTR or pGEM and treated with Mith A or DMSO. 
At 1 and 5 days posttreatment, DNA was analyzed for DpnI resistance. qPCR was used to measure 
the enrichment of replicated plasmid DNA relative to input DNA. (E) ChIP assay of latently infected 
HPCs treated with Mith A or DMSO. Occupancy relative to GAPDH was measured for each protein at 
the TR or myoglobin genomic region. (F) Western blot of Sp1 knockdown in 293L cells relative to a 
scramble control cell line and expression of transfected pEGFP-IE1x4. (G) ChIP assay showing 
knockdown of Sp1 reduces IE1x4 binding to TR. Occupancy is calculated relative to GAPDH. (H) 
Knockdown of Sp1 expression reduces replication of pTR. Sp1 knockdown or scramble control cells 
were transfected with IE1x4-GFP and pTR. At 5 days posttreatment DNA was analyzed for DpnI 
resistance. qPCR was used to measure the enrichment of replicated plasmid DNA relative to input 
DNA. Three separate experiments were performed for all qPCR experiments, and error bars are the 
standard deviation of the mean from the three experiments. See also Figures S6 and S7. 
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Discussion 
One striking difference between HCMV latency in CD34 (+) HPCs and CD14 (+) 
monocytes was that the transcript encoding IE1x4 was present in HPCs (Rossetto et al., 
2013). One explanation for this difference is that two distinct mechanisms may have 
evolved to maintain the viral chromosome in CD34 (+) cells verses nondividing CD14 (+) 
cells. This distinction could be due to the fact that monocytes are short-lived, nondividing 
cells in vivo, whereas CD34 (+) HPCs are a long-lived, self-renewing cell population 
(Kataoka et al., 2011, Kikushige et al., 2011, Piacibello et al., 1998, Reya, 2003, Reya 
et al., 2003, Seita and Weissman, 2010, Wilson et al., 2004, Zon, 2008). Hence, viral 
genome persistence may depend on efficient tethering and maintenance in a self-
renewing cell type such as CD34 (+) HPCs. 
Although the presence of IE1 mRNA in infected HPCs was reported previously 
(Maciejewski and St Jeor, 1999), we observed expression of a protein originating entirely 
from exon 4 in the same reading frame context as full-length IE1. RNAPII occupancy 
data show that transcription from the MIEP is stalled and that an internal promoter most 
likely regulates the expression of IE1x4 in HPCs. The sequence upstream of IE1x4 
contains multiple transcription factor binding sites including AP-1, GATA-1, STAT, and c-
ETS. The expression of only exon 4 in the absence of exons 2 and 3 may explain why 
many previous studies failed to detect the IE1 mRNA during latent infection by PCR, 
since primers specific for exons 2 and 3 are typically used to show the absence of 
IE1/IE2 in latently infected HPCs. These data are also in agreement with previous 
observations showing that epigenetic modifications as well as control of transcriptional 
elongation are significant factors regulating herpesvirus latent virus gene expression 
(Abraham and Kulesza, 2013, Palermo et al., 2011, Toth et al., 2012). 
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Similar to KSHV LANA, which also interacts with DNA through histones, ChIP-seq data 
suggest that IE1x4 associates with mitotic chromosomes with a preferential localization 
to areas near centromeres (Vázquez et al., 2013). We postulate that HCMV IE1x4 
functions in the same capacity as EBNA1 and LANA in that they tether viral genomic 
DNA to cellular chromatin and mediate amplification of the viral genome (Barbera et al., 
2006, Ceccarelli and Frappier, 2000, Cotter and Robertson, 1999, Fujita et al., 2001, Ito 
et al., 2002, Marechal et al., 1999, Nayyar et al., 2009, Piolot et al., 2001, Wang and 
Frappier, 2009). This premise was reinforced recently by the published report showing 
that IE1 and LANA share some of the same properties with respect to interaction with 
DNA through histones (Mücke et al., 2014). Also, the TR region of HCMV, which 
mediates episome persistence, is consistent with the location of the viral DNA 
maintenance element in KSHV (Ballestas et al., 1999, Ballestas and Kaye, 2001,Collins 
and Medveczky, 2002, Cotter et al., 2001, Garber et al., 2001, Lim et al., 2002). The 
KSHV maintenance element or latent origin contains several LANA binding sites, of 
which at least one is required for efficient plasmid replication (Garber et al., 2001). EBV 
OriP is also composed of complex repeat elements and contains EBNA-1 binding sites 
(Yates et al., 2000). In both EBV and KSHV, latent origins are G+C rich and contain 
multiple repeat sequences; this is consistent with the sequence of the TR region of 
HCMV. HCMV TR interacts with components of the cellular replication machinery, which 
is again consistent with EBV OriP and KSHV TR regions (Aiyar et al., 1998, Chaudhuri 
et al., 2001, Dhar et al., 2001, Rossetto et al., 2013, Schepers et al., 2001, Stedman 
et al., 2004). 
The work presented here supports a model of HCMV latency where a viral-
encoded protein, IE1x4, interacts with the TR region and acts in trans to replicate and 
maintain the viral genome in HPCs. We show that IE1x4 interacts with Sp1 in the context 
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of the transient TR replication assay. Using this assay we show that inhibition of binding 
of Sp1 to the TR also decreased the amount of IE1x4 interacting with the TR in both 
transiently transfected cells. The lack of binding of Sp1 and IE1x4 to the TR element 
resulted in a decrease in amplification of the TR-containing plasmid, adding more weight 
to the evidence that IE1x4 is the viral-encoded factor regulating viral genome 
maintenance and replication. The interaction of IE1 with Sp1 was previously described in 
HCMV lytically infected cells (Yurochko et al., 1997). Lastly, we demonstrate that IE1x4 
interacts with at least one cellular replication protein, TOPOIIβ, also consistent with 
KSHV LANA. Hence, the DNA sequence properties and location of the HCMV TR, 
coupled with the observation that IE1 mediates persistence of the pTR plasmid, strongly 
suggest that the TR element is the functional equivalent of KSHV and EBV latent origins 
and that IE1 is the functional equivalent of LANA and EBNA1. 
Data show that IE1x4 is the only viral-encoded protein required to both amplify 
the viral genome and mediate efficient transfer to daughter cells, although other factors 
expressed during HCMV latency in HPCs may contribute to maintenance/replication of 
the viral genome. pTR copy number stabilized at approximately two copies per cell after 
20 cell passages, consistent with what was observed for EBV OriP (Leight and Sugden, 
2001). During lytic infection HCMV IE1 interacts with STAT1/STAT2 and subsequently 
counteracts type I IFN-mediated antiviral host response during lytic infection (Huh et al., 
2008, Krauss et al., 2009, Paulus et al., 2006). Also, IE1 localizes with and disrupts 
ND10 compartments through an interaction with PML (Ahn and Hayward, 1997, Ahn and 
Hayward, 2000, Korioth et al., 1996, Wilkinson et al., 1998). These properties of IE1 are 
thought to facilitate an evasion of host cell immune response leading to enhanced virus 
replication and growth under lytic conditions (Korioth et al., 1996,Tavalai et al., 2006). 
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In summary, we provide evidence for a mechanism of HCMV genome 
maintenance in latently infected HPCs involving expression of IE1x4. The factor 
described in this study is specific to HCMV latent infection in CD34 (+) HPCs and 
mediates viral genome maintenance and replication.  
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Experimental procedures  
 
Western Blots for the Detection of HCMV IE1 in CD34 (+) HPCs. 
IE1 western blots were performed with approximately 1 × 106 latently infected 
CD34 (+) HPCs lysed in Laemmli sample buffer, and protein lysates were separated 
through an 8%–16% SDS-PAGE gel. Protein was transferred to PVDF membranes and 
reacted with either a commercially available IE1 antibody (exon 4-specific, Abcam 
#ab30924) at 1:1,000 or with an IE1 antibody (p63-27) generously gifted from William 
Britt at 1:20,000 (Andreoni et al., 1989, Britt and Vugler, 1987). A mouse IgG LI-COR 
fluorescent secondary antibody was used at 1:5,000, and imaging was performed using 
a LI-COR scanner. Blots were reacted with an anti-actin-specific antibody (Santa Cruz 
sc-7210) and rabbit IgG secondary to show the amount of protein loaded for each lane. 
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IE1 Exon-Specific RT-PCR in Latently Infected CD34 (+) HPCs. 
Total RNA was isolated from 2 × 106 10 days postinfection CD34 (+) HPCs and 
2 × 106 4 days post infection HF cells as previously described (Rossetto et al., 2013). 
Five microliters of the RNA was then used in QIAGEN OneStep RT-PCR Kit reaction 
following the manufacturer’s instructions, using the strand-specific primers specific for 
indicated MIE exons in FixBac (VR-1814). The resulting strand-specific PCR products 
were run on a 1.5% agarose gel using 1× TAE (40 mM Tris-HCl [pH 7.6], 20 mM acetic 
acid, 1 mM EDTA) buffer and visualized by ethidium bromide staining. 
 
Infection of CD34 (+) HPCs with FixBacΔEX4 Virus and Evaluation of Viral DNA 
Maintenance. 
FixBacΔEX4 virus was generated by transfection of FixBacΔEX4 DNA into HF-
IE1 (ihfie1.3)-complementing cell line (Greaves and Mocarski, 1998). HF-IE1 cells were 
transfected with FixBacΔEX4 DNA as previously described (Gao et al., 2010; 
Supplemental Experimental Procedures). 
 
Transient pTR Replication and Maintenance Assays in 293L-IE1x4 Cells. 
The IE1x4-expressing cell line (0.5 × 106 cells) was transfected with pTR (1 ug = 
24,000 copies/cell) or pGEM (0.3 µg = 24,000 copies/cell) or pTRΔSp1 using Mirus 
TransIT (Supplemental Experimental Procedures). 
 
Replication of pTR in Experimentally Latently Infected CD34 (+) HPCs. 
CD34 (+) HPCs were isolated from cord blood (deidentified, not human subjects) 
using positive isolation and magnetic purification according to the manufacturer’s 
instructions (STEMCELL Technologies). For experimentally infected cells, approximately 
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0.7 × 106 CD34 (+) cells plus 5 µg (6.6 × 1011 copies) of either TR or oriLyt (5.5 × 1011 
copies) containing plasmids were transfected using a Nucleofector instrument and CD34 
(+) kit according to the manufacturer’s instructions (Lonza) using program U008. After 
transfection cells were cultured in normal conditions for 120 hr before DNA was 
harvested. Cells were pelleted and DNA was extracted using DNA lysis buffer (2% SDS, 
10 mM EDTA, 10 mM Tris-HCl [pH 7.4]) with the addition of 25 µg Proteinase K and 
incubated for 2 hr in a 65°C water bath, followed by phenol-chloroform and ethanol 
precipitation. The final DNA pellet was resuspended in 100 µl 1× TE (pH 7.4) and 
cleaved with either HindIII alone or HindIII and DpnI for 1 hr in 37°C water bath, followed 
by inactivation at 80°C for 20 min. One microliter of sample DNA was used in a 20 µl 
TaqMan PCR reaction using TaqMan Universal PCR 2× master mix (Life Technologies), 
plus primers and probe. TaqMan primer and FAM-labeled probes were designed over 
DpnI junctions of pGEM that would allow for signal to be detected from only replicated 
DNA, not input DNA. The following qPCR program was used: one cycle of 95°C hot start 
for 5 min and 40 cycles of 95°C for 15 s and 60°C for 1 min. DpnI-resistant DNA from TR 
was calculated using HindIII digested alone as the total input value for each plasmid set 
and TR fold enrichment over oriLyt DpnI DNA. Input plasmid determined at 24 hr 
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Figure S1.  Confirmation of latency by mRNA accumulation for selected transcripts from 
HCMV latently infected CD34 (+) HPCs and confirmation of IE1x4 (Figure S1 is related to 
Figure 1).  (A) Cells were infected with HCMV (FixBac virus) and total cell RNA was harvested 13 
and 30 days post infection and qPCR was performed to detect viral transcripts.  Primers and 
probes used are described in materials and methods. Viral mRNA levels are normalized to 
cellular cyclophilin mRNA.  (B) Confirmation of a smaller protein species of IE1 expression in 
latently infected CD34 (+) cells using an alternate IE1 specific antibody.  A) Shown is a western 
blot of lytically infected HF cells and latently infected CD34 (+) cells initially incubated with IE1 
specific antibody followed by sequential incubation with IE2 specific antibody.  The smaller form of 
IE1 is indicated as IE1L.  After re-probing with IE2 antibody the presence of full length IE2 (IE2-
p86) as well as the 40kD isoform (IE2-p40) is indicated in the lytically infected HF cells and is not 
present in the latently infected CD34 (+) cells. Lane 1: mock infected HF cells, Lane 2: HF cells 
4dpi strain FIX, Lane 3: mock infected CD34 (+) cells, Lane 4: latently infected CD34 (+) cells 
30dpi strain FIX. WB: western blot.  Lytically infected HFs (lane 2) are included as a size 
reference for full length IE1 compared to latently infected CD34 (+) HPCs.  Due to the relatively 
high abundance of full length IE1 during lytic infection in HFs, fewer cells are used as indicated by 
re-probing with anti-actin specific antibody. B) Western blot of IE1x4 immunoprecipitated from 
latently infected CD34 (+) cells.  Blot was reacted with both IE2 and IE1 (W. Britt) specific 
antibodies.  Shown is (Lane 1) lytically infected HF cells, (Lane 2) immunoprecipitation with a non-
specific control antibody from latently infected CD34 (+) HPCs, and (Lane 3) immunoprecipitation 
with IE1 antibody from latently infected CD34 (+) HPCs.  The slightly different motilities of the 
non-specific control IgG heavy chain and the IE1 antibody IgG heavy chain are indicated by black 
arrows.  




Figure S2.  Transfection efficiency of CD34 (+) HPCs and subcellular localization of IE1 
subclones (Figure S2 is related to Figures 2 and 3). (A) Cells (1x106) were transfected with pEGFP 
using Nucleofector 2b device (Lonza) and CD34 transfection solution.  Cells were visualized by 
fluorescent microscopy 24 hours post transfection. Left panel, Fluorescent field. Right panel bright field. 
(B) Schematic of IE1 full length-GFP, AD-GFP, and CTD-GFP subclones. Western blot showing relative 
expression in transfected 293-FT cells used for ChIP analysis.  (C) Immunofluorescence showing that 
IE1 exon 4 and IE1 subclones localize to the nucleus similar to the full-length protein: full length, exon 
4, AD, and CTD.  GFP tagged subclones were transfected into 293-FT cells and nuclear localization is 





Figure S3. FixBac∆EX4 expresses similar levels of expression 
of IE1 and LUNA compared to wtFixBac at early times post 
infection (Figure S3 is related to Figure 4).  CD34 (+) HPCs 
were infected with wtFixBac or FixBac∆EX4 mutant viruses at an 
MOI of 5.  qPCR was performed at various days post infection to 
detect IE1 exon 4, IE2 and LUNA mRNA.  Fold changes were 
calculated using mRNA accumulation of wtFixBac compared to 
FixBac∆EX4 infected cells. FixBac∆EX4 showed a decrease in 
mRNA accumulation of LUNA at days 3 and 27.  At day 27, no 
HCMV specific mRNA was detected in FixBac∆EX4 infected cells 






Figure S4.  The AD region of IE1 is required for interaction with pTR and 
amplification in a transient replication assay (Figure S4 is related to Figure 
5).  A pEGFP subclone of IE1x4 with a deletion in the AD region was 
cotransfected with pTR for a transient replication assay in 293L cells.  A) 
Schematic comparing pEGFP IE1 expression vectors containing full length IE1, 
IE1x4, and IE1ΔADx4.   The relative locations of AD and CTD regions are 
indicated by brackets.   B) Western blot of 293L cells cotransfected with either 
pEGFP IE1x4 or pEGFP IE1ΔADx4 and pTR in the transient replication assay. C) 
ChIP assay of 293L cells cotransfected with either pEGFP IE1x4 or pEGFP 
IE1ΔADx4 and pTR.  Negative controls are IP with GAPDH and PCR for the 
Myoglobin genomic region.  Relative occupancy is calculated using GAPDH as a 
reference.  D) Transient replication assay of 293L cells cotransfected with pTR 
and either pEGFP IE1x4 or pEGFP IE1ΔADx4.  Fold change in DpnI resistant 
DNA vs. input DNA is shown at 2 and 5 days post transfection. E) 
Immunofluorescence of 293L cells transfected with pEGFP IE1ΔADx4 showing 















Figure S5. TOPOIIß and Sp1 interact with IE1x4 and the TR element (Figure S5 
is related to Figure 6). (A) Interaction of IE1x4 with topoisomerase IIß. Co-
immunoprecipitation of IE1x4 and TOPOIIß.  The IE1x4 expressing cell line was 
used to immunoprecipitate either IE1x4 or TOPOIIß with specific antibodies or 
control antibodies. Left panel: immunoprecipitation with anti- TOPOIIß or IE specific 
antibodies followed by Western blot using anti-IE1 specific antibody; Right panel: 
immunoprecipitation with anti-TOPOIIß or IE1 specific antibodies followed by 
Western blot using anti-TOPOIIß specific antibody. 5% of cell lysate was loaded for 
input. (B) Interaction of TOPOIIß with HCMV TR during latency. ChIP assay from 
latently infected HPCs using anti- TOPOIIß specific antibody or control antibodies 
specific for GAPDH or IgG isotype specific antibody. The DNA component from the 
immunoprecipitated complexes was amplified using PCR primers specific for the 
HCMV terminal repeat region (TR) or the HCMV UL25 loci as a control for non-
specific binding.  (C) IE1x4 interacts with Sp1. The 293 IE1x4 expressing cell line 
was used to co-immunoprecipitate Sp1 and IE1x4.  Left panels: Immunoprecipitation 
using anti-Sp1 specific antibody followed by western blot with Sp1 or IE1 antibodies.  
Right panels: Immunoprecipitation using anti-IE1 specific antibody followed by 
western blot with Sp1 or IE1 antibodies.  IgG control immunoprecipitations are also 
are shown and 5% of cell lysate was loaded for input. (D) Sp1 interacts with the 
HCMV TR element.  ChIP analysis from latent infection of CD34 (+) HPCs. ChIP was 
performed using anti-Sp1 specific antibody or control antibodies specific for GAPDH 
or IgG isotype antibody. PCR of the immunoprecipitated DNA was performed with 
primers specific for the TR region or a non-specific viral genomic region (UL25). (E) 
To show that IE1 interaction with Sp1 and TOPOIIb is not DNA dependent, 293L-
IE1ex4 cell lysates were treated with DNAse I prior to immunoprecipitation with IE1 
specific antibody.  Shown is a western blot of IE1 IPs reacted with either Sp1, 
TOPOIIb or IE1 antibodies. IgG and GAPDH antibody immunoprecipitations are 
included to control for non-specific interaction. 10% of the sample was used as input.  
(F) 10 ul of DNAse I treated cell lysate was separated on a 0.75% agarose gel to 
confirm digestion of DNA.  Lanes loaded with untreated cell lysate and treated cell 
lysate are shown following a molecular weight marker. (G) Flow cytometry of 
propidium iodide stained 293L-IE1x4 cells treated with DMSO or Ellipticine for 3 days 
shows that inhibition of TOPOIIβ via Ellipticine prevents cell cycle progression and 
arrests cells at S and G2.  Curve fitting to determine percentage of cells in each 
cycle was performed using the Watson method. Left panel: DMSO treatment. Right 




   
Figure S6.  (A) ChIP analysis shows that Mithramycin A decreases Sp1 and IE1x4 
binding to the TR in the transient pTR replication assay (Figure S6 is related to Figure 
6).  293L-IE1x4 cells were treated with 100 nM Mith A or DMSO. Transfection with pTR was 
performed 24 hours after Mith A treatment.  ChIP was performed at 2 days post 
transfection/3 days post Mith A treatment with Sp1 or IE1 antibodies.  GAPDH antibody was 
used as a control for non-specific interaction.  Shown is the relative occupancy of IE1 and 
Sp1 at the TR locus or a non-related locus, the myoglobin (MYO) gene using qPCR.  Data is 
plotted as the occupancy of IE1x4 or Sp1 relative to GAPDH.  (B) Mithramycin A mediated 
knockdown of expression of c-Myc in latently infected CD34 (+) HPCs.  RT-qPCR for c-
myc expression in latently infected CD34 (+) HPCs.  Shown is the expression of c-myc in 
cells treated with 25nM or 50nM Mithramycin A relative to a DMSO vehicle control.  Cells 
were treated for 2 days and drug or vehicle control was replenished every 24h. C) MTT 
assay for cells treated with Mithramycin A.  Viability of cells treated with Mithramycin A 
was evaluated using an MTT assay.  Shown is the fluorescence (OD570nm – background 
OD750nm) of either 293L-IE1x4 cells or latently infected CD34 (+) HPCs in the presence of 
0-100nM Mithramycin A.  Cells were treated for either 5 days (293L-IE1x4) or 2 days (latent 























































Figure S7.  Sp1 sites in pTR are required for amplification in the 
transient replication assay and HCMV TR comparison with KSHV TR 
functional regions (Figure S7 related to Figure 7).  (A) Schematic 
indicating number and relative locations of Sp1 sites in the TR region of pTR.  
pTRΔSp1 contains a ~2,000bp deletion that removes 7 of the 10 predicted 
Sp1 sites. B) Replication of pTR or a TR deletion mutant in 293L-IE1x4 cells. 
C) ChIP assays for interaction of IE1, Sp1 or a GAPDH control with the TR 
region of pTR or pTRΔSp1.  (D) The central HCMV TR region is composed of 
multiple sequence repeats (orange bars) the ‘a’ sequences.   The ‘a’ 
sequences are flanked by TRS (terminal repeat short) and TRL (terminal 
repeat long).  Residues shown in red are conserved between the two TR 
sequences.  Black boxes indicate putative Sp1 transcription factor binding 
sites. The LANA binding region and AT rich region have approximately 65% 
and 54% homology with the HCMV TR respectively. Alignment of the two viral 
TR regions was performed by ExPASy LALIGN. (E) IE1 shares homology with 
gamma herpesvirus tethering proteins LANA and EBNA1.  IE1x4 contains a 
large central region composed of hydrophobic amino acids (HPB) followed by 
an acidic region, the AD (acidic domain) and the CTD (chromatin tethering 
domain).  The IE1 acidic domain contains repeats of glutamic acid and 
aspartic acid similar to the acidic region of LANA.  Amino acids shown in red 
indicate either aspartic acid or glutamic acid.  Comparison of LANA chromatin 
tethering domain, aa 5-22, with IE1 chromatin tethering domain, aa 476-491.  
Identical amino acid positions are shown in blue boxes. CTD: chromatin 
tethering/binding domains, DB: TR DNA binding domain, LZ: leucine zipper, 
QEP/QERP/QED: repetitive region of LANA composed of amino acids Q, E, 
P, R, and D. 
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Table S1.  Identification of IE1x4 peptides. 
 
I  P  L  S  S  V  I  V  A 
T  M  C  N  E  Y  K  V  T  S  D 
I  T  K  P  E  V  I 
I  T  K  P  E  V  I  S  V  M  K  R  R  I  E 
I  V  A  Y  T  L  A  T  A  G  V  S  S  S  D 
K  C  I  G  L  T  M  Q 
C  I  G  L  T  M  Q  S  M 
K  L  G  G  A  L  Q  A  K 
G  G  A  L  Q  A  K  A  R  A  K  K  D  E 
K  Y  T  Q  T  E  E  K 
M*  L  K  K  Y  T  Q  T  E  E  K  F 
L  S  S  V  I  V  A  E  N  S  D  Q  E  E  S  E  Q  S  D 
E  E  G  A  Q  E  E 
L  V  S  P  P  E  S  P  V  P 
M  C  Y  R  N  I  E 
M  Y  M  C  Y  R 
D  V  S  K  G  A  A  N 
P  F  E  E  M  K  C  I  G  L  T  M  Q  S 
P  S  V  D  D  L  R 
K  L  G  G  A  L  Q  A  K  A  R 
M  L  K  K  Y  T  Q  T  E  E  K  F 
P  D  E  I  M  A  Y  A  Q  K  I  F  K  I  L 
R  E  D  T  V  S  V  K  S  E  P  V 
S  D  S  L  V  S  P  P  E  S  P  V 
S  Q  A  M  A  A  L  Q  N  L  P  Q  C  S  P  D 
S  V  I  V  A  E  N  S  D  Q  E  E  S  E  Q 
T  M  C  N  E  Y  K  V  T  S  D 
T  Q  T  E  E  K  F  T 
V  I  S  V  M  K  R  R 
V  P  E  D  K  R  E  M  W  M  A  C  I  K  E  L  H  D  V  S  K  G  A  A  N  K  L  G  G  A  L  Q 
V  S  K  G  A  A  N  K  L  G  G  A  L  Q  A  K  A  R  A  K 
Y  T  L  A  T  A  G  V  S  S  S  D 
A  Y  T  L  A  T  A  G  V  S  S  S  D 
A  K  K  D  E  L  R  R 
C  I  G  L  T  M  Q  S  M 
D  E  E  E  A  I  V  A  Y  T  L  A  T  A  G  V  S  S  S  D  S  L  V 
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D  E  E  E  E  E  G  A  Q  E  E  R  E  D  T  V  S  V 
D  G  A  E  E  P  T  A  S  G  G  K  S  T  H 
E  A  I  V  A  Y  T  L  A  T  A  G  V  S  S  S  D  S 
E  E  E  D  G  A  E  E  P 
E  E  G  A  Q  E  E  R  E  D  T  V  S  V 
E  E  R  D  K  V  L  T  H  I 
E  E  S  D  E  E  E  A  I  V  A  Y  T  L  A  T  A  G  V  S  S  S 
E  F  F  T  K  N  S  A  F  P  K  T  T  N  G 
E  N  S  D  Q  E  E  S  E  Q  S  D  E  E  E  E  E  G 
E  P  V  S  E  I  E  E 
F  N  M  M  G  G  C  L  Q  N  A  L  D  I  L 
G  A  E  E  P  T  A  S  G  G  K 
G  A  F  N  M  M  G  G  C  L  Q 
G  G  A  L  Q  A  K  A  R  A  K  K  D  E 
T  M  Y  G  G  I  S  L  L  S 
S  E  F  C  R  V  L  C  C  Y  V  L 
T  S  V  M  L  A  K  R  P 
I  F  M  D  I  L  T  T  C  V 
Table S1.  IEx4 peptides identified from immunoprecipitated IE1x4 from latently 
infected CD34 (+) HPCs (Table S1 related to Figure 1).  Top panel shows the 
identification of a peptide corresponding to the second Methionine in IE1x4 (Red Box).  
Arrows show the putative mRNA initiation sites identified by 5-Prime RACE.  Peptides 
shown cover approximately 80% of the IE1x4 protein sequence and are greater than 
95% confidence. * Indicates peptide containing the putative IE1x4 protein initiation 





Table S2.  Proteins interacting with the HCMV TR. 
Viral Genes  
 
                                                          
 
GENE (PROTEIN) 
UL44  (Processivity factor) 
UL87 (Interacts with UL95 and UL79)  
UL123 (IE1, Tethers Chromatin)                                                 
UL133 (Interacts with UL138) 
                   
Cellular Genes 
ACCESSION GENE PROTEIN 
P17096 HMGA1 High mobility group protein HMG-I/HMG-Y 
P06748 NPM Nucleophosmin 
Q96IK1 BOD1 Biorientation of chromosomes in cell division protein  
Q8NCN4 RN169 RING finger protein 169  
Q02880 TOP2B DNA topoisomerase 2  
P15927 RFA2 Replication protein A  
Q04837 SSBP Single-stranded DNA-binding protein, mitochondrial  
P19338 NUCL Nucleolin  
Q96T17 MA7D2 MAP7 domain-containing protein 2 
P08047 Sp1 Transcription factor 
P16989 DBPA DNA-binding protein A  
Q9Y2T7 YBOX2 Y-box-binding protein 2 
Table S2. Identification of factors interacting with HCMV TR (Table S1 related to 
Figure 2).  As an initial effort toward the understanding of the mechanism used for 
maintenance/replication of the TR element in latently infected HPCs, we employed an in 
vitro affinity column protocol to identify proteins that interact with the TR element during 
latency. We used the TR element as bait for proteins present in nuclear extracts 
prepared from latently infected HPCs. The viral proteins identified were previously 
shown to be expressed in both experimental and natural infections of CD34 (+) HPCs 
(Rossetto et al., 2013). UL87, UL95 and UL79 encode essential early transcripts that 
produce proteins that apparently affect late gene expression including the UL44 late 
kinetic transcription and colocalize with UL44 prior to initiation of viral DNA synthesis 
(Isomura et al., 2011). UL44 is the DNA polymerase processivity factor, however 
herpesvirus polymerase processivity factors have recently been shown to have diverse 
functions with respect to regulation of gene expression and initiation of DNA synthesis 
(Appleton et al., 2004; Komazin-Meredith et al., 2008; Rossetto et al., 2011; Strang et al., 
2010a; Strang and Coen, 2010; Strang et al., 2010b). The expression of UL133/135 
proteins are apparently required for promotion of latency in CD34 (+) cells and these 




Supplemental Experimental Procedures. 
 
Isolation of CD34 (+) cells from blood. Cord blood was received from the Colorado 
Cord Blood Bank (Univ. of Colorado) and pooled peripheral blood from Renown medical 
center (Reno, NV) was immediately processed to isolated HPCs.  All samples are de-
identified and exempt from human subjects protocol. Cell isolations were preformed as 
described previously (Rossetto et al., 2013). 
Purity of isolated CD34 (+) cells was assessed by flow cytometry using antibodies for 
human CD34-PE (STEMCELL Technologies), along with human CD45-FITC (BD 
Biosciences) for total cell staining.  Isotype controls included IgG1-PE (BD Biosciences) 
and IgG1-FITC (BD Biosciences).  Approximately 0.5 x 106 cells were stained for 30 
minutes at 4°C with the fluorescently labeled antibody, washed once and resuspended in 
1X PBS with 0.5%FBS, 2 mM EDTA and 1% methanol-free formaldehyde.  Samples 
independently analyzed by Flow Contract Site Laboratory (Kirkland, WA).  CD34 (+) cell 
purity was routinely above 80%. 
Culturing conditions for CD34 (+) HPCs. HPCs were cultured were grown as 
previously described (Rossetto et al., 2013). Media was refreshed every three days until 
latency had been established and verified. Latency was determined to be established 
when no IE gene expression was detected by qPCR analysis, detection of the virus 
genome and expression of LUNA and UL138. To reactive latent virus, HPCs were 
stimulated to proliferate and differentiate by adherence to plastic tissue culture dishes 
supplemented with 100 ng/mL IL-6 (R&D Systems) and 1 X StemSpan CC110 
(STEMCELL Technologies) for three days, followed by the addition of 50 ng/ml 
lipopolysaccharide (LPS) (Sigma-Aldrich) for an additional four days. 
Generation of Fix BAC virus.  To generate FIX virus, purified FIX BAC DNA was 
electroporated into HF cell line. For each transfection 5 x 106 actively dividing HF cells 
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were pelleted and resuspended in 0.4 ml of DMEM with 10% FBS and mixed with 100 
ug (approximately 100 ul) of column purified (NucleoBond Xtra BAC, Clontech) BAC 
DNA, 10 ug sheared salmon sperm DNA (Life Technologies) and 2 ug pcDNA-pp71 
plasmid. The mixture was placed in a 0.4 mm gap cuvette and electroporated using 
1600 uF capacitance and 200 V. Cells were allowed to recover on ice for 5 minutes and 
then resuspended with 7 ml of culture media into a 25-cm2 tissue culture flask. Culture 
media was changed 24 hrs post transfection.  14 days post transfection cells were 
scraped, the cells and culture media were placed into a 15 ml conical and two freeze-
thaw cycles were used to release virus. To expand the virus further, the virus 
supernatant was passed up into a confluent 75-cm2 flask of HF’s. The process was 
repeated 2 more times passing cells up to a 225-cm2 flask and the final virus was titered 
according to standard plaque assay on HF cells.  
5’-rapid amplification of cDNA ends (RACE).  Total RNA was harvested from 
0.2 x 106 latent HCMV infected HPCs using RNA/DNA/Protein purification kit (Norgen 
Biotek Corp.) according to manufactures instructions, followed by removal of genomic 
DNA using Turbo DNA-free (Life Technologies).  cDNA was generated from the Purified 
RNA using the SMARTer RACE cDNA amplification kit (Clontech) according to 
manufactures instructions. For 5’ RACE PCR the resulting cDNA was used along with 
Advantage GC 2 polymerase mix (Clontech) and gene specific primers. Primers were 
designed to be used with the Touchdown PCR cycling protocol according to the 
manufactures instructions.  The resulting PCR product was ethanol precipitated and 
resuspended in 10 ul of TE.  One microliter of PCR product was mixed with loading dye 
and electrophoresed on a 1X TAE 0.8% agarose gel to check for PCR products.  TA-
cloning was used to insert the 5’ RACE PCR product into the pGEM vector using pGEM-
T Easy vector system (Promega). The pGEM plasmids with 5’ RACE PCR inserts were 
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extracted from the E. coli using FastPlasmid mini kit (5 PRIME).  Purified plasmids were 
subjected to EcoRI (New England Biolabs) restriction enzyme digestion at 37°C for 1 hr 
before being electrophoresed on a 1X TAE 0.8% agarose gel to estimate the size of 
insertion.  Plasmid DNA was sequenced at Nevada Genomics Center (University of 
Nevada, Reno) using primers that sequenced from the SP6 site in the pGEM plasmid 
into the 5’ RACE PCR insert. 
ChIP assay for RNA polymerase II occupancy. HCMV latently infected HPCs were 
harvested and chromatin immunoprecipitation was performed as previously described 
(Rossetto and Pari, 2012). For each immunoprecipitation approximately 2  g of RNA pol 
II antibody (Active Motif, cat # 39097) was used. An antibody isotype control (GAPDH, 
Abcam cat# ab128915) immunoprecipitation was also performed.  1 ul of each purified 
DNA sample was used per qPCR reaction.  All reactions were performed in triplicate, in 
a 20 ul reaction volume using 2X SsoAdvanced SYBR Green Supermix (Bio-Rad) with 
250 nM final concentration of primers. The qPCR reactions were performed using a CFX 
Connect (Bio-Rad) with the manufacturers cycling conditions. To calculate the fold 
enrichment at each locus point, the raw Ct value for RNA Pol II and Input were 
normalized using the IgG isotype control Ct value at each point. The fold change was 
calculated using the delta Ct for normalized RNA pol II value against the normalized 
Input value. 
IE1 immunoprecipitation from latently infected CD34 (+) HPCs and protein 
sequencing.  IE1 was immunoprecipitated from 5x106 latently infected HPCs.  Cells 
were lysed in 2 ml of NP-40 lysis buffer (0.5% NP-40, 150mM NaCl, 10mM Tris, pH 7.5) 
and sonicated for 3 cycles of 10s ON/10s OFF at amplitude 40.  100 ul protein G 
agarose beads (Santa Cruz) and 5 ul IE1 antibody (W. Britt) was used for 
immunoprecipitation overnight at 40C. Immunoprecipitated protein was eluted from the 
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beads by the addition of 100ul 1x Laemmli sample buffer.  The eluted protein species 
were identified by mass spectrometry by Protea Biosciences Inc (Morgantown WV). 
Protea performed lyophilization of the sample and LC-ESI-MS analysis. 
Real-time PCR (qPCR).  Total RNA was isolated from CD34 (+) HPCs using 
Purelink RNA mini kit (Life Technologies), followed by removal of genomic DNA using 
Turbo DNA-free (Life Technologies).  cDNA was synthesized from 1 ug of total RNA in 
the presence of random hexamers, dNTPs, and Superscript III reverse transcriptase 
(Life Technologies) according to manufactures instructions.  1 ul of the resulting cDNA 
was then used along with Taqman Universal PCR Master Mix (Life Technologies) and 
specific primers and FAM labeled probes (IDT) in an Eppendorf RealPlex.  All reactions 
were performed in triplicate in a 20ul total reaction volume.  The following real-time PCR 
program was used: one cycle of 95°C hot start 5 minutes, and forty cycles of 95°C for 15 
seconds and 60°C for 1 minute.  Primers for qPCR were previously reported (Rossetto 
et al., 2013).  Levels of mRNA are shown normalized to cellular cyclophilin mRNA. 
from a standard curve of log (copy number) vs Ct value of a dilution series of pTR 
plasmid DNA. 
Identification of viral proteins interacting with HCMV terminal repeat region.  
The proteomics assay used for the identification of viral proteins interacting with the TR 
region during an HCMV latent infection was performed as previously described (Kagele 
et al., 2009). Briefly, the pTR subclone (Rossetto et al., 2013) was linearized (0.5 mg) 
and immobilized on CnBr-activated sepharose beads (GE Lifesciences) according to 
manufacture’s directions.  To control for non-specific binding, analysis with CnBr beads 
immobilized with empty vector DNA (pGEMz/f-) was also performed.   Nuclear extract 
from 5x106 latently infected (strain FIX) CD34 (+) cells was prepared (Sigma 
#NXTRACT) and applied to each DNA coupled column. After several washes the bound 
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proteins were eluted with 2.5M NaCl and identified by mass spectrometry (LC-ESI-MS) 
performed by Protea Biosciences Inc. (Morgantown WV).  Protea performed sample 
cleanup and concentration with Amicon centrifugal filter units.  Samples were then 
quantitated and trypsin digested in solution overnight.   Samples were lyophilized and 
analyzed by LC with a Shimadzu LC-20AD HPLC and ESI-MS with an AB Sciex 
QTrap5500 ESI.  
IE1 exon 4 mutant virus generation (FixBac∆EX4).  To generate an IE1 
mutant virus in strain FIXBac, exon 4 of the immediate early locus was deleted without 
interfering with the IE2 specific exon 5 (FixBac∆EX4) by galK-kan based BACmid 
mutagenesis as previously described (Kagele et al., 2009). FixBac∆EX4 virus was 
propagated on the complementing cell line, ihfie1.3 (Greaves and Mocarski, 1998).  The 
removal of exon4 was confirmed by sequencing at Nevada Genomics Center 
(http://www.ag.unr.edu/genomics/). A revertant virus was also created using galK-kan 
based BACmid mutagenesis. The repair of the IE1 exon 4 coding region was confirmed 
by sequencing at the Nevada Genomics Center (University of Nevada, Reno).   
     Infection of CD34 (+) HPCs with FixBac∆EX4 virus and evaluation of viral 
DNA maintenance.   Infection of CD34 (+) cells with wild-type FIX virus or FIXD∆EX4 
was done at a multiplicity of 5 pfu/cell. Cells were incubated with virus for 1 hour and 
then washed twice with Hanks Balanced Salt Solution (HBSS). Total DNA was 
harvested from 0.5 x 106 cells at the indicated time points. Cells were pelleted and 
washed once in 1X PBS before be resuspended in 400 ul of DNA lysis buffer (2% SDS, 
10 mM EDTA, 10 mM Tris-HCl [pH 7.4]) with the addition of 25 ug Proteinase K and 
incubated for 2 hours in a 65 °C water bath, followed by phenol-chloroform and ethanol 
precipitation.  The final DNA pellet was resuspended in 100 ul 1X TE (pH 7.4).  1 ul of 
DNA sample was used in a 50 ul total volume PCR reaction using PrimeStar GXL DNA 
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polymerase (Clontech). Viral DNA as a percent of total DNA was determined by qPCR 
for HCMV DNA (UL95 genomic locus) and compared to cellular DNA (RNA7SK genomic 
locus) as a reference.  
Generation of IE1x4 expressing cell line.  IE1x4 was PCR amplified from pCMV-
IE1aa1-491GFP and cloned into the EcoRI and NotI sites of a lentiviral packaging vector 
containing the EF1α promoter, pLVX EF1α, Lenti-X Expression system (Clontech) to 
generate pLenti-IE1x4.  pLenti-IE1x4 was transfected using manufacturer supplied 
plasmid packaging mix and transfection reagent into a 10cm dish containing 4-5X106 
293FT cells.  Supernatant containing lentivirus was collected 48hpt and concentrated 
overnight using Lenti-X Concentrator (Clontech). 0.25X106 293L cells (NIH AIDS reagent 
program Cat. # 3553) were transduced in a 35mm dish with 500 ul of concentrated 
lentivirus followed by selection at 48hpi with 2 ug/ul puromycin. Resultant puromycin 
resistant colonies were pooled, maintained on 0.5ug/ul of puromycin and used for pTR 
replication assays. 
 Transient pTR replication and maintenance assays in 293L IE1x4 cells. 
Cells were split every 3 days and 25% of the cells were subjected to DNA extraction by 
the method of Hirt (Hirt, 1967) and resuspended in a final volume of 100ul. 2ul of the Hirt 
extracted DNA was cleaved with HindIII or HindIII+DpnI in a volume of 40ul.  1ul of the 
cleaved DNA was used for qPCR analysis. qPCR was performed with a Taqman 
primer/probe set designed to amplify a region of the pGEM backbone (common to both 
pGEM and pTR) spanning three DpnI sites. Accumulation of DpnI resistant DNA was 
normalized to input (HindIII cleaved) and fold change in pTR DpnI-resistant DNA versus 
pGEM control was determined using the method of 2-ΔΔCt.  Three biological replicates 
were performed and error bars are the standard deviation of the mean. Copy number 
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was determined from a standard curve of log (copy number) vs Ct value of a dilution 
series of pTR plasmid DNA.  
 IE1-x4-ΔAD generation and pTR replication assay.  IE1-x4-ΔAD was 
generated by two-stage PCR. Two sets of primers used in the first stage were designed 
to amplify the two regions flanking the AD.  The first stage products were gel purified and 
used as template in the second stage.  In the second stage primers are designed to 
amplify across the two products from stage one and result in a single product carrying 
the desired deletion.   Stage two primers contained XhoI and EcoRI sites for subsequent 
sub-cloning into pEGFP.  500,000 293L cells were co-transfected with 10 ug pEGFP-
IE1x4ΔAD or pEGFP-IE1x4 and 0.5 ug (12,000 copies) pTR for the replication assay as 
described above.  Data shown is the amplification of pTR with either pEGFP-IE1x4ΔAD 
or pEGFP-IE1x4 and is normalized to input. 
IE1, TOPOIIB, and Sp1 ChIPs from latently infected CD34 (+) cells and 
transiently transfected 293FT cells.  Chromatin immunoprecipitation from 
approximately 2x106 latently infected CD34 (+) cells was performed as previously 
described using either IE1 specific antibody (Abcam #ab30924), TOPOIIB antibody 
(Bethyl #A300-950A) or Sp1 antibody (Santa Cruz #sc-59 X) (Rossetto et al., 2013).  To 
map the region of IE1x4 interacting with the TR, ChIP was performed using 0.5x106 
293FT cells transfected with Mirus TransIT–LT1 and 1ug pTR plus 5ug pCMV-IE1aa1-
491GFP (full length IE1), pEGFP-IE1aa421-475GFP (IE1 acidic domain), or pCMV-IE1aa476-
491GFP (IE1 chromatin tethering domain) (Reinhardt et al., 2005). pCMV-IE1aa1-491GFP  
and pCMV-IE1aa476-491GFP  were generous gifts from E. Mocarski.   pEGFP-IE1aa421-
475GFP (AD)  was subcloned from pCMV-IE1aa1-491GFP into the XhoI and HindIII sites of 
pEGFP. Chromatin immunoprecipitations were performed using anti-EGFP antibody and 
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primers to the TR and UL25 control regions as previously described (Rossetto et al., 
2013).   
IE1 and CTD ChIP-Seq. IE1 ChIP-Seq from approximately 5x106 latently infected 
HPCs was performed using IE1 specific antibody (Abcam #ab30924). CTD ChIP-Seq 
was performed by transfecting pCMV-IE1aa475-491GFP (CTD) (gift from E. Mocarski) into 
5x106 non-infected CD34 (+) HPCs followed by immunoprecipitation with anti-GFP 
antibody (Abcam #ab290) three days post transfection. Libraries were created from 10ng 
ChIP DNA or 10% of starting material for Input, using a Bioo Scientific ChIP-seq Library 
kit (cat# 5143-02). Quality and size distribution of the libraries was determined with an 
Agilent Bioanalyzer.  Libraries were quantitated using a KAPA Biosystems qPCR kit 
(KK4824). 10pM of ChIP library and 6pM of Input were sequenced on an Illumina MiSeq.  
CLC Genomics Workbench was used for analysis of ChIP-seq data.  Reads from the 
latently infected CD34 (+) IE1 ChIP were mapped to FIXBAC genome (NCBI accession 
GU179289) and reads from the IE1-CTD-GFP transfected CD34 (+) HPCs to the human 
genome (NCBI accessions NC_000001 - NC_000024). To obtain binding consensus 
sequences from the reads associated with ChIP peaks, the ChIP peaks were called 
using CLC Genomics Workbench (with Input as a reference) and their sequences 
uploaded to Regulatory Sequence Analysis Tools (http://www.rsat.eu/).  This software 
analyzes the entire set of reads for a consensus and cross-references the consensus 
against known transcription factor binding sites.  The sequencing files used for this 
analysis can be found at NCBI SRA (http://www.ncbi.nlm.nih.gov/sra) using the study 
accession number SRP040115. 
  IE1x4 and TopoIIβ or Sp1 co-immunoprecipitations. IE1x4, TopoIIβ or Sp1 
was immunoprecipitated from the 293L-IE1x4 cell line using approximately 5x106 cells.  
Cells were lysed in 1ml NP40 lysis buffer (0.5% NP40, 150mM NaCl, 50mM Tris pH7.5, 
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1mM EDTA).  Cell lysate was split equally among 50ul each of agarose protein-G beads 
(Santa Cruz Biotechnology) prepared with either 2ug of IE1 antibody (William Britt), 
TopoIIβ antibody (Bethyl #A300-950A), Sp1 antibody (Santa Cruz #sc-59 X) or their 
corresponding species-specific IgG negative control and immunoprecipitated overnight 
at 4oC.  The immunoprecipitated complexes were washed three times with TBS and 
eluted by the addition of 75ul Laemmli sample buffer.  30ul of each immunoprecipitation 
was used for Western Blot analysis.  The IE1, TopoIIβ and Sp1 antibodies were used for 
detection at 1:20,000, 1:1,000, and 1:5000 respectively.  DNAse treatment controls were 
performed by incubation of cell lysates with 5U of DNAse (Sigma D5319) for 15 minutes 
at 370C before performing immunoprecipitations. To indicate efficiency of the DNAse 
treatment 10 ul of treated or non-treated lysate was separated on a 0.75% agarose gel. 
 Sp1 inhibition with Mithramycin A in 293L-IE1x4 and latently infected CD34 (+) 
HPCs and subsequent experiments. 293L IE1x4 cells were treated with 100nM 
Mithramycin A (Mith A, Cayman Chemicals #11434) which is a selective inhibitor of Sp1 
binding to GC rich target DNA sequences..  Approximately 500,000 cells/well of a 12-
well dish were treated with Mith A (or DMSO vehicle control) for 1 day followed by 
transfection with 0.5 ug pTR/well using Mirus TransIT.  Drug was refreshed every 24 
hours.  At 2 days post transfection (3 days Mith A treatment), one well of cells was 
harvested for either western blotting, ChIP analysis, or TR replication assay.  A single 
well of cells was passed 1:3 and re-plated for analysis of pTR replication at 5 days post 
transfection.  pTR replication was analyzed by qPCR as described above in which 
replicated DNA is normalized to input for each time point. Western blot showing c-myc 
protein expression in Mith A treated 293L IE1x4 cells was performed using rabbit anti-c-
myc antibody (Santa Cruz, #sc-789).  qPCR of ChIP DNA was performed using Biorad 
Sso Advanced SYBR reagent (#172-5261) with primers to the TR region and a cellular 
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control region (myoglobin). Enrichment is shown as a percent of starting material and 
was calculated based on 10% input: %input = 100x2^(corrected input – IP).  The relative 
occupancy or specificity was calculated as a ratio of specific enrichment over the 
background: Occupancy (Specificity) = (%input specific antibody)/ (% input GAPDH 
antibody).  GAPDH control antibody used in ChIP experiments was Abcam #ab128915.  
For latently infected CD34 (+) ChIP assays in the presence of Mith A, approximately 
500,000 CD34 (+) cells were incubated in the presence of 50nM Mith A for 2 days 
followed by ChIP experiments with either Sp1, IE1, or GAPDH antibody.  All experiments 
utilized the Santa Cruz Sp1 antibody, W. Britt IE1 antibody, and Abcam GAPDH 
antibodies described above. C-myc gene expression in Mith A treated 293L IE1x4 or 
CD34 (+) cells was evaluated by qPCR and normalized to cyclophilin. 
 Assessment of cell viability during Mithramycin A treatment. Cell viability during 
Mith A treatment was evaluated using a Promega MTT assay (CellTiter 96 Non-
Radioactive Cell Proliferation Assay #G4000).     
Sp1 knockdown by shRNA and subsequent experiments.   ShRNA knockdown of 
Sp1 expression was performed in 293L cells using lentivirus expressing either Sp1 
specific shRNA or a scramble control (Santa Cruz sc-29487-V and sc-108080). 10ul 
(50,000 infectious units) of the lentivirus particles were used to transduce 100,000 293L 
cells. At 2dpi, the cells were placed on 2ug/ml puromycin for selection of a stably 
transduced population. After 4 days, puromycin was reduced to 0.5ug/ml for 
maintenance.  For TR replication and ChIP assays, 500,000 of the 293L-Sp1 stably 
transduced knockdown cells or control cells were transfected with 10ug pEGFP-IE1-
exon4 and 0.5 ug pTR (12,000 copies) per well of a 12-well dish using Mirus TransIT. At 
2dpt, cells were harvested for western blot, ChIP, and replication experiments as 
described above for the Mithramycin treatment assays and a single well was passed 1:3 
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and re-plated for a 5 day replication time point.  pEGFP IE1–exon4 was subcloned from 
pCMV-IE1aa1-491GFP (full length IE1) and ligated into the XhoI and EcoRI sites of pEGFP.  
Western blot showing expression of pEGFP-IE1exon4 in the 293L-Sp1 knockdown cells 
or control cells was performed using IE1 specific antibody (W. Britt). 
TopoisomeraseIIβ inhibition with ellipticine and TR replication assay.  500,000 
293L-IE1x4 cells were treated with 10uM ellipticine (Santa Cruz sc-200878) or DMSO 
vehicle control for 1 hour followed by transfection with 0.5 ug (12,000 copies) of pTR.  At 
1 and 3 days post transfection/ellipticine treatment DNA was Hirt extracted for analysis 
of TR replication as described above.    pTR replication is shown as the fold change of 
ellipticine treated cells relative to DMSO treated cells at 3 days post 
transfection/treatment.  Ellipticine treatment was maintained throughout the 3-day period.  
Western blot showing sustained expression of IE1exon 4 in the 293L-IE1x4 ellipticine 
and DMSO treated cells was performed using IE1 specific antibody (W. Britt).   
Flow Cytometry.  Cell cycle arrest of ellipticine treated cells was confirmed by 
propidium iodide staining and flow cytometry on a FACSCalibur equipped with CellQuest 
Pro software and analyzed using FlowJo software.  Cell cycle histograms were fitted 
using the Watson method.  DMSO or Ellipticine treated cells were fixed in ice cold 70% 
ethanol for 15 min on ice, washed once with PBS, then resuspended in staining solution 
containing 50ug/ml propidium iodide, and 0.2 mg/ml RNAse A for 30 min prior to flow 
cytometry. 
Cloning of pTRΔSp1 and replication assay. pTRΔSp1 was generated by 
restriction digest of pTR with Spe1 followed by re-ligation of the plasmid.  The resultant 
plasmid contains a 2kbp deletion within the 4.7kbp TR, which includes removal of 7 of 10 
Sp1 binding sites.   
 
  164 
Primers used in cloning and qPCR: 
Strand specific primers used for RT-PCR of IE1 expression in latently 
infected CD34 (+) HPCs: 
Exon 2-3 forward: 5’-TGGAGTCCTCTGCCAAGAGA 
Exon 2-3 reverse: 5’-TGAGAGATTCTTCGGCCAATT  
Exon 3-4 forward: 5’-CACGACGTTCCTGCAGACTATG 
Exon 3-4 reverse: 5’-CATCCACATCTCCCGCTTAT 
Exon 4 forward: 5’-TATACCCAGACGGAAGAGAAAT 
Exon 4 reverse: 5’-CCTTCAGTGCACCCCCTAACTT 
GAPDH forward: 5’-TACTAGCGGTTTTACGGGCG 
GAPDH reverse: 5’-TCGAACAGGAGGAGCAGAGAGCGA 
 
Taqman primers and probes for evaluation of expression of HCMV genes 
during latency: 
IE1/2 (exon 2-3): 
Forward:  5’-CCAAGAGAAAGATGGACCCTG 
Reverse:  5’-AACATAGTCTGCAGGAACGTC 
Probe:  5’-/56-FAM/CCCGAGACA/ZEN/CCCGTGACCAAG/3IABkFQ 
LUNA (UL81-82ast): 
Forward:  5’-ATG ACG TTG CTC CGT GGA AAG AGA 
Reverse:  5’-ATC AGG CCG TTC ATT TGG AAC ACC 
Probe:  5’-/56-FAM/TTT GTC CGG /ZEN/TTT ACC GGG TGT GAG A/3IABkFQ/ 
UL138: 
Forward: 5’-TCC ACG TCG CTA ACC AGA GAA ACA 
Reverse: 5’-AAT GTA CCA TGG CTA CGG TGG TGA 
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Probe: /56-FAM/ATC TGT TGA/ZEN/AAC CCG TGA CGG GAT/3IABkFQ/ 
UL105 
Forward:  GAG GTG CAG GCT TAC TTC AA 
Reverse:  GTT GTT GAC CAC GCA GTA GA 
Probe:  /56-FAM/CGC CAC CGT /ZEN/CTC TTT GAT TTG CC/3IABkFQ/ 
UL54 
Forward:  TTG CGG CGT GTC ATC TT 
Reverse:  GTA GTG GTT GGG CAG GAT AAA 
Probe: /56-FAM/TAT CTA CAC /ZEN/CTC GCT GCT GGA CGA/3IABkFQ/ 
 
Primers for evaluating DpnI resistant DNA in pTR replication assays: 
Taqman qPCR primers (IDT) are the following:  
Forward: 5’-TCC CAA CGA TCA AGG CGA GTT ACA 
Reverse: 5’-ACT GCG GCC AAC TTA CTT CTG ACA 
Probe: /56-FAM/AAA GCG GTT /ZEN/AGC TCC TTC GGT CCT /3IABkFQ/. 
 






Primers for generation and sequencing of FixBac∆EX4 and revertant: 







The double stranded oligo used for the final recombination and removal of exon 4: 
5’ATTGAGTAGGATTACAGAGTATAACATAGAGTATAATATAGAGTATATCACATACAT
GTCAACAGACTTACCGAGTTCTGCCAGGACATC 
Primer for sequencing FixBac∆EX4: 5’-GCCCGAGACACCCGTGTCCAAGGCC 
Primers for generation of a revertant virus by reinsertion of IE1 exon 4 (amplified from 




Endpoint PCR primers for detection of viral and cellular DNA in CD34 (+) 
HPCs infected with FixBac∆EX4: 
Primers to detect HCMV viral DNA were:  
Forward: 5′-ACA CCT CCG ACG TCC ACT ATA TAC CA 
Reverse: 5′-CGT CCA CAC ACG CAA CTC CAA TTT 
 Control primers for the cellular DNA amplified the c-fos promoter locus (Diagenode).   
 
 Taqman qPCR primers for detection of viral and cellular DNA in CD34 (+) 
HPCs infected with FixBac∆EX4: 
Viral DNA (UL95 genomic locus): 
 Forward: 5’-ATT TGC CTT TAA AGC CCG TCT CGC,  
Reverse:  5’-TCA CGC GCG AGA TCT AAA CAG AGA 
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Probe:  /56-FAM/TGT TTG TTG /ZEN/TGC GCG CTC TAC AGT CA/3IABkFQ/  
Cellular DNA (RNA7SK genomic locus): 
Forward: 5’-GTCAAGGGTATACGAGTAGCTG 
Reverse: 5’-TGACTACCCTACGTTCTCCTAC 
Probe: 5’-/56-FAM/CCCTGCTAG/ZEN/AACCTCCAAACAAGCT/3IABkFQ/).   
 








qPCR primers for ChIP experiments in Mithramycin A treated cells: 
TR region:  
Forward: 5’-AAAGTTGGTGTTGTTGCC 
Reverse: 5’-ACGCCGTCCACCGGGTAG 
Primers to myoglobin exon 2 genomic region (Diagenode #C17011006-50) were used to 
control for non-specific DNA binding.    
 
C-myc gene expression in Mith A treated 293L IE1x4 or CD34 (+) cells was 














 Primers to generate IE1-x4-ΔAD by two stage PCR: 
First stage primers: 


















Primers for 5’-rapid amplification of cDNA ends (RACE):   
IE1x4 5’ RACE primer#1: 5’-GGC TTG GTT ATC AGA GGC CGC TTG GCC ATC A 
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SUMMARY AND CONCLUSIONS  
 
 We have now shown data in support of our hypothesis that IE1 is a viral tethering 
protein expressed during HCMV latency that mediates both maintenance and replication 
of the viral genome (Figure 1).  Additionally, in support of the theory that the HCMV 
genome undergoes replication, we identified an origin of replication that is similar to 
other herpesvirus latent origins and is necessary and sufficient for replication.  We have 
Figure 1. IE1x4 tethers and maintains the viral episome during latent infection.  
Shown is a mechanism for tethering of the latent viral episome via interaction with IE1x4 AD 
region and the terminal repeat sequences.  IE1 tethers to chromosomes through interaction 
with histones and CTD.  Topoisomerase and Sp1 are required for this interaction and are 
inhibited by ellipticine and mithramycin A, respectively. 
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also suggested an alternative mechanism for control of the major immediate early 
promoter involving RNA4.9, an abundantly expressed viral long non-coding RNA.   
 However these topics remain controversial, as it is not widely accepted that a 
product of the major immediate early promoter can be expressed during latency or that 
the viral genome even undergoes replication.  By its very definition it is argued that the 
presence of a major immediate early gene product during latency is oxymoronic.  As to 
how latency is truly maintained within the host reservoir and whether, or not, latency is 
merely “bursts” of low levels of lytic replication followed by expedient host mediated 
repression, we have put forth convincing evidence that this is not case. While this is an 
intriguing possibility, and may still occur on occasion, this type of mechanism as the sole 
source of maintenance in a competent host would likely trigger an immune response 
beyond the evasion capabilities of a low copy latent viral genome and ultimately lead to 
viral clearance.  
It has also been argued that the HCMV genome could be passed on without 
undergoing replication – that is the unreplicated viral genome would be passed on to 
only one of the daughter cells.  Other herpesviruses, in particular the 
gammaherpesviruses, have developed a simplistic yet efficacious method for tethering 
the viral genome with minimal viral gene expression and it is likely that HCMV has 
evolved something similar (14). Our evidence suggests that viral DNA is maintained at 
constant levels (23). If each genome was passed to only one of two daughter cells it 
would ultimately become diluted and this ratio would decrease over time. While the 
CD34 (+) cells of the bone marrow are not a highly proliferating type under normal 
conditions, they do undergo a process of self-renewal and when mobilized to peripheral 
blood they must rapidly replenish themselves (19, 25, 32).  The HCMV genome is 
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already maintained at very low numbers and would be lost if not replicated during normal 
CD34 (+) mobilization (26). 
There is no evidence that any herpesvirus maintains a life-long infection via 
bursts of lytic replication. Each of the herpesviruses have evolved a repertoire of 
calculated steps to ensure genome maintenance and it is highly improbable that HCMV 
after hundreds of millions of years of fine tuning latency would have distanced itself from 
other herpesviruses (1, 2, 7, 16, 30).  In addition to the gammaherpesvirus family’s well-
described mechanism of episomal DNA maintenance by tethering, another herpesviral 
member of the same slow growing family of betaherpesviruses as HCMV, HHV-6, has 
developed a non-lytic dependent mechanism of latency.  HHV-6 can integrate within the 
telomeric repeats of chromosomes for maintenance and even be inherited via the germ-
line (1, 2).  
Unfortunately, some researchers remain highly convinced that immediate early 
gene expression cannot exist in tandem with latency.  The major immediate early 
promoter is a highly dynamic transcriptional element that has shown the ability to 
produce a broad range of temporally regulated splice isoforms during infection with 
varying function and regulation.  It is by no means improbable that there could be a level 
of regulation during latency that allows for a major immediate early gene product to 
assist in viral genome maintenance.  If anything, the MIEP is a perfect candidate for 
tightly controlled transcription of a latent gene product.  The study of IE1 truncation 
mutants has shown that the individual properties of the domains are conserved even 
when expressed independently of each other — suggesting that these domains have 
evolved to function as independent units and giving weight to our hypothesis that there is 
expression of a latency specific IE1 tethering protein.  
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Genomic elements, regardless of classification – bacterial, viral, fungal, or 
mammalian – contain a specialized region for initiation, or origination, of DNA replication.  
Herpesviruses have separate replication origins dedicated to both lytic and latent DNA 
replication. This uniquely evolved herpesviral feature is a mechanism for fine-tuning 
genomic propagation in various cell types and most importantly for lytic vs. latent 
replication regulation. Origins are a crucial site of recruitment for both viral and cellular 
factors contributing to virus propagation, thus mapping a replication origin can yield 
invaluable information. Our discovery of the TRE as a putative latency specific origin of 
replication will provide a valuable contribution to the field and allow for further 
experimental investigation of replication factors.   
Some form of episome maintenance is an indisputable requirement for latent 
infection persistence, making this area of the viral life cycle a prime target for antiviral 
therapeutic agents. Until the work described here, the knowledge and research potential 
of latency-associated genes was very limited.  As one of the major missing links in our 
understanding of HCMV latency, the identification and characterization of the 
relationship of IE1 with TRE as a putative tethering mechanism for replication and 




 Development of a mechanism of HCMV genome maintenance has now made it 
possible to develop a high throughput assay for identification of drug inhibitors of 
latency.  A strategy has already been developed for investigation of small molecule 
inhibitors of EBV and KSHV tethering proteins that could be easily applied to HCMV. 
Since it is well established that IE1 CTD is sufficient for interaction with histones and our 
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proposed mechanism requires that IE1 tether to chromosomes via this interaction, it 
would be feasible to develop an assay similar to current gammaherpesvirus high 
throughput screens that have been previously developed whereby purified histones are 
reacted with a fluorescently labeled peptide, in our case IE1 CTD, and added to plates 
containing an FDA validated small molecule library (3, 29). Changes in binding between 
IE1 CTD and histones can be measured by fluorescent polarization.  Such an assay 
could potentially yield small molecule inhibitors of great clinical significance. 
The study of human cytomegalovirus latency is hampered by lack of a permissive 
animal model, due to the extreme species specificity of herpesviruses, and further 
hampered by lack of an easily manipulated cell model for long-term studies.   Available 
cell based latency models are primary CD34 (+) stem cells and monocytes, and are not 
easily transduced, transfected, or selected, have a limited life span and require 
expensive maintenance with cytokines.  Transformed blood cell lines such as Kasumi-3, 
are only slightly better (18).  Therefore current cell models are very limiting in terms of 
manipulation of cellular and viral processes for experimental determination of 
mechanisms of latency.  A glioblastoma derived cell line, T98G, has been recently 
shown to support long-term infection and maintenance of HCMV genomes and may be a 
potential model for further study of HCMV latency (9, 15). Glioblastoma multiform is the 
most common and most aggressive form of brain tumor in adults with an average 
survival of only 6 months (24).  While HCMV is not considered an oncogenic virus like 
the gammaherpesviruses, EBV and KSHV, HCMV has been implicated in glioblastoma 
malignancy and progression, however findings have been very contradictory as some 
groups report detection of HCMV and some groups do not (4, 5, 13, 20, 22).   
Nonetheless, there has been some preliminary success in clinical studies treating 
glioblastoma multiforme (GBM) patients with ganciclovir in addition to traditional 
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therapies, radiation and temozolomide (27, 28).  Additionally, HCMV antigen primed 
dendritic cells have been shown to be efficacious at targeting and killing GBM tumors, 
further evidence of an HCMV presence and the value of HCMV directed immunotherapy 
for glioblastoma (6, 17).  Not only will development of a glioblastoma model greatly 
advance the study of HCMV latency, it will also shed light on the controversial role of 
HCMV in glioblastoma multiforme malignancy, as well as support development of more 
efficacious glioblastoma therapeutics, including HCMV targeted immunotherapy. 
Using the T98G glioblastoma model, in which we can transfect BACmids 
containing a mutant viral genome, something that cannot be accomplished with any 
efficiency in any other latency model, we have preliminary results indicating that the viral 
genome can be retained for long periods in the absence of lytic replication proteins UL54 
(DNA polymerase) and IE2.  In any other cell model, this type of experiment would not 
be feasible because the only way to transfer viral genomic material into cells is by 
infection and it is not possible to propagate replication defective virus. However, in 
T98Gs, the naked genomic DNA can be transfected and latency is established, thereby 
circumventing the need for virus.  Our finding that the viral episome is retained over 
multiple passages and at least 120 days (currently) in the absence of required lytic 
replication proteins supports our hypothesis that the genome is maintained during 
latency without lytic reactivation. 
 Another exciting and useful new technology is the advent of genome editing 
utilizing the CRISPR-Cas9 RNA-guided system (8). CRISPR-Cas9 technology targets 
genomic regions with a CRISPR (clustered regularly interspaced palindromic repeat) 
derived guide RNA that recruits the editing nuclease enzyme Cas9 to the desired locus.  
Entire genes can be knocked out, mutated, or substituted at a germ-line level.  It is  
feasible that the HCMV genome could be targeted and purged by delivery of a CRISPR-
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Cas9 protein-RNA complex targeting the genome either in cells prior to transplant or 
directly to an individual (10-12, 21, 31).  Now that an origin of replication has been 
identified this would be an attractive target for deletion.  Alternatively, multiple regions 
within the HCMV genome could be targeted, increasing the likelihood of clearing virus 
genomes, however this could lead to a greater incidence of off target effects.  
We plan to use CRISPR technology to further characterize regions of the virus 
required for latency in an experimental setting.  The use of the T98G latency model with 
CRISPR guided gene editing could be used to systematically knock out portions of the 
viral genome as a screen for new therapeutic targets.   The demonstration that HCMV 
can be purged from latently infected cells in the laboratory would provide preliminary 
steps in establishing CRISPR-Cas9 genome editing as a method for treating latent 
infection in patients.  
  Thus, this body of work brings to the forefront a mechanism for study of HCMV 
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